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Abstract 
 
Introduction: Sub-optimal treatment adherence in Cystic Fibrosis (CF) is commonplace, and 
is known to deteriorate in adolescence, increasing risk of early morbidity and mortality. Although, in 
other chronic conditions, research focusing on psychological models of beliefs, and in particular the 
Necessity-Concerns Framework, has proved promising to understand this problem, comparatively 
little exists within CF. Importantly, the devices used to deliver nebulised treatments in CF provide 
objective recording of dose consumption, offering a singular opportunity to overcome the largest 
barrier in adherence research - subjective adherence measurement. However, the existing studies in 
CF which have examined this model in these treatments, have either relied on subjective measurement 
of adherence, and/or inadequately adapted the measure used to assess these beliefs.  
Method: This thesis was completed in two parts. Study one developed a systematic process 
for adapting the BMQ-S into two versions, to separately capture necessity and concern beliefs of 
patients and their parents which may influence adherence behaviour to both categories of nebulised 
medications. This process included a modified two-round Delphi survey which elicited feedback from 
an expert panel on the value and clarity of the adapted questionnaires. Study two examined the 
relationship between beliefs elicited by the measures, and objectively-recorded adherence behaviour, 
to assess their relative utility in predicting adherence behaviour to nebulised treatments, from 
both patients’, and their parents’, beliefs. 
Results: In study one, consensus on the value of items in both questionnaires was positive, 
but more variable for clarity, causing two original items to be removed, eight revised, and three 
created in each of the adapted measures. Study two found no significant relationships between 
patients’ or parents’ necessity and concern beliefs, and objectively-recorded adherence behaviour, in 
either medication category, in the original or adapted measures. Although analyses were 
underpowered by inadequate sample sizes, findings suggest that the Necessity-
Concerns Framework may relate to adherence differently between nebulised medication categories 
and respondents, and, most importantly, that the original measure may be superior in capturing these 
relations. 
Discussion: Although the results of this research are provisional, the novelty of design in 
both studies highlights several important considerations for future research, including the importance 
of assessing the psychometric properties of adapted belief measures, rather than assuming that refined 
versions will necessarily be superior to original versions. They also highlight the importance of 
considering parents beliefs when trying to understand adherence behaviour in adolescent populations. 
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Chapter 1: Introduction 
 
Overview of the introduction section 
 This introduction will begin by presenting a narrative review of the literature. First, the illness 
of cystic fibrosis and its medical management will be described, and definitions of medication 
adherence introduced. Following this, the extent and impact of non-adherence in the CF population 
will be examined, and difficulties in measuring and operationalising adherence explained. 
Relationships between sociodemographic, health, and treatment factors on adherence behaviour will 
then be outlined, after which practical, social and psychological barriers and facilitators to adherence 
will be considered. Finally, an overview of the predominant psychological health belief models, 
which attempt to understand and treat non-adherence in individuals with chronic health conditions, 
will be presented. This chapter will conclude by providing a context and rationale for the two 
empirical studies completed in this thesis. 
 
Background on cystic fibrosis and adherence research 
Cystic fibrosis and its medical management 
Cystic fibrosis (CF) is the most common life-limiting genetic disease in Caucasian 
populations (O’Riordan, Robinson, Donaghue & Moran, 2008). The recessive gene carrier frequency 
is cited at 4% in the UK, and prevalence rates at 1: 2000/2,500 live births (Cystic Fibrosis Trust, 
2015). CF is a multi-system disease which primarily impacts the respiratory and gastrointestinal 
tracts. It is caused by a dysfunctional protein, the cystic fibrosis transmembrane conductance 
regulator, which creates generalised abnormalities in the exocrine gland systems (Van Goor et al., 
2009). Patients experience lung disease, pancreatic exocrine insufficiency, and symptoms such as 
meconium ileus and recurrent pulmonary infections. Respiratory disease is the main cause of 
morbidity, and respiratory failure the most cited cause of death (Yankaskas, Marshall, Sufian, Simon 
& Ridam, 2004). 
Although no cure yet exists, advancements in the healthcare management and medical 
treatment of CF, have dramatically improved patients’ quality of life and life expectancy. CF is no 
longer considered a fatal childhood genetic disorder, but a life-limiting disease of adulthood. Most 
patients are now of adult age, and in 2015, median life expectancy reached 45.1 years (Cystic Fibrosis 
Trust, 2015). These improved outcomes have, however, come with the cost of ever-increasingly 
complex, invasive, and time-consuming treatment regimens (Bell et al., 2020). 
These multi-component regimens begin early in life, are life-long, and average two hours per 
day, every day. They aim to treat problematic symptoms, slow CF’s progression (by preventing 
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pulmonary exacerbations and airway inflammation), and identify and treat common comorbidities 
such as diabetes, gastrointestinal conditions and mood disorders (Sawicki & Tiddens, 2012). At a 
minimum, they usually include vitamin and nutritional supplements, nebulised or oral antibiotics, 
nebulised mucolytics, pancreatic enzymes, and airway clearance (Sawicki, Sellers & Robinson, 2009). 
Unfortunately, symptom and treatment burden only increase as patients age, due to disease 
progression and age-related comorbidities (e.g. cardiovascular disease and renal failure), which 
themselves require further independent treatments (Brennan, Geddes, Gyi & Baker, 2004). Due to this 
high illness and treatment burden, CF teams are highly active in monitoring disease progression, 
adherence levels, and in providing support. 
 
Defining adherence 
Adherence has been defined as ‘the extent to which a person’s behaviour – taking 
medications, following a diet, and/or executing lifestyle changes – corresponds with agreed 
recommendations from a healthcare provider’ (WHO, 2003, pg.3). Conversely, non-adherence has 
been defined as occasions ‘where doses are missed, extra doses are taken, or doses are taken in the 
wrong quantity or at the wrong time’ (Verbrugghe, Verhaeghe, Lauwaert, Beeckman & van Hecke, 
2013, pg.610), and is widely considered to be either intentional (e.g. avoidance of side-effects) or 
unintentional (e.g. poor understanding) (Johnson, 1996).  
Within this field, much research focuses on investigating adherence rates and the factors 
which influence them, in order to identify facilitators and barriers to optimal adherence. It is reasoned 
that this knowledge would allow patients at risk of sub-optimal adherence to be identified, and 
effective interventions developed for them (e.g. Owen & Jones, 2016). Interestingly, however, such 
research has historically focused on the adult population and on treatment regimens as a whole, and 
has assumed that findings can be generalised across treatments and populations. Recently, authors 
such as Owen and Jones (2016) have argued that such assumptions are erroneous, and that they 
underlie the limited effectiveness of current adherence interventions in chronic health conditions. As a 
result, more recent research has started to examine adherence across and within treatments in both 
adult and paediatric populations, with the aim of creating more targeted and effective interventions. 
This research will now be discussed with a focus on CF and nebulised treatments in the paediatric 
population, where possible. 
 
Adherence to treatment in cystic fibrosis 
Non-adherence to treatment is commonplace in CF and is viewed as the single largest barrier 
to treatment success, and the main challenge faced by CF care teams (Owen & Jones, 2016). 
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Adherence rates have been found to range between 35% and 75% depending on several factors, 
including treatment component, population characteristics, and data-collection methods (Eakin and 
Riekert, 2013). Sub-optimal adherence is problematic, as it limits the effectiveness of treatments, 
creating negative outcomes, both for patients (increased morbidity and mortality rates), and healthcare 
systems (increased consultations, admissions and wasted resources through unused medications and 
unnecessary treatment escalation). Such issues also constrain research by undermining treatment 
evaluation (Owen & Jones, 2016). For children and families, sub-optimal adherence also relates to 
increased time away from school, academic and social deficits, and enhanced stress and financial 
burden on families (Narayanan, Mainz, Gala, Tabori & Grossoehme, 2017). Consequently, adherence 
behaviour in CF has been positioned as a public health concern and research priority. 
 
Measuring adherence 
Within the adherence literature, non-adherence has been measured in a variety of ways, using 
both subjective and objective recording methods. However, almost all of these methods have been 
found to suffer from limitations, which undermine the validity and reliability of findings produced by 
studies which employ them. 
Across treatments and illnesses, the most utilised method to assess adherence is self-report 
questionnaire; however, research has consistently shown that such subjective reports are inaccurate. 
For instance, within the CF population, patients and family members have been shown to 
overestimate adherence through recall biases including social desirability and retrospective memory 
bias (Quittner, Modi, Lemanek, Levers-Landis & Rapoff, 2008; Barker & Quittner, 2010), while 
health professionals have been found to underestimate adherence (Daniels, Goodacre, Sutton, Pollard, 
Conway & Peckham, 2011). Research has also shown that concordance rates between self-report and 
objective measures are low across treatments in the CF paediatric population. Modi, Lim, Yu, Gellar 
and Wagner (2006) found that objective adherence data (e.g. pharmacy refill history, and electronic 
monitors) was on average lower (<50% vs. 80%) and more variable (22%-71% vs. 67%-100%) than 
data collected through subjective methods (e.g. patient self-report, parent report). This highlights how 
subjective treatment adherence data can be significantly inaccurate and suggests that research should 
rely on objective measurement alone.  
However, it is important to recognise that even seemingly objectively acquired data is also 
open to bias. For instance, frequently-used supposedly objective measures such as pill count data (i.e. 
a count of the number of pills remaining, compared with the number prescribed within a timeframe), 
pharmacy prescription refill records and electronic medication vial caps (which record the time of 
bottle opening) only indicate that a medication has been used or removed, with no guarantee that it 
was appropriately consumed. It is therefore impossible to know whether individuals have discarded 
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pills, consumed their prescribed dose, or taken their medications at the appropriate time. Such 
potential errors highlight how supposedly objective measures may also fail to provide a true 
representation of adherence data.  
In recent years, however, new technologies have emerged to overcome such difficulties in 
measuring adherence for certain treatments. Within CF, technological advancements in the form of 
interactive nebuliser inhalation devices (trademarked as "I-nebulisers" / “I-nebs”) have allowed 
adherence to nebulised medications to be objectively recorded since 2006 (Profile Pharma, Zambon 
SpA, Chichester, UK). I-nebulisers use an electronic microchip to record the date and time medication 
is taken, and the dose inhaled. They also feature an adaptive aerosol delivery (AAD) system which 
ensures precise, reproducible doses are delivered to patients during the active inspiratory phase 
(inhalation) of their respiratory cycle, thereby minimising drug wastage from incorrect administration 
(Kesser & Geller, 2009). Together, this data recording and AAD technology allows accurate and 
highly reliable rates of treatment adherence to be calculated, leading many to promote the I-nebuliser 
as a ‘gold standard’ objective measure of inhaled medication adherence (McCormack, Southern & 
McNamara, 2012). Importantly, one study by Daniels et al. (2011) using I-neb data as an adherence 
measure has shown just how inaccurate self-report can be in nebulised CF therapy; adult self-report 
placed adherence at 80%, while downloaded I-neb data showed only 36%. Therefore, the remainder 
of this section will focus on objective measurement and, where possible, purely objective recording 
through such electronic monitoring devices. 
Despite the availability of such accurate measures, it is important to recognise that further 
challenges exist in measuring adherence. First, adherence can be calculated in several ways using the 
same data. For instance, an overall measure of adherence can be determined by calculating the 
percentage of times that a medication is taken across the number of times it is prescribed, across a set 
period of time. Alternatively, one can measure how consistently a medication is taken, by calculating 
the percentage of days a patient fully adheres to their prescription. Finally, a minimum standard 
measure can be determined by calculating the percentage of days that the device was used at least 
once. Importantly, a study by Latchford, Duff, Quinn, Conway and Conner (2009) demonstrated that 
I-nebuliser adherence data calculated through these three different methods led to markedly different 
findings. Second, there is no established cut-off point for ‘poor’/‘insufficient’ adherence in these 
treatments, which makes adherence data difficult to interpret. The established clinical cut-offs for 
non-adherence which do exist typically rely on arbitrary thresholds proposed by expert clinicians, 
rather than values based on empirical evidence of treatment effectiveness (WHO, 2003). Third, most 
of these studies simply report an average percentage of adherence or non-adherence within a given 
sample. Such group-level data overlooks potential important individual differences, a flaw known as 
aggregation bias (Johnston & Johnston, 2013).  
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Objectively recorded adherence rates to nebulised treatments in cystic fibrosis 
For nebulised therapies in adult populations, objective data collected through electronic 
medication monitors has shown that combined nebulised medication adherence can range between 
36% and 50%, with large variability occurring between patients (i.e. IQR 5-84.5%, SD 39.7) (Daniels 
et al., 2011; Latchford et al., 2009). Within nebulised medication categories, average rates between 
31% and 53% have been reported for antibiotics (Quinn, Latchford, Duff, Conner, Pollard & 
Morrison, 2004; Latchford et al, 2009), 24 to 82% for mucolytics (Burrows, Bunting, Masel & Bell, 
2002), and between 41% and 72% for hypertonic saline (Elkins, Robinson, Rose, Harbour, Moriarty 
& Marks, 2006). However, only the studies examining nebulised antibiotic adherence used purely 
objective monitoring through electronic devices; the remainder relied instead on pharmacy refill data. 
 
Interestingly, in the paediatric population, electronically-recorded adherence rates are higher 
and less variable than in the adult population. Ball et al. (2013) (N=24) found a mean adherence rate 
of 65% (SD 28%) for combined nebulised medications in adolescents, and a range of between 37% to 
93%. They also found that patients on average took approximately 1.4 treatments a day, regardless of 
whether they were prescribed two or three treatments, and that adherence was higher on weekdays 
than weekends, and during school terms than holidays. For nebulised antibiotics alone, McNamara, 
McCormack, McDonald, Heaf and Southern (2009) (N=28) reported a similar average adherence rate 
of 67% (SD 31%) for children and adolescents. They also noted that adherence greatly varied both 
within and between patients’, e.g. that adherence was higher in mornings than evenings. For 
mucolytic medications, however, no purely objective adherence data exists, although pharmacy refill 
data has placed average adherence rates at a higher level of between 67% and 84% (Modi, et al. 2006; 
Suri, Wallis, Bush, Thompson, Normand & Flather, 2002; Zindani, et al., 2006). 
Overall, in the paediatric population, very little research exists which objectively examines 
adherence to nebulised medications, and that which does is limited by either small sample sizes, or a 
reliance on pharmacy refill data rather than objective recording. Importantly, while some studies 
suggest that mucolytic adherence may be higher than antibiotic adherence, no existing research 
provides a purely objective adherence rate for nebulised mucolytics. Nonetheless, it can be concluded 
that adherence rates to nebulised treatments are sub-optimal and variable in paediatric populations, 
and that adherence behaviour patterns appear to exist. 
Evidence of poor adherence, alongside a paucity of research, is concerning due to the primary 
role that nebulised medications are argued to play in mucus clearance, and in preventing and treating 
lung infections – the key causes of morbidity and early mortality in CF (Eakin Bilderback, Boyle, 
Mogayzel & Riekert, 2011; Ryan, Singh & Dwan, 2011; Yang, Chilvers, Montgomery & Nolan, 
2016). Supporting this, health outcome research across several studies has shown that increased 
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nebulised medication use relates to reduced use of intravenous antibiotic therapy, fewer pulmonary 
exacerbations and hospital admissions, reduced length of hospital stays, and better baseline lung 
function (Eakin et al., 2011; Briesacher, Quittner, Saiman, Sacco, Fouayzi & Quittell, 2011). This 
suggests that the negative consequences of non-adherence to nebulised medications alone can be 
significant, although it should be noted that the causal direction of these relationships is not always 
clear.  
 
Correlates of treatment adherence 
Adherence and demographic factors 
Adherence is widely cited to decline with increasing age in CF populations (e.g. Masterson et 
al., 2011), with many studies across different treatments reporting adherence to be significantly poorer 
in adolescents than children (Zindani et al., 2006; Modi, Marciel, Slater, Drotar & Quitner, 2008; 
Lloente, Garcia & Martin, 2008; Bucks, Hawkins, Skinner, Horn, Seddon & Horne, 2009; 
Goodfellow, Hawwa, Reid, Horne, Shields & McElnay, 2015), or in older vs. younger adolescents 
(Bucks et al., 2009), suggesting that different barriers to adherence operate and possibly compound at 
different ages. Such adherence decline has been observed to start when individuals are approximately 
10 years old, and to peak at roughly age 16 (Riekert, Mogayzel, Bilderback, Hale & Boyle, 2007; 
Quittner et al., 2014). At this point, sub-optimal adherence in adolescents has been reported to be 
almost three times more likely than in children (69% vs. 24%) (Llorente, et al., 2008).  
It is not clear if this trend applies at similar levels, or at all, with nebulised medications, as 
relevant research is extremely limited. While some studies have found this same trend (Zindani, 
Streetman, Streetman & Nasr, 2006; McNamara, McCormack, McDonald, Heaf & Southern, 2009), 
others have found the converse (Modi, et al. 2008). If such a gradual but substantial decline does exist 
for nebulised medications in adolescence, it is important to understand and address it. A failure to 
adhere at this age may arguably allow the disease to progress at a faster rate, and create a poorer 
precedent for self-care in adulthood, since the transition from parent-led care to self-care usually 
occurs at this time.  
Little research exists examining the impact of gender on treatment adherence in the paediatric 
CF population, and that which does is also inconsistent. While some research finds adolescent boys to 
be more adherent than girls (Miller, Willis & Wyn, 1993), others report the opposite (Patterson, Wall, 
Berge & Milla, 2008), or no difference (Llorente, et al, 2008; Bucks et al., 2008; Masterson et al., 
2011). However, the former studies suffered from key methodological flaws, including assessing 
adherence with just a single question. Although the remaining studies gathered more robust adherence 
data, they only considered gender broadly, rather than within treatment subcomponents. Therefore, 
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the link between adherence and gender is unclear in the paediatric population, and unknown in 
relation to specific components of the treatment regimen, including nebulised medications. 
 
Adherence and disease severity 
Although the impact of disease severity on adherence rates in CF has been investigated, the 
research findings are mixed. While some studies report that treatment adherence is lower in children, 
adolescents, and adults when the disease is more severe (Conway, Pond, Hamnett & Watson, 1996; 
Hamutcu, Francis, Krakoc & Bush, 2002; Kettler, Sawyer, Winefield & Grenville, 2002, Llorente, et 
al., 2008), others report the opposite (Michaud, Frappier & Pless, 1991; Abbott, Dodd & Webb, 1996; 
Zindani et al., 2006; Hoo, Boote, Wildman, Campbell & Gardner., 2017), or find no association at all 
(Abbott et al., 1994; Daniels et al., 2011). For nebulised medications specifically, in the paediatric 
population, this relationship is unclear, as research is almost non-existent, and the studies which do 
exist (e.g. Modi et al., 2006) may be unreliable as they rely on medication vial data alone to examine 
adherence. 
 
Adherence and treatment components 
Differences exist between the treatment components in terms of their impact on symptoms, 
and in the time and effort they require. Higher rates of adherence have generally been found in 
simpler treatments which provide symptomatic benefit (e.g. pancreatic enzyme supplements and oral 
medications), with lower rates for more burdensome and/or prophylactic therapies (e.g. nebulised 
mucolytics and chest physiotherapy), in both adult and paediatric populations (Zindani et al, 2006; 
Modi et al., 2006; White, Stiller & Haensel, 2007; Sawicki, Heller, Demars & Robinson., 2015). For 
instance, in children with CF, objectively recorded adherence rates between treatment components 
have been found to range from 22% to 71% (Modi et al., 2006). These differences in adherence rates 
suggest that different factors mediate adherence behaviours between treatments, highlighting the 
importance of investigating them individually. 
 
Summary  
Overall, within paediatric populations in CF, adherence rates appear to differ based on certain 
demographic and clinical factors, and components of the treatment regimen, though the scarcity of 
research prevents firm conclusions. Research has attempted to investigate the reasons behind these 
adherence differences, identifying a multitude of barriers and facilitators. Although much early 
research was completed in the adult population, over the last decade, more studies have examined the 
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child and adolescent CF population. This research will now be discussed, with a focus on nebulised 
medications where possible. 
 
Barriers and facilitators to treatment adherence 
The influence of treatment burden and competing priorities on adherence  
The time-consuming nature of treatments and competing life priorities, are often cited as 
barriers to adherence across treatments in children, adolescents and adults with CF (e.g., Conway et 
al., 1996; Modi & Quittner, 2006; Modi et al., 2006; Williams, Mukhopadhyay, Dowell & Coyle, 
2007; Bucks et al., 2009; George, Rand-Giovannetti, Eakin, Borrelli, Zettler & Riekert, 2010; 
Bregnballe, Schiøtz, Boisen, Pressler & Thastum, 2011; Sawicki et al., 2015). Within nebulised 
treatments specifically, questionnaire-based and qualitative studies have shown that adults, children, 
adolescents, and/or their parents report time-burden (including preparation, administering treatment 
and cleaning equipment) and competing demands (balancing treatment with their social and 
occupational lives) to be a main, if not the primary, barrier in completing such treatments (Modi and 
Quittner, 2006; Llorente et al., 2008; Dziuban et al., 2010; Bregnballe et al., 2011; Hogan, Bonney, 
Brien & Karamy., 2014; Sawicki et al., 2015). The importance of time and convenience can also be 
seen in the recorded adherence rate differences between arguably easy-to-administer oral antibiotics 
(80%–95%) and more burdensome nebulised antibiotics (65%–80%) in adults (Abbott et al., 1994; 
Conway et al., 1996; Kettler et al., 2002). 
However, despite such reports, adherence rates have not improved as nebulised treatment has 
become increasingly convenient and time-efficient; modern nebulisers do not require patients to 
reconstitute drugs, or engage in time-consuming preparation, cleaning and disinfecting procedures 
(Kesser & Geller, 2009). Patients also report new nebuliser devices as 'easy' or 'very easy' to use 
(Denyer, Black, Nikander, Dyche & Prince, 2010; Denyer, Prince, Dixon, Agent, Pryor & Hodson, 
2010), which suggests that complexity of use is not a barrier. Finally, reducing prescribed daily doses 
has not been found to improve adherence in the long term (McNamara et al., 2009). Together, such 
findings suggest that the time and complexity of treatment preparation and administration does not act 
as a barrier in nebulised treatments. Contrary to self-report, 'competing demands' also do not appear to 
function as a barrier to adherence behaviour. As highlighted above, paediatric populations have been 
found to be significantly more adherent to nebulised therapy at times when free time is arguably 
sparser - for example, in mornings rather than evenings (McNamara et al., 2009), and during term-
time rather than holidays (Ball et al., 2013). Such patterns of poor weekend adherence have also been 
found in young adults (George et al., 2010). Together, such findings suggest that time-burden and 
competing demands are not the originating factors of poor adherence. 
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The influence of forgetting on adherence  
Recently, certain authors (e.g. George et al., 2010, McNamara et al., 2013) have suggested 
that routine change can cause individuals to simply forget to take medication, a factor they further 
promote as the general underlying barrier to adherence. Supporting this, interview- and questionnaire-
based studies have shown that adults, children, adolescents, and/or parents report forgetting as a 
major, even primary, reason for non-adherence across treatments, including within nebulised therapy 
(Modi & Quittner, 2006; Dziuban et al., 2010; George, et al. 2010; Bregnballe et al., 2011; Llorente et 
al., 2011). Such studies equally highlight an established routine as a major, even primary, facilitator to 
adherence. 
Despite such reports, it is surprising that forgetfulness arising from routine change would 
constitute such a fundamental barrier for CF treatments, considering the daily and life-long nature of 
the treatment regimes. Dziuban et al. (2010) suggest that what parents and patients label as 'forgetting' 
may represent a superficial explanation for deeper originating obstacles, e.g. beliefs within or outside 
of individuals' awareness. Supporting this, Sawicki et al. (2015) found that parents understood their 
child’s ‘forgetting’ of treatments as a reflection of their denial around their need for therapy, or a 
failure to appreciate the long-term benefits, rather than an act of simple forgetfulness. They also noted 
that such lapses were often discussed in the context of competing priorities, suggesting that the 
process of ‘forgetting’, and beliefs driving it, may also underlie the barrier of ‘competing demands’. It 
is also interesting to note that Modi and Quittner (2006) found that approximately half of parents were 
unable to identify the barriers to nebulised therapy for their children, possibly supporting the 
influence of less conscious processes.  
Such findings suggest that improvements in treatment administration times, reminder 
systems, and setting routines alone would not significantly impact adherence levels, as it would not 
address the underlying factors driving such apparent forgetfulness: beliefs about the treatment itself.  
 
The influence of family on adherence 
The high treatment burden imposed by CF often causes individuals to rely on support from 
others, especially family members, to manage their treatments. Highlighting the importance of this, 
research has shown that strong family cohesion and support relates to improved treatment adherence 
in adults (McGuffie, Sellers, Sawicki & Robinson, 2008; Hogan et al., 2015) and children (Foster et 
al., 2001; DeLambo, Ievers-Landis, Drotar & Quittner, 2004; Hamutcu et al., 2002; White, Miller, 
Smith & McMahon 2009). Conversely, family dysfunction, including reduced parent-child 
attachments and psychological wellbeing, and increased conflict and stress, relate to lower adherence 
(Foster et al., 2001; DeLambo, Levers-Landis, Drotar & Quittner 2004; Badlan, 2006; Smith & 
Wood, 2007; Modi et al., 2008; Smith, Modi, Quittner & Wood., 2010; Szyndler, Towns, van 
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Asperen & McKay, 2005; Dziuban et al., 2010). Interestingly, Bregenbelle et al. (2011) found that 
adolescents who reported feeling less supported, and reported more family conflict, also described 
other treatment barriers more frequently, leading the authors to suggest that family dynamics not only 
act as a barrier or facilitator in themselves, but also create and remove other adherence barriers. 
Importantly, such dynamics undergo changes as children reach adolescence; autonomy and 
independence are increasingly promoted through alterations in roles and responsibilities, including a 
transfer of treatment responsibility from parents/guardians to the adolescent. Many authors, including 
Foster et al. (2001) and Modi et al. (2008) suggest that the decrease in adherence to CF medications 
between childhood and adolescence likely reflects this decrease in parental involvement.  
Overall, these findings suggest that family dynamics and functioning impact adherence rates, 
and that families also have a strong role in both creating and mediating other adherence barriers. 
 
The influence of developmental changes on adherence 
Several developmental challenges (e.g. changes in education, vocation, independence, self-
identity, cognition and peer relationships) occur in adolescence, which may help to explain the 
reduced adherence rates observed. Adolescents need to learn to navigate these changes alongside 
managing their health-needs and their transition to adult care teams, which requires them to form new 
relationships with healthcare professionals and take increasing responsibility for managing their own 
treatments (McLaughlin, Diener-West, Indurkhya, Rubin, Heckmann & Boyle, 2008; Sawicki et al., 
2015). Unfortunately, alongside these challenges, the disease often suddenly worsens, with symptoms 
becoming more problematic, and the regimen, consequently, increasingly intensive and prevention-
focused (Sawicki et al., 2015).  
Unsurprisingly, considering such changes, research has identified differences in some self-
reported treatment barriers between children and adolescents in CF. While younger children and their 
parents report barriers in oppositional behaviours, such as taste and swallowing dislikes (Modi & 
Quittner, 2006), adolescents/young adults and/or their parents report factors such as: fatigue (George, 
et al., 2010), privacy concerns (e.g. reluctance to disclose their diagnosis and/or take medications in 
front of others) (Bregnballe et al., 2011), increased social demands (e.g. preference for being with 
friends rather than adhering to scheduled treatment) (George et al., 2010), a wish to be 'normal' and 
experiences of embarrassment (Dziuban et al., 2007). These adolescent beliefs were found in relation 
to CF treatment broadly, though several were also reported in relation to nebulised treatments 
specifically. In the adult-focused literature, all of these beliefs have also been reported in relation to 
nebulised therapy alone (Hogan et al., 2015). 
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Although it is understandable that adherence would become more difficult for adolescents 
alongside so many changes and new barriers, it remains surprising that individuals would neglect their 
treatments at a time in their lives when disease progression would presumably make their health status 
more pertinent. Interestingly, Llorente et al. (2011) and Sawicki et al. (2015) suggest that illness- and 
treatment-related beliefs are likely to change at this time due to the number of developmental and 
situational changes highlighted above, and suggest that it is these belief changes that influence 
adherence behaviour. 
 
The influence of illness and treatment beliefs on adherence  
Arguably, certain characteristics of CF and nebulised medications may lead adolescents to 
develop beliefs that act as barriers to adherence. For instance, patients with CF can feel relatively 
healthy and asymptomatic, even when their organ functions are declining (Peckham & Whittaker, 
2013). The preventive nature of nebulised mucolytics means that direct symptom relief is not 
experienced, and that immediate negative consequences from missed doses do not occur (Abbott et 
al., 1996). Also, the nature of the disease means that its progression is inevitable, even with optimal 
adherence. These observations and experiences may cause individuals to underestimate their disease 
severity, and to question their need for daily adherence, or even for nebulised treatments at all. 
Supporting this, interview studies have found that adolescent patients can hold beliefs such as 
feeling they do not need to adhere to their medication (including nebulisers) if they feel fine (Sawicki 
et al., 2015; George et al., 2015), or during periods when they feel healthy more often (Dziuban et al., 
2010), and may believe that a lack of immediate benefit means that preventive medications (including 
nebulised mucolytics) are not effective (Sawicki et al., 2015; George et al., 2015). Dziuban et al., 
(2010) found that a third of adolescents consider it acceptable to miss a treatment every few days, or 
when they are busy, with a minority of individuals further believing that taking extra doses later could 
counteract earlier non-adherence. A heightened awareness of disease trajectory has been found to lead 
adolescents to weigh up the importance of completing treatments in relation to their overall length and 
quality of life (Sawaicki et al., 2015), and specifically in relation to treatment sub-components, as 
they may vary by burden vs. perceived benefit (Llorente et al., 2008). 
Similar beliefs regarding the lack of perceived need for daily nebulised medication, and the 
perceived low importance of this treatment relative to others, and life overall, have also been reported 
in the adult literature (Hogan et al., 2015; Hoo et al., 2017). In addition, adults have reported that 
nebulised medication is an exhausting activity, expressed concerns regarding short-term side-effects 
such as excessive coughing (Hogan et al., 2015), and have reported beliefs that it is boring and time-
consuming (Hoo et al., 2017). 
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Interestingly, differences in beliefs have been reported between different nebulised 
medications. Dziuban et al. (2010) found that no adolescent in their study felt it acceptable to miss 
nebulised tobramycin, an antibiotic typically prescribed in 28-day on-and-off cycles. The authors 
speculate that the time-limited nature of this treatment, and its potential immediate symptomatic 
benefit, may have led to it being perceived as more useful and tolerable. Similarly, in the adult 
literature, Hoo et al. (2017) found that adults reported finding hypertonic saline easier to adhere to 
than dornase alfa, as the former causes an immediate effect by stimulating vigorous coughing and 
sputum expectoration. Importantly, such findings highlight the need to examine how barriers, 
including beliefs, can differ even within a treatment, depending on the medication being delivered. 
 
Summary 
In short, numerous psychological, social and practical barriers and facilitators influence 
adherence rates in adolescents with CF, several of which act specifically within nebulised therapy. 
These include treatment burden, competing demands, forgetting to adhere, decreased parental 
involvement, and perceptions of treatment necessity and value. Such findings highlight the complex 
and multifaceted nature of adherence, and the challenge of considering which factors to target for 
intervention, and/or which may be most amenable to change. 
Importantly, it appears that some of these practical and psychosocial factors may originate 
from, influence, and/or be influenced by, individuals’ underlying beliefs. However, the studies 
highlighted above investigating such beliefs have largely been conducted outside theoretical models, 
have been qualitative and exploratory in nature, or have used quantitative designs with inconsistent 
means of assessing beliefs. Crucially, frameworks and means to assess such beliefs have been 
developed, enabling cross-study comparisons and the relative importance of beliefs to be examined - 
these will be discussed next. 
 
Health belief models of treatment adherence 
 Social cognitive models focus on individuals’ motivations and intentions in order to 
understand the role of rational decision-making and planning processes in behaviour (Brawley & 
Culos-Reed, 2000). Such models have been used to provide theoretical frameworks to understand and 
study illness behaviour, including adherence, and are considered among the most effective in 
predicting and improving adherence behaviour in chronically-ill patients (Roter, Hall, Merisca, 
Nordstrom, Cretin & Svarstad, 1998). Several such models address how cognitive factors, including 
beliefs, determine how health information is understood, evaluated, and responded to (DiMatteo, 
Haskard-Zolnierek & Martin, 2012). So the challenge now is to identify which of these models are 
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useful for predicting adherence, so that targeted interventions can be developed to improve low 
adherence. Two of the most widely accepted belief models, and their relations to adherence behaviour 
will now be considered.  
 
The self-regulatory model 
 Leventhal’s self-regulatory model of illness representations (Leventhal, Zimmerman, & 
Gutmann, 1984) suggests that patients are active problem-solvers, who are motivated to construct 
cognitive and emotional representations about their illness and its treatment, in order to make sense of 
it. These representations, in turn, influence the formation of coping behaviours and expectations of 
physical and emotional outcomes, which help to guide an individual’s behaviour towards managing it 
(Leventhal, Nerenz, & Steele, 1984). This model suggests that forming mental representations occurs 
through two partially-interacting parallel processes; cognitive and emotional (Diefenbach & 
Leventhal, 1996). 
The first process is responsible for the development of cognitions, known as ‘illness 
representations’. Cognitions are activated in response to internal or external cues about symptoms and 
health threats. They are argued to directly influence patients’ awareness and interpretation of 
symptoms, and their expectations of treatment, which in turn influence their problem-based coping 
strategies, including adherence behaviour. It is argued that individuals’ with more negative cognitive 
representations regarding their illness, therefore develop more negative coping styles and strategies, 
including poorer adherence to their treatments (Hagger & Orbell, 2003). Illness representations are 
argued to be structured around five separate dimensions: 1. cause (i.e. beliefs about what factor(s) 
underlie illness development); 2. illness identity and associated symptoms (i.e. beliefs about what is 
wrong); 3. illness consequences (i.e. beliefs about how the condition will impact physical, mental, and 
social functioning); 4. illness duration (i.e. whether it will be chronic, transient or cyclical); and 5. 
cure/control (i.e. beliefs about one’s personal control over the illness, and treatment control: beliefs 
regarding the efficacy, necessity, and concerns of completing treatment) (Leventhal, Leventhal & 
Cameron, 2001).  
The second process constructs emotional representations and feelings that can arise from the 
disease. These representations can be activated by illness representations, or by external and internal 
cues (e.g. bodily sensations). To attenuate or control these negative emotions, coping strategies are 
implemented which may be helpful or unhelpful. It is argued that this pathway interacts with the 
illness perception pathway, leading erroneous beliefs regarding illness, or unhelpful strategies for 
coping with associated emotions, to develop (Diefenbach & Leventhal, 1996). 
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These systems are argued to be built on information from sources such as personal and family 
experience, healthcare professionals, and the media. This model places the process of adapting to an 
illness into three inter-relating stages: i) ‘interpretation’, referring to the patient’s attempt to make 
sense of their perceived symptoms; ii) ‘coping’, denoting maladaptive and adaptive of management of 
the problem, and iii) ‘appraisal’, a review process where patients evaluate how effective their coping 
has been. Therefore, illness representations are argued to be continuously evaluated and updated, as 
patients appraise the efficacy of their coping behaviours and acquire new illness- or health-threat-
related information. This leads an individual to either persist with a coping behaviour, or to try 
alternatives. This model is presented in Figure 1 below:  
 
Figure 1: The self-regulation model (Diefenbach & Leventhal, 1996). 
 
The Illness Perception Questionnaire (IPQ) (Weinman Petrie, Moss-Morris & Horne, 1996), 
the Illness Perception Questionnaire-Revised (IPQ-R) (Moss-Morris, Weinman, Petrie, Horne, 
Cameron & Buick, 2002) and the Brief Illness Perception Questionnaire (Brief IPQ) (Broadbent, 
Petrie, Main & Weinman 2006) were developed as means to assess the self-regulatory model. They 
are generic measures which aim to assess in varying levels of detail, illness perceptions that are 
commonly held across a range of acute and chronic illnesses. Each of these measures has been 
validated and has been found to have good psychometric properties across chronic conditions (Moss-
Morris et al., 2002; Hagger & Orbell, 2005; Broadbent, Wilkes, Koschwanez, Weinman, Norton & 
Petrie, 2015).  
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The self-regulatory model and adherence behaviour 
Within the literature, hundreds of studies across chronic conditions have used these IPQ 
questionnaires to examine relations between illness perceptions and a variety of outcomes, including 
treatment adherence in adult and paediatric populations. For instance, illness perceptions reported by 
children, adolescents, and parents, have been found to relate to treatment adherence across a range of 
conditions, including hypertension (Skinner, John, & Hampson, 2000), functional constipation 
(Koppen, van Wassenaer, Barendsen, Brand & Benninga, 2018), diabetes (Griva, Myers, & Newman, 
2000; Skinner, Hampson & Fife-Schaw, 2002; Gaston, Cottrell and Fullen, 2011; Prikken et al., 
2019), asthma (Horne & Weinman, 2002; Sonney, Insel, Segrin, Gerald & Moore, 2017; Kosse, 
Koster, Kaptein, de Vries & Bouvy, 2019) and CF (Bucks et al., 2009), supporting the utility of this 
model. However, it should be noted that other studies have found no such relationship (e.g. Klok, 
Kaptein, Duiverman & Brand, 2012). Interestingly, some recent studies (e.g. Gaston et al., 2011; 
Sonney et al., 2017; Koppen, et al., 2018; Prikken et al., 2019) have started to examine the influence 
of both patients’ and parents’ illness perceptions on adherence behaviour, as they argue that parents’ 
illness and treatment beliefs are likely to influence the development of their children’s illness 
representations, and that examining both sets of beliefs may therefore offer new insights into self-
management behaviour in paediatric populations.  
Within CF, just one study has assessed illness perceptions in the adult population (Sawicki et 
al., 2011), and one in the paediatric population (Bucks et al., 2009), although only the study by Bucks 
et al. (2009) did so in the context of treatment adherence. Bucks et al., (2009) found that perceptions 
that CF is not amenable to treatment control, and that CF is not permanent, related to poorer self-
reported adherence to antibiotic treatments, but not to chest physiotherapy or enzyme supplements. 
Indeed, they found that no illness perceptions related to adherence for these treatments, suggesting 
that this model does not apply to all treatments, even within a single illness. They also found that age 
related to adherence for antibiotics, but that timeline chronicity beliefs appeared to be mediating this 
relationship, and that emotional representations became more adaptive with age. Such findings 
suggest that treatment control and timeline beliefs appear to relate to adherence in CF within 
antibiotic treatments, that beliefs may mediate relations between demographic variables and 
adherence, and that illness perceptions and emotion representations appear to change with age.  
However, the paucity of research in this area prevents firm conclusions from being drawn - in 
fact, recent reviews examining the strength of such effects across treatments and illnesses suggest that 
they are weak and inconsistent. Brandes and Mullan (2014) completed a meta-analysis of twenty-
three studies across chronic conditions to examine the predictive relationships between illness 
perceptions and adherence to medication, exercise, and diet recommendations in adults and 
adolescents. Findings showed that, although the illness perceptions of personal control, treatment 
control and coherence were found to be significant predictors, they only accounted for a small amount 
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of the variance in adherence outcomes, and effect sizes were very weak ranging from -.02 to .12. 
They also found variety in the illness perceptions that most strongly predicted adherence across 
studies. Such weak and inconsistent relationships were also found in a systematic review of fifteen 
studies by Law, Tolgyesi and Howard (2014) examining the relationship between illness perceptions 
and self-management in children and adults across conditions. Findings showed that, out of all beliefs, 
those relating to treatment control most consistently related to self-management. This led Law et al., 
(2014) to argue that this dimension should become the focus for research and the target for 
intervention. 
 
Summary 
Together, these findings show that illness beliefs relate to adherence behaviour in adult and 
paediatric populations, providing support for Leventhal’s self-regulatory model. However, it remains 
unclear whether this model applies to all treatments and illnesses, and where it does apply, which 
specific beliefs relate to adherence behaviour. It appears that this relationship largely differs between 
conditions and treatments, with only treatment control beliefs showing some consistency across 
conditions and/or treatments. Only one study has examined these relationships in CF, and although 
this study found timeline and treatment control beliefs to predict adherence behaviour to antibiotic 
treatments, it found no such relations for chest physiotherapy and enzyme supplements. The weak 
relationships between illness perceptions and adherence outcomes suggest that this model is not the 
most appropriate for understanding adherence behaviour. Such findings have led researchers to 
attempt to identify improved cognitive predictors. As hoped, stronger and more consistent 
relationships have arisen from examining treatment beliefs in such a manner, discussed next 
 
The Necessity-Concerns Framework 
In the late 1990s, the cure/control dimension of Leventhal’s self-regulatory model was 
extended, and the notion that beliefs about medications may be more potent predictors of adherence 
behaviour was developed (Horne, Cooper, Gellaitry, Date & Fisher, 2007). This model is known as 
the Necessity-Concerns Framework (Horne, Weinman & Hankins, 1999), and considers that primary 
common-sense evaluations people make about their medications fall into two categories. The first, 
necessity beliefs, refers to implicit judgements about personal need and benefits of the medication for 
current and future health (e.g. reduction of symptoms, improved quality of life). The second, concern 
beliefs, considers implicit views held about actual or potential adverse reactions or undesirable 
consequences of taking the medication (e.g. side-effects, disruption to daily life). The model proposes 
that the strength of these beliefs lies on a spectrum from low to high, and that their strength influences 
an individuals’ decision to adhere to treatment recommendations. Necessity beliefs are argued to 
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promote adherence, while, conversely, concern beliefs hinder it. It is also theorised that an implicit 
cost-to-benefit analysis occurs between these belief types, in which patients judge their personal need 
for treatment, relative to concerns they hold about potential adverse effects. Individuals with high 
necessity beliefs relative to concerns are predicted to be most likely to adhere, while those with 
stronger concerns than necessity beliefs, less so. 
The Beliefs about Medicines Questionnaire (BMQ) was developed as a generic measure to 
assess this model across conditions and treatments. It aims to provide direct quantification of 
commonly-held prescribed treatment beliefs, which are considered to fall into two categories: 
‘specific’ and ‘general’ (Horne et al., 1999). The ‘specific’ category captures beliefs about specific 
medications prescribed for an illness, and is examined through two subscales; necessity and concerns. 
The ‘general’ category considers more beliefs about medication as a whole, through two subscales; 
general harm, which captures an individual’s views on potential harm from medications, and over-
use, reflecting views on how medications are used. This review and thesis will only concentrate on 
this specific scale, which is assessed by the BMQ-Specific (BMQ-S) questionnaire. Its constituent 
items (questions / statements with which responders may indicate a  level of agreement/disagreement) 
were developed from the existing literature and interviews, and with six chronic illness groups 
(asthma, diabetes, renal, general medicine and psychiatric) to ensure that the developed questionnaire 
reflected a variety of disease and treatment characteristics.  
Within this original study, the two-factor structure of this the BMQ-S was identified through 
exploratory principle component analysis, and verified across the five illness groups by confirmatory 
factor analysis.  Subsequent evaluation of the psychometric properties of the BMQ-S was generally 
favourable, and included assessment of internal consistency, test-retest reliability, discriminant 
validity, criterion validity and predictive validity. Regarding internal consistency, almost all alpha 
values across the two subscales in each of the five diagnostic groups fell above 0.7, even with the 
small number of items in each subscale, leading the authors to conclude that it was adequate. 
Similarly, test-retest reliability was found to be acceptable for both necessity and concern subscales 
(r=0.77 and 0.76 respectively), although this was only examined in the asthmatic group. 
Discriminatory validity was examined through the ability of the BMQ-S subscale scores to distinguish 
between patients in different illness and treatment groupings, and findings showed that the measure 
was able to do so in accordance with predictions. Criterion validity was assessed through correlations 
with theoretically-related subscales from other illness and belief measures (including the IPQ), and 
was found to be lie in the predicted directions, and to be significant. Finally, expected correlations 
were obtained between BMQ-S scale scores and self-reported adherence to medication, and were 
found to be significant although weak in strength (necessity rs=0.19 and concerns -0.28). Overall, the 
authors conclude that the psychometric properties of the scale are encouraging, but also highlight how 
the scope of their evaluation of criterion validity and predictive validity were limited; the former due 
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to a paucity of existing validated measures, and the latter by only considering the outcome factor of 
adherence.  
Since then, the BMQ-S has been validated further in adult populations in a variety of chronic 
conditions, including rheumatoid arthritis (e.g. Neame & Hammond, 2005; Treharne, Lyons & Kitas, 
2004), hypertension (e.g. Ruppar, Dobbels & De Geest, 2012), diabetes (e.g. De Vries et al., 2014), 
CF (Bucks et al., 2008) and in mental health conditions (e.g. Cuevas, Rivero-Santana, Parestelo-
Parez, Gonzalez-Lorenzo, Perez-Ramos & Sanz, 2011), and has been successfully translated into 
several languages (e.g. Fall, Gauchet, Izaute, Horne, & Chakroun, 2014; Gatt, West, Calleja, Briffa & 
Cordina, 2017). However, the thoroughness of such psychometric evaluation in these chronic illnesses 
has been limited. Although some studies have examined internal consistency and the predictive 
validity of the BMQ-S measure to various outcomes (e.g. Treharne, Lyons & Kitas, 2004; Bucks et 
al., 2008), others have only examined the predictive validity of the measure (e.g. Neame & 
Hammond, 2005; Ruppar, Dobbels & De Geest, 2012; De Vries et al., 2014). This minimal evaluation 
is problematic, since it could be the case that that the properties of this measure, do not generalise 
across all chronic illnesses. 
The dynamic and self-regulatory nature of this model has also been increasingly shown 
through longitudinal studies, which have indicated that treatment beliefs and adherence behaviour 
change over time (e.g., Aikens, Nease, Nau, Klinkman & Schwenk, 2005; Horne, Cooper, Gellaitry, 
Date & Fisher, 2007; de Thurah, Norgaard, Harder, & Stengaard-Pedersen, 2010; Aikens & 
Klinkman, 2012). It is important to note that, although the BMQ-S was developed to represent a 
variety of chronic health conditions, it is relatively commonplace to tailor the questionnaire (i.e. 
modify wording, remove or add items) to allow idiosyncratic characteristics of the individual 
condition and medication(s) of interest to be captured. Without such adaptations, it is considered that 
key beliefs relevant to the specific condition of interest could be missed, and that certain items 
within the BMQ-S may simply not be applicable for certain treatments. Indeed, within Horne et al.’s 
(1999) original paper, during validation, they identified that the generated factor structure differed by 
one item in psychiatric conditions, and two items in diabetes. Since then, such observations have led 
to the development of several further condition-specific adapted BMQ-S measures, including the 
BMQ-AET-Specific for Adjuvant Endocrine therapy in cancer (Brett et al., 2018), and BMQ-
HAART-Specific for HIV and aids (Horne, Buick, Fisher, Leake, Cooper & Weinman, 2004).  
The psychometric properties of these adapted measures were examined. Of the two studies 
above, Brett et al. (2018) completed quite a thorough assessment, first examining the factor structure 
of the BMQ-AET-Specific through principal component analysis, and finding that their measure fitted 
the original two sub-scales model. They then examined several aspects of validity and reliability. 
They found the internal consistency of the adapted measure to be adequate for both necessity and 
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concern subscales (0.77 and 0.80 respectively) and, indeed, to reflect those found in Horne and 
Weinman’s (1999) original study. Regarding convergent validity, they found that relations between 
the subscales and self-reported adherence behaviour fell in the expected directions, albeit only 
significantly so for necessity beliefs. Finally, they reported acceptability of the measure to be good, 
which they assessed through the rate of missing data, floor and ceiling effects, and face validity, 
which was examined through a discussion with both clinicians and service users. Although for the 
BMQ-HAART-Specific Horne et al., (2004) also examined internal consistency and found this to be 
high for both necessity and concern beliefs (0.80 and 0.82), and also examined convergent validity 
through self-reported adherence and found this to be as expected, they did not complete further 
psychometric evaluation.  Various aspects of validity and reliability for this measure are therefore 
unknown, including whether the adapted items map onto the two-factor model of this measure and the 
strength of their loadings. This highlights the level of discrepancy between studies in such 
considerations.  
 
The Necessity-concerns framework and adherence  
Many studies using the BMQ (including adapted versions) in the adult population have 
supported the predictions of the Necessity-Concerns Framework by relating scores from the 
questionnaire to observed adherence behaviour. Such studies have been completed across a variety of 
healthcare settings, cultures, and chronic conditions, including asthma (e.g. Byer & Myers, 2000; 
Horne & Weinman, 2002; Menckeberg et al., 2008; Sofianou, et al., 2013; Foot et al., 2019), 
cardiovascular disease (e.g. Unni & Farris, 2011; Berglund, Lytsy & Westerling, 2013), mental illness 
(e.g. Russell & Kazantzis, 2008; Al Jumah, Hassali, Al Qhatani & El Tahir, 2014), HIV (e.g. Horne, 
Cooper, Gellaitry, Date, Fisher, 2007), diabetes (e.g. Aitkens & Piette, 2009), rheumatoid arthritis 
(e.g. Neame & Hammond, 2005), and cancer (e.g. Grunfeld, Hunter, Sikka & Mittal, 2005; Arriola  et 
al., 2014; Brett et al., 2018). Interestingly, the relationship between the types of items (necessity or 
concern) and adherence has been found to vary between studies, with some studies only finding 
necessity beliefs to significantly relate to adherence behaviour (e.g. Byer & Myers, 2000; Berglund, 
Lytsy & Westerling, 2013; Van Steenis et al., 2014; Brett et al., 2018), while others only concern 
beliefs (e.g. Neame & Hammond, 2005; Russell & Kazantzis, 2008; Al Jumah, et al., 2014), or a 
combination (Foot, La Caze, Baker, Cotrell, 2019). Importantly, some studies have shown that the 
difference between necessity and concern belief subscales has a stronger relationship to adherence 
than the strength of either necessity or concern beliefs alone (e.g. Horne, Weinman & Hankins, 1999; 
Emilsson et al., 2011; Iudici, Russo, Mitidieri, Cuomo & Valentini, 2014). This calculation is known 
as the necessity-concerns differential, and accounts for the implicit cost-benefit analysis described in 
the Necessity-Concerns Framework.  
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Recently, two meta-analyses were completed to examine the explanatory value of this 
framework on a population level for predicting medication adherence in adults with long-term 
conditions. The first, by Horne, Chapman, Pargam, Freemantle, Forbes & Cooper (2013), examined 
ninety-four studies and found aggregate effect sizes to be moderately strong for both necessity 
(OR=1.74) and concern (OR=.50) beliefs. This effect stayed stable when data was stratified by 
condition, study design, sample size, adherence measurement method and country of origin. Overall, 
they conclude that this model is a potentially useful means to understand patients’ evaluations of their 
prescribed medicines. However, in post-hoc analysis, they did not explicitly compare the differences 
in effect sizes between health conditions, and they only examined relationships in isolation (i.e. how 
necessity beliefs and concern beliefs separately related to adherence behaviour), despite recent studies 
increasingly considering how patients “weigh up” these beliefs by computing the necessity-concerns 
differential. 
Foot, La Caze and Cottrell (2016) completed a second meta-analysis of ninety-four studies to 
overcome the former’s limitations. Overall, on a population level, they found significant effects for 
necessity, concerns, and the differential, although these were all relatively weak, at 0.17, -0.18 and 
0.24 respectively. Importantly, although these effects were present across almost all conditions, 
stratification by health condition revealed that the effect sizes for two of the conditions were very 
different from the aggregated results. A stronger overall effect size between necessity beliefs and 
medication adherence was found for asthma (r=0.33), while a very weak effect size was found for 
cardiovascular disease (r=0.07). Further analysis revealed that the asthma group’s necessity beliefs 
were the most important correlate for adherence behaviour, regardless of concerns, while for the 
cardiovascular group, the opposite was true. From these findings, the authors argue that the relative 
importance of the belief scales in the Necessity-Concerns Framework, and their relation to adherence 
behaviour, is likely to vary between conditions, depending on the unique and varied symptoms, 
treatments and outcomes of different illnesses. They also argue that the necessity-concerns differential 
should be examined more in research studies, as it shows promising results, and allows the cost-
benefit assumption of this model to be tested. 
Overall, these findings suggest that both subscales, as well as the necessity-concerns 
differential, need to be examined separately for each illness and treatment. Ultimately, such 
understanding would allow interventions to be developed that appropriately target the beliefs 
that influence adherence in specific conditions and treatments. Both studies raised the need for future 
studies to employ objective measurement to overcome the limitation of subjective methods. 
Although Horne et al. (2013) did not find a difference in effect sizes between beliefs and adherence 
data collected through objective or subjective measures, Foot et al. (2016) found that concern beliefs 
had a lower mean effect size when assessed with objective adherence data. It is also important to note 
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that neither of these meta-analyses included the illness of CF, and that both were completed in adult 
populations alone. 
Increasingly, the BMQ measure has been used in paediatric populations, and has been 
validated with parents and children of 7 years and above, allowing it to be completed by both patient 
and/or parents. These studies have reported findings supporting the predictions of the Necessity-
Concerns Framework across conditions including CF (Bucks et al., 2009; Goodfellow et al., 2015), 
asthma (e.g. Conn, Halterman, Lynch & Cabana, 2007; Klok, Kaptein, Duiverman & Brand, 2012; 
Koster, Philbert, Winters & Bouvy, 2015; Sonney et al., 2017; Kosse et al., 2019), ADHD (e.g. 
Emilsson, Gustafsson, Öhnström & Marteinsdottir, 2017), haemophilia (e.g. van Os, Troop, Sullivan 
& Hart, 2017) and heart failure (e.g. Wray, Waters, Radley-Smith & Sensky, 2006). Like for the adult 
population, relationships between the subscales to adherence have been found to vary between 
studies; some report only necessity beliefs to significantly relate to adherence (Klok et al., 2012; 
Koster et al., 2015), while others studies only concerns (Wray, Waters, Radley-Smith & Sensky, 
2006; Conn, et al., 2007), or only the necessity-concerns differential (Emilsson et al., 2017; Sonney et 
al., 2017), and yet others, a combination of these factors (van Os, Troop et al., 2017; Kosse et al., 
2019). Interestingly, some studies have examined both patients' and parents’ beliefs, as they recognise 
that the responsibility for medication management is often shared between children, particularly at 
school-age, and their parents (e.g. Yilmaz, Eroglu, Ozalp & Yuksel, 2012; Goodfellow et al., 2015; 
Sonney et al., 2017; Koppen et al., 2018). Such studies allow comparison of predictive validity 
between beliefs and adherence between parents and their children, and/or examination of the level of 
interdependence between parents' and children's treatment beliefs. In the next section, the paediatric 
studies which have considered CF specifically will be considered in further detail. 
Importantly, although the relationships between medication-related beliefs and adherence 
behaviour are, on average, classified as weak-to-moderate, studies in this field have highlighted the 
superiority of this relationship over socio-demographic (education, gender, age), clinical variables 
(illness severity, number of medications) and other beliefs (e.g. illness perceptions) (Horne & 
Weinman, 2002; DiMatteo  2004; DiMatteo, Haskard & Williams, 2007). Treatment-related beliefs 
have even been found to mediate relationships between adherence and other demographic factors, 
including age (Bucks et al., 2009), gender (Ross, Walker & MacLeod, 2004), minority status (Tao et 
al., 2008), depression (Hilliard et al., 2015), health literacy (Federman et al., 2013), personality traits 
(Axelsson, Cliffordson, Lundbäck & Lötvall, 2013), medication burden (Phatak & Thomas, 2006), 
and even illness perceptions (Horne & Weinman, 2002).  
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Adaptations of the BMQ-S measure 
As described, despite being intended as a generic measure, the BMQ-S has been adapted to 
individual treatments and conditions, in the hope of improving its psychometric properties. Several of 
the studies presented above, in both adult and paediatric populations, have tailored the wording and 
content of the BMQ-S with the aim of more effectively capturing beliefs that influence adherence 
behaviour. These modifications include minor revisions to the wording of existing items, removals of 
existing items and/or illness-specific additions. Without these adaptations, it is considered that certain 
unusual characteristics of the illness and treatment of interest could render items in BMQ-S irrelevant, 
and/or lead beliefs idiosyncratic to a particular illness and treatment to be missed entirely. Ultimately, 
this would reduce the utility of the BMQ-S, falsely reduce the predictive validity of the Necessity-
Concerns Framework and in turn the foundation for developing interventions based on this 
model. Within this literature, great variability exists in the rigour of such adaptations. However, 
despite this, modified questionnaires have been found to generally have acceptable psychometric 
properties (i.e. internal consistency and construct validity). This lack of methodological rigour may 
nonetheless be limiting the development of such questionnaires, and, in turn, assessment of this 
model. 
In several studies, details regarding the rationale and/or process of creating refined BMQ-S 
measures are minimal or simply omitted. For instance, some authors simply state which items were 
removed or added, but do not elaborate on the justification for these decisions (Bucks et al., 2009; 
Goodfellow et al., 2009), while others simply present the process for creating such changes as ‘a 
discussion’ (Bucks et al., 2009; Brett et al., 2018), or omit details of the procedure entirely and just 
state the changes made (Horne et al., 2004; Goodfellow et al., 2009). Also, where further details have 
been provided regarding the process of adaptation, methodological limitations have been noted. For 
instance, some studies have primarily relied on the knowledge of the research team alone to make 
modifications (Goodfellow et al., 2009), which existing research in questionnaire development 
suggests is likely to reduce the heterogeneity of opinion, and thereby the validity of the measure 
(Hardy et al., 2004). Also, none of the above studies provided an explanation for how, during said 
‘discussions’, agreement was met on the changes to be made, and it is has been suggested within 
wider literature that without provision of a systematic agreement process, group dynamics may 
adversely impact such decision making processes (Rowe & Wright, 1999).  
Perhaps more important than a less-than-ideal modification process, is the realisation that no 
study identified within this review appears to have directly assessed the superiority of such 
adaptations for predictive validity against the original measure. Instead, it appears that improved 
psychometric properties are simply assumed. Although validity and reliability assessments are often 
completed with these adapted measures as reported above, they are not, on the whole, compared to the 
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original measure for the same treatment in the same population. Overall, this lack of comparison 
appears to be a significant oversight. 
 
Summary 
Overall, although such findings provide support for the predictions of the Necessity-Concerns 
Framework, they suggest that the observed relationships are only of a weak-to-moderate strength. 
However, when these effects are examined alongside other correlates, they become a relatively strong 
predictor of adherence behaviour, and even a mediator for other correlates. Importantly, it appears 
that the strength of correlations between medication belief subscales and adherence behaviour does 
vary between conditions and treatments, suggesting that such beliefs may be of more importance to 
some conditions and treatments than others. Also, while the rationale for adapting the BMQ-S seems 
logical, the process of adapting the BMQ-S to treatments of interest across health conditions is often 
not well described or systematic within existing adherence literature,  with some studies seemingly 
relying on the research team's knowledge alone, and/or simply describing the process as a 'discussion', 
if it is described at all. Crucially, the superiority of such adaptations compared to the original measure 
has not been directly assessed in most studies, just assumed. Ultimately, these oversights may be 
limiting assessment of the Necessity-Concerns Framework if these adapted questionnaires assess 
beliefs which are, in fact, less strongly related to adherence than those elicited in the original 
questionnaire. These assumptions could present a major unexplored methodological issue in this 
research area. 
The existing research examining relations between medication beliefs and adherence in CF 
will now be considered in detail, in order to explore how such beliefs relate to adherence in this 
illness across different treatments. Alongside this, it will also be highlighted if, and how, the authors 
adapted the BMQ-S for this illness group and the treatments of interest, and the validation process 
they completed. 
 
The necessity concerns framework and adherence in Cystic fibrosis 
Bucks et al. (2009) examined the relationship between treatment beliefs, illness perceptions 
and emotional representations to self-reported adherence across three treatments – antibiotic 
medications, enzyme supplements and chest physiotherapy – in adolescents with CF (N=38, aged 11-
17 years). The authors created modified versions of the BMQ-S for each treatment, and similarly 
modified the IPQ-R. These revisions sought to improve the pertinency of questions to CF, and/or 
specific CF treatments. They named the revised BMQ questionnaires the Belief about Treatment 
Questionnaires (BTQ). Alterations included the rewording, addition and replacement of certain 
questionnaire items. In the enzyme and antibiotics concern subscales, one item was added: ‘My 
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enzymes/antibiotics give me unpleasant side-effects’, and for chest  physiotherapy, two items: ‘I 
sometimes worry about the long-term effects of my treatment’ and ‘I sometimes worry about becoming 
too dependent on my treatment’, were substituted for: ‘My CPT is a hassle’ and ‘My CPT is difficult 
because I need help from others to do it properly’. The internal reliability of these measures was 
assessed, but was found to be poor for the concern subscales of the antibiotic and physiotherapy 
questionnaires (Cronbach’s alpha = 0.55), so the authors chose not to examine the relationships 
between these subscales and adherence behaviour. 
Findings showed that stronger necessity beliefs related to higher self-reported adherence for 
antibiotic medications (r = 0.38) and chest physiotherapy (r = 0.71), while increasing age related to 
poorer adherence to both treatments.  Interestingly, a hierarchical multiple linear regression analysis 
revealed that, for chest physiotherapy, necessity beliefs appeared to mediate the relationship between 
age and adherence. Together, these findings support the utility of the necessity-concerns framework in 
understanding treatment adherence in adolescents with CF. They also highlight how relationships 
between age and adherence may be underpinned by differences in treatment-related beliefs between 
younger and older adolescents. However, it is important to note that this framework did not relate to 
adherence behaviour for enzyme supplements, supporting the notion that such beliefs may have 
higher pertinence to certain treatments over others, even within the same illness. 
This study, however, had several limitations, including reliance on self-report (which is 
known to be unreliable), and inadequate concern subscales for antibiotic and physiotherapy 
treatments, which prevented consideration of relationships between these scales and adherence. The 
authors therefore highlight the importance of using objective measurement methods in future studies 
and of developing these subscales to ensure that they are relevant and useful to specific treatments. It 
is also noteworthy that the process through which these questionnaires were developed was simply 
referred to as “a discussion with the paediatric team”, that the study did not consider parents’ beliefs, 
and did not differentiate between antibiotic treatments administered through very different methods 
(i.e. oral vs. nebulised). 
Goodfellow et al. (2015) examined the influence of treatment beliefs and parental depression 
on adherence to chest physiotherapy, enzyme supplements and vitamins in adolescents (N=100, aged 
0-18 years). This study partially responded to the limitations highlighted above by: i) examining 
adherence through several methods (self-report, medication records, pharmacy prescription refill data 
and GP prescription issue data); ii) exploring both parents’ and patients’ beliefs; iii) further refining 
the medication belief questionnaires. These modifications were made after consulting the author of 
the BMQ-Specific, and included three additions to the  chest physiotherapy concerns scale: ‘I/My 
child finds chest physiotherapy tiring’, ‘I/My child finds it embarrassing to carry out chest 
physiotherapy’, ‘Chest physiotherapy makes me/my child feel worse’, and one concern item to all 
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treatments: ‘This treatment gives me/my child unpleasant side effects’. Internal reliability was 
adequate across subscales, questionnaires and respondents.  
 Findings showed that weaker parental necessity beliefs, and increasing child age, were both 
significant predictors of non-adherence to enzyme supplements (OR: 0.79, 1.05) and chest 
physiotherapy (OR: 0.82, 1.05), while no significant predictors were found for vitamins. They also 
showed that the strength of beliefs held about treatments varied across treatments and respondents. 
While concern beliefs were low across all treatments, necessity beliefs were only high for enzymes 
and physiotherapy, and parents were found to have significantly stronger necessity beliefs than their 
children across all three treatments, and significantly stronger concerns about chest physiotherapy.  
Together, these findings suggest that parents’ beliefs can predict their child’s adherence 
behaviour, and that parents’ necessity beliefs are more pertinent to adherence behaviour for enzyme 
supplements and chest physiotherapy, than their concerns. For vitamin supplements neither of these 
beliefs offered a means to predict adherence behaviour. Therefore, these findings also support the 
notion that the Necessity-Concerns Framework does not apply equally across treatments, and that the 
belief subscales are not equally important within treatments. They also highlight how the strength of 
beliefs appear to differ by treatment and respondent (i.e. patient or parent). However, the findings of 
this study are, like most research in this field, limited by a lack of genuinely objective measurement. 
An unpublished feasibility study by Maclean, Duff, Ball, Bowmer and Masterson (2015) 
responded to this problem of subjective adherence measurement when examining the influence of 
medication beliefs on adherence to nebulised medications (antibiotic and mucolytic) in children and 
adolescents with CF (N=18, aged 9-16). They used I-nebuliser technology to measure adherence, 
which, as previously described, is considered a ‘gold standard’ measure in terms of objectivity, and 
collected data retrospectively over an 8-week period. Medication beliefs were examined through the 
antibiotic-specific version of the Beliefs about Treatment Questionnaire, as developed by Bucks et al. 
(2009). Patients’ or parents’ beliefs were elicited with this measure, with parents completing a parent 
version of the measure for patients aged under 12 years (N=6).  
Findings showed that concern beliefs alone significantly related to adherence, with 
participants who reported higher concerns having poorer adherence than those who expressed fewer 
concerns. Importantly, the results showed an interesting trend; participants with concern scores of >3 
had adherence rates of <70%, while adherence rates of those with concerns score of <3 were >80%. 
These findings therefore suggest that concern beliefs could be the most important factor in predicting 
adherence behaviour to nebulised medications. The authors also highlight the clinical utility of the 
findings as a potential cut-off point to enable clinicians to quickly identify and respond to patients at 
risk of poor adherence from high concern beliefs, thereby allowing the BMQ-S to function as a 
screening measure. 
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However, several limitations exist in this study. The internal consistency of the BTQ measure 
was not assessed, which is problematic since the concern subscale of this measure was found to have 
inadequate internal consistency in Bucks et al.’s (2009) study, and it was not designed for mucolytic 
medications. Only 18 participants completed this study (12 patients and 6 parents), limiting the 
generalisability of its findings. Also, as only one BTQ was completed per patient-parent pair, 
differences between respondents could not be examined, and in its analysis, this study combined these 
reports, which is problematic as authors studies such as Goodfellow et al. (2015) suggest that beliefs 
are likely to differ between respondents. This study also combined all nebulised treatments into one 
category, rather than considering the different nebulised medications separately for the purposes of 
beliefs and adherence. Such a lack of differentiation is a significant limitation, when one considers the 
body of research showing that beliefs are likely to differ by treatment, as previously highlighted in 
this review. Finally, this study like much of the research in this field only examined adherence data 
retrospectively, so the predictive utility of the proposed cut-off for future adherence behaviour is 
unknown. 
 
Summary  
The chronic health research findings suggest that the Necessity-Concerns Framework is a 
useful model to understand adherence behaviour, and the BMQ-Specific an effective tool to elicit 
beliefs pertinent to this model, in patients and their parents. 
Importantly, it appears that the importance of the two dimensions - necessity and concerns, 
both when assessed separately and in terms of the relative difference between them, can differ 
between therapies, even within the same medical condition. Interestingly, it also appears that, in the 
paediatric population, parents’ medication beliefs are also a predictor of their children’s adherence 
behaviour. However, these relationships remain acutely under-researched within CF, and especially 
within nebulised treatments, despite I-nebulisers’ unique potential to allow purely objective 
measurement, thereby overcoming the major methodological limitation in existing adherence 
research.  
As discussed, the existing research which does focus on nebulised medication adherence 
suffers from several methodological flaws. Bucks et al. (2009) combined data for orally-delivered and 
nebulised antibiotics, and used self-report adherence measures, and their revision of the BMQ for 
antibiotic medications was found to have inadequate internal consistency on the concerns subscale. 
While an unpublished feasibility study by Maclean et al. (2015) did examine the necessity-concerns 
framework in relation to nebulised treatments specifically, and objectively recorded adherence data, it 
used the measure that Bucks et al. (2009) had reported as having poor reliability and combined 
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analysis across nebulised medications and respondents. This study also suffered from general 
limitations, including a limited sample (N=18), reducing its validity and generalisability. 
 
Overall summary and rationale for the project 
Healthcare provision can only create optimal outcomes if treatments are completed. However, 
sub-optimal adherence is common across chronic conditions, particularly in adolescents and 
preventative therapies. Poor adherence has subsequently been positioned as the largest barrier to 
treatment success, and as a public health concern. To address this problem, research has sought to 
identify factors which influence this behaviour, and to create models of these factors in order to 
understand and improve adherence. 
Increasingly, patients’ beliefs about their illness and medications have been identified as 
factors that relate to adherence behaviour across chronic conditions, an observation which has led to 
the development of various models, including the Necessity-Concerns Framework of treatment 
beliefs. This framework has proved to be a particularly promising avenue in understanding adherence, 
with its predictions offering greater explanatory power than similar models. 
 Within CF, whilst most current research identifies practical barriers such as time constraints 
and forgetfulness, psychological barriers such as illness and treatment beliefs have increasingly been 
included in such assessment. Indeed, such research has led several authors to suggest that beliefs may 
be the underlying cause of more commonly referenced practical barriers. However, research 
examining such beliefs, and in particular the Necessity-Concerns Framework, is almost absent in the 
CF population, including within the paediatric population, despite adherence within CF rapidly 
declining during adolescence. Adherence to nebulised medications is often reported to be particularly 
problematic in this group, and the underlying factors appear acutely under-researched. This paucity of 
research is concerning when considering the primary role of such treatments in preventing lung 
infections, one of the key causes of morbidity and mortality in CF. It is also surprising when one takes 
into account the unique position that I-nebulisers, with their objective adherence recording, afford in 
overcoming the largest methodological barrier in adherence research: inaccurate self-report data. No 
other chronic condition or treatment has a purely objective measure available through which to record 
adherence behaviour. 
Three studies have examined the influence of medication-related beliefs on adherence to 
treatments in the paediatric CF population using the Necessity-Concerns Framework (Bucks et al., 
2009; Maclean et al., 2015, Goodfellow et al., 2015), and all supported the potential clinical utility of 
this framework. However, only the former two studies considered this model in relation to nebulised 
medications, and each suffered from several limitations. Most notably, the study by Bucks et al. 
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(2009) relied on self-report data, and conflated orally-delivered and nebulised antibiotics, rather than 
considering each in isolation. Maclean et al. (2015), while considering only nebulised medications, 
similarly conflated two separate treatments by examining nebulised antibiotics and mucolytics 
together. Also, the belief measure used in both studies was found by Bucks et al. (2009) to have 
inadequate reliability on the concern scale for antibiotic medications. As such, the BMQ-Specific has 
never been specifically tailored to nebulised medications in CF. More generally, within the wider 
literature, it is interesting to note that the rationale and processes for adapting the BMQ-Specific to 
specific treatments is often poorly described. For instance, Bucks et al. (2009) simply referred to this 
process as a “discussion with the research team”, a level of detail which appears commonplace. The 
lack of a comprehensive process to adapt such measures is concerning, considering the relatively 
common nature of such practice, and since the psychometric properties of the developed measure 
depend on appropriate adaptation. Indeed, inadequate adaptation of this measure would in turn, 
adversely impact assessment of the Necessity Concern Framework. 
Overall, there is a clear rationale for the necessity and value of research which can address the 
methodological limitations highlighted above, namely the lack of objective measurement and 
inadequate refinement of the existing BMQ-Specific measure to assess necessity and concern beliefs 
for both nebulised medication treatments (i.e. antibiotics and mucolytics, separately) in CF. 
 
Introducing the studies 
The proposed studies will replicate and extend the research reviewed above. Study one will, 
similarly to previous research, modify the BMQ-Specific to create versions specifically adapted to the 
treatment(s) of interest. Unlike much of this research, however, this study will undertake this 
refinement through an explicit and systematic process, and will create separate revised BMQ-Specific 
questionnaires for both categories of nebulised treatments in CF (mucolytics and antibiotics); thereby 
enabling this study to determine whether necessity and concern beliefs differ between these 
medication categories and if they relate to adherence differently. This decision was made and 
considered important for three reasons. First, the BMQ-Specific was created to be applied 
to individual treatments, not categories of treatment delivery. Secondly, the properties and purposes of 
these nebulised medication categories typically differ, including by their nature of action 
(prophylactic vs. symptomatic) and burden level (life-long vs. time-limited), which is very likely to 
lead to the development of different treatment beliefs. Thirdly, as highlighted above research has 
shown that the relations between treatments and adherence behaviour can change, even within the 
same illness, so amalgamation of these effects would obscure such differences. 
A two-part process will be used to increase the rigour of these adaptations. First, the research 
and supervisory team will refine the original questionnaire to each medication category, using the 
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current literature and their clinical experience, to create initial draft versions. Second, a Delphi survey 
will be used to gain opinions from an expert group on the value and clarity of items in these 
questionnaires, as well as any recommendations for new items. These questionnaires will be named 
the CF-BMQ-Specifics and will consist of an antibiotic and mucolytic version. A second version of 
each questionnaire will also be created for completion by parents, to allow their medication beliefs to 
be examined, and the relationships between these and their child’s adherence behaviour. 
Study two will examine relations between nebulised medication beliefs and adherence 
behaviour to assess the predictive validity of the Necessity-Concerns Framework for these treatments, 
similarly to previous research reviewed above. Patients and their parents will be asked to complete a 
BMQ-S and CF-BMQ-S for each category of nebulised medication that the patient takes through an I-
nebuliser device. This will allow examination of the relationship between necessity and concern 
beliefs, as assessed by the patient and parent versions of the BMQ-S and CF-BMQ-S, to objectively 
recorded adherence behaviour. This study will compare findings between the revised and original 
BMQ measures, between the categories of nebulised medications, and between patient and parent 
beliefs, comparisons which have not previously been explored for nebulised medications. Importantly, 
no other study using the BMQ-Specific, even outside of nebulised medications and CF, is known to 
have examined compared predictive validity between the original and revised measures. 
Acquisition of ‘gold-standard’ objective adherence data in this study through the I-nebuliser 
will build upon previous studies, by responding to the main methodological difficulty faced by 
adherence studies generally. The use of prospective adherence data will allow the predictive validity 
of the developed questionnaires for future behaviour to be determined, unlike previous research which 
has relied on retrospective data. Like previous CF research, this study will explore the relationship 
between illness perceptions and adherence data, but through the B-IPQ rather than IPQ-R, and this 
relationship will be examined separately for patients and parents, which has not been completed 
before in CF. In turn, this will allow consideration of the strength of these relationships to adherence 
behaviour, compared with the BMQ-S. Finally, participants’ sociodemographic and clinical properties 
will be recorded to allow adherence and belief data to be considered in relation to these factors. 
This project therefore contains several novel elements which will extend the existing body of 
research which evaluates the utility of the Necessity-Concerns Framework in this patient group, and 
has the potential to inform both clinical and future research practice. 
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Research aims and hypotheses 
Primary research aims  
Study one: 
1. To use a systematic process to create versions of the BMQ-Specific tailored to nebulised 
mucolytic and antibiotic nebulised medications in CF.  
Study two: 
1. To assess the utility of the Necessity Concerns Framework, assessed by the BMQ-S and CF-
BMQ-S, to predict adherence behaviour to both categories of nebulised medications in 
adolescents with CF. 
 
Secondary research aims  
1. To examine whether adherence behaviour is influenced by medication type, 
sociodemographic and health factors. 
2. To assess if medication beliefs differ between the two categories of nebulised medications 
(antibiotics or mucolytics) or by respondent (patient or parent). 
3. To explore if illness perceptions differ by respondent, and if they relate to nebulised 
medication adherence in adolescents with CF. 
 
Study hypotheses 
 Based on the primary aims of study two this project has three specific hypotheses in 
accordance with the predictions of the necessity-concerns framework. 
1. Stronger necessity beliefs held by patients and parents will result in increased treatment 
adherence. 
2. Stronger concern beliefs held by patients and parents will result in reduced treatment 
adherence. 
3. Patients and parents with higher necessity and lower concern beliefs will have higher 
treatment adherence, than those with low necessity beliefs and high concern beliefs. 
The first study within this two-part project will now be presented, with the method, results 
and discussion sections presented in turn. Following this, the same sections will also be described for 
the second study. Finally, a combined discussion will be presented which considers both studies 
together, and examines their clinical and research implications. 
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Chapter 2: Study One Method  
Adapting the BMQ-Specific to nebulised medication categories 
 
The CF-BMQ-Specific questionnaires were developed in two stages. The first stage involved 
the research team tailoring the existing BMQ-Specific separately to nebulised antibiotic and 
mucolytic medications, creating two adapted questionnaires: the CF-BMQ for Antibiotics (CF-BMQ-
A) and the CF-BMQ for Mucolytics (CF-BMQ-M). The second stage evaluated and further refined 
these questionnaires using a two-stage Delphi survey. 
 
Design 
Initial development of the CF-BMQ-Specifics  
To support initial adaptation of the BMQ-Specific for nebulised antibiotic and mucolytic 
medications, two sources of information were used. First, the qualified clinicians in the supervisory 
team used their clinical experience to evaluate the content and wording of the original BMQ-Specific 
for use with nebulised mucolytic and antibiotic medications in CF. Two are clinical psychologists 
with over 20 years of experience working in CF, and the other clinician is a physiotherapist with over 
10 years of experience. These discussions led to items being modified, removed, or added based on 
complete agreement. Second, literature relating to adapting the BMQ-Specific to other treatments was 
examined, alongside research identifying necessity and concern beliefs in CF treatments. This process 
resulted in a list of potential items for inclusion in the two new CF-BMQ-Specifics. The supervisory 
team then rated these items for inclusion in the questionnaires on a 3-point Likert scale, ranging from 
‘Very useful’ to ‘Not useful’. Only items that were considered ‘Very useful’ by all were included in 
the initial item set. Lastly, the team developed two variants for parents: the CF-BMQ-Specific-
Antibiotic-Parent and CF-BMQ-Specific-Mucolytic-Parent. The subject of each of each item in the 
newly-developed questionnaires was simply modified for completion with parents (i.e. 'your child' 
instead of 'you').  
 
Refinement and evaluation of the CF-BMQ-Specifics  
The resulting CF-BMQ-Specific measures were then subject to further refinement from a 
larger number of clinicians with expertise in this field – physiotherapists in CF teams. The aim was to 
use a Delphi survey to evaluate and further refine the CF-BMQ-A and CF-BMQ-M, and to obtain 
consensus on the final item set for each questionnaire. The Delphi method is a structured process for 
collecting and organising judgements from a group of experts (Norcross, Pfund & Prochaska, 2013). 
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Although some authors within the research literature refer to Delphi as a methodology (Jairath and 
Weinstein, 1994; McKenna, 1994, Hasson et al., 2000), a variety of terms are used to describe it, the 
most notable of which include: ‘process’, ‘approach’, ‘survey’ and ‘technique’ (Suckley, 2012). These 
terms will also be used interchangeably here.  
 
Delphi technique overview and application  
The Delphi technique was developed by an intelligence think-tank named the RAND 
corporation in the 1950s, with the aim of developing a method that would provide an objective and 
reliable means of gaining consensus from expert groups for complex issues (McMillan, King, Tully, 
2016). It was based on the premise that, and findings showing, that group decisions are more reliable 
than decisions made individually (e.g. Kaplan, Skogstad & Girshick, 1950). To accomplish this, this 
method structures group communication in a manner which aims to maximise helpful aspects of 
discussion and interaction (e.g. shared and developed knowledge and ideas), while minimising 
unhelpful group attributes (e.g. personal conflicts, unequal participation) (Rowe & Wright, 1999). 
This technique is often applied to support problem-solving and idea-generation, and its strength lies in 
its ability to facilitate decision-making through consensus where research evidence is inconclusive, or 
even absent (Mirtoff & Turoff, 2002).  
The success of this method is clearly shown through its diverse applications across industries 
(McMillan, King, Tully, 2016). While early Delphi studies were limited to use in short- and long-
range forecasting of future events, they are currently used within a variety of applications. Within 
healthcare research, this approach has been used to: identify research priorities (e.g. Ramelet & Gill, 
2012), develop health quality indicators (e.g. Uphoff et al., 2012), clinical guidelines (e.g. Conway et 
al., 2013), education assessment tools (e.g. Sowter et al., 2011), as well as item generation for 
questionnaires (e.g. Eigenmann, Skinner & Colagiuri, 2011; Ski et al., 2019). The Delphi method 
therefore seemed like a natural fit for this study’s research aim, i.e. the development and validation of 
the CF-BMQ-Specifics, especially considering the scarcity of research identifying necessity and 
concern beliefs in nebulised medications within CF. 
 
Key features of the Delphi method  
The Delphi method comprises four main features: i) anonymity, ii) iteration, iii) controlled 
feedback, and iv) statistical aggregation of group response. These features will now be described by 
considering the classic procedure of a Delphi survey. Delphi surveys are completed over several 
stages, which are referred to as rounds. Traditionally, the first round of a Delphi survey presents an 
open-ended questionnaire, which aims to identify pertinent issues for further exploration. After 
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completion of this round, panel members' responses are collated and analysed in order to develop a 
structured questionnaire (Rowe & Wright, 1999). In subsequent rounds, this questionnaire is 
presented, and panel members are asked to evaluate it. Typically, such evaluation is completed 
quantitively, with participants ranking each item individually (Jones & Hunter, 2000). Between each 
of these rounds, participants' responses are analysed, and each individual is normally presented with a 
statistical summary of the data. This summary allows panel members to consider their own responses 
and views in relation to group trends, and in the next round they have the option of retaining or 
altering their ratings in light of this. This process of iteration i.e. presenting questionnaires for 
evaluation, followed by anonymous group feedback, can allow convergence of opinion, or continued 
disagreement, and continues until predetermined stop-criteria are met, such as a set number of rounds, 
or level of stability in panel member responses (i.e. more than 70% of panel members consider an 
item useful (Rowe & Wright, 1999). Regardless of the criteria set, it is considered important to gain 
the balance between result accuracy and participant fatigue (Rowe & Wright, 1999).  
 
Methodological considerations  
  In practice, over the years, the Delphi method has been implemented in a multitude of ways 
depending on several factors, including the research question and resources. Indeed, Hanson and 
Keeney (2011) lists over 10 variations of this technique, including classical, modified, decision, 
policy, real time, e-Delphi, technological, online, argument and disaggregative. Currently, no 
standardised definition of a Delphi survey exists, and no standardised guidelines exist for how it is 
conducted, including the meaning and measurement of consensus, and the criteria for defining an 
expert (Hasson & Keeney, 2011). Within the literature, the methodological rigour of different 
approaches is strongly debated, with attempts to establish guidelines remaining inconclusive, and 
strongly criticised (e.g. Rowe, Wright, & Bolger, 1991, Hasson & Keeney, 2011). Ultimately, it 
seems that while this technique can be applied flexibly, and guided by the research question and the 
situation, it remains important to consider methodological factors and to explicitly describe how this 
process is implemented, so that the study’s rigour can be considered. A pragmatic stance was taken in 
applying the Delphi technique within this study. 
 
Application of the Delphi method in this study 
The Delphi method employed in this study differed from the classic design in several ways. 
Firstly, the initial round presented pre-existing, structured questionnaires for evaluation, rather than an 
unstructured list of items. An unstructured first round was not required in this study since it aimed to 
gain opinion on and refine an existing questionnaire, rather than generate a new one. This difference 
also partly underpinned the decision to complete the survey in just two rounds, alongside the fact that 
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the existing questionnaires had already been adapted by the supervisory team, as highlighted above. It 
was considered that panel members' evaluations would not significantly differ from the research team, 
and that an increased number of rounds would unnecessarily increase participant burden. This 
decision is in line with recommendations which suggest that a two-round survey is sufficient where a 
clear base exists and the survey simply aims to examine the temperature of opinion on a topic (Petry, 
Maes & Vlaskamp, 2007). Practical advantages of this two-round format include a reduced timescale, 
and lowered attrition rates (Cantrill, Sibbald, & Buetow, 1996). This is important since attrition rates 
in the Delphi method tend to be high, due to the relatively long-term commitment it can require, and 
potential distractions between rounds (Donohue & Needham, 2009). Such considerations were 
especially important in this study due to the time restrictions imposed on the project and the low 
target sample size.  
Individualised or general statistical summaries were also not provided between the rounds in 
this survey; instead, feedback was provided by updating the second-round questionnaires in response 
to first-round feedback (i.e. majority opinion and clinician comments). This decision, too, was made 
for practical reasons; as already discussed, it was expected that participants' responses would be 
generally favourable, with little disparity between respondents. It was also considered that requiring 
busy NHS clinicians to examine both statistical and qualitative summaries for each item in the two 
questionnaires across both rounds would likely reduce participation and increase attrition rates. 
Therefore, in this instance, the advantage of asking practicing NHS clinicians to consider summaries 
between rounds was considered less clear. Finally, a mixed method approach was used to allow 
participants to also comment on individual items and suggest new items for consideration. It was 
considered that a purely quantitative approach would have reduced participants’ role in shaping the 
questionnaires, as they would have been unable to provide comments which explained their ratings 
for individual items, and suggestions for improvements or additions. Equally, a purely qualitative 
approach using analyses, such as interpretative phenomenological analysis or grounded theory, would 
have been inappropriate, as such methods would seek to understand the personal meanings of items to 
participants, which was not the aim of this study. 
Regarding methods of delivery, the Delphi method has traditionally been paper-based. In 
recent years, however, this method has increasingly been delivered electronically (Young & 
Jamieson, 2001). Importantly, although research has shown that no difference exists in the quality of 
data collected between paper and electronic means (e.g. Geist, 2010), research is less clear regarding 
response rates. While some studies find reduced response rates for electronically-presented Delphi 
methods compared to mail or telephone (Fan & Yan, 2010), others report high and sustained response 
rates for electronic methods (Gill, Leslie, Grech & Latour, 2014). Considering such findings, 
alongside an appreciation of enhancing convenience for busy NHS clinicians, the decision was made 
to deliver this survey electronically through a web-based software tool named ‘Online Surveys’. This 
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software was selected as it is user-friendly, is supported by varied web browsers, and employs robust 
data-protection measures. 
 
Alternative approaches  
Other consensus methods were considered, the most notable of which is the nominal group 
technique (NGT; Delbecq & Van de Ven, 1971). It takes the form of a structured face-to-face meeting 
between experts and is typically completed in several stages. Initially, participants are requested to 
submit ideas independently and anonymously on paper. These ideas are then collated, and the group 
considers each in turn and ranks them. This process is supported by a facilitator who seeks to ensure 
equal participation and constructive consideration of all ideas. Like the Delphi method, this approach 
aims to overcome problematic group processes. The controlled feedback process in both approaches 
theoretically reduces unequal participation by ensuring that all panel member judgements and 
opinions are heard, regardless of personality and professional standing differences (Hsu & Sandford, 
2007). However, the effectiveness of this process in practice is ultimately dependent on the skills of 
the facilitator.  
Like the Delphi method, the NGT is also used to develop consensus where an evidence-base 
is absent or inconclusive (Cantroll, Sibbald & Bluetow, 1996). Despite these similarities, it was 
considered that the Delphi method's format offered several advantages for this study. Practically, the 
Delphi survey does not impose geographical constraints on participant selection, as it does not require 
participants to attend a meeting in person at a set date and time (Fink, Kosecoff, Chassin, & Brook, 
1984). Such pragmatic considerations were important for this study, as CF is a very specialist area 
with limited physiotherapists locally, which meant nationwide recruitment was required. It was also 
considered that, even if an adequate number of clinicians could be recruited locally, or the method 
could be delivered online, they would likely find it problematic to meet together at a specified date 
and time due to clinical commitments. Further, although submission of ideas in the NGT can be 
anonymous, subsequent discussion is not. The increased anonymity in the Delphi method is 
considered to increase free communication and open critique by reducing social pressures to agree 
with others, especially more senior individuals (Skulmoski, Hartman & Krahn, 2007). Equally, it 
reduces fear of critique, allowing lower-'status' individuals to introduce ideas without fear of outright 
rejection (Turoff & Hiltz, 1996). Again, it was considered that these qualities of the Delphi method 
would better lend themselves to this study, as it aimed to recruit clinicians with a range of clinical 
experience, and required systematic consideration and critique to be produced for each item. Unlike 
the NGT, the Delphi method also allows a mixed statistical methodology, which was considered a 
better fit for the research aims.  
 
47 
 
Participants 
Recruitment 
Purposeful sampling was used to recruit ‘expert participants’ for the study. It is important in 
the Delphi method to ensure that the individuals recruited have the required knowledge and skills to 
consider the topic under investigation, so that their level of expertise are unlikely to be challenged 
(Hasson & Keeney, 2011). The decision was made to define experts for this study as both clinicians 
with experience of supporting adherence to nebulised medications in CF, and adolescents and parents 
with experience of using or supporting use of these medications. The decision was made to recruit 
experts by profession and experience to increase the heterogeneity of the sample and thereby validity, 
in line with research recommendations (e.g. Hardy et al., 2004). It was planned that five expert 
clinicians and one expert patient and parent would be recruited for the study, which would meet the 
minimum recommended Delphi method recruitment figure of seven (Linstone, 1978).  
Clinicians were recruited for the survey by an invitation email, which was circulated to a 
nationwide special-interest group for physiotherapists working in CF, by a member of the supervisory 
team who is an administrator for this group (Appendix A). The email provided a summary of this 
study and contained a participant information sheet (Appendix B) and an eligibility form (Appendix 
C). Clinicians who wished to participate in the study were asked to express interest by emailing the 
researcher and returning their completed eligibility form. Clinicians had two weeks in which to 
respond to the invitation email before the study began, a timeframe selected due to the time 
constraints placed on this project. However, only four clinicians had replied within the first two 
weeks, which was considered insufficient, so a reminder email was sent, and the recruitment deadline 
extended by one month. 
Patients and parents were approached regarding the study during their outpatient 
appointments in their local paediatric CF clinic.  After their eligibility had been assessed by their 
physiotherapist, they were provided with an information sheet during their appointment and were 
asked to email the researcher to express interest (Appendix D.1 to D.2). A voucher incentive of the 
value of ten pounds was offered to patients and parents to take part. Although four patients and four 
parents were approached regarding the study, no patient or parent contacted the researcher to take 
part. Unfortunately, due to time constraints, further recruitment was impossible.  
 
Inclusion criteria 
In regard to defining experts by profession, it was decided that physiotherapists would be 
best-placed to support development of the questionnaires, as their job roles involve considering 
patients' adherence to nebulisers. Although other healthcare professions were considered, it was 
decided that their expertise and knowledge would be weaker due to the very specific nature of the 
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area of investigation (i.e. beliefs regarding specific medication categories within nebulised 
treatments). Equally, it was considered that input from academics, due to the lack of research in this 
field, would be less useful, and could reduce the real-world applicability of the measure. The 
eligibility criteria requirements for experts by profession was set to: clinicians who i) hold a 
professional qualification in the discipline of physiotherapy, ii) have worked clinically within the area 
of CF for at least one year. This timespan was chosen to ensure that clinicians were experienced 
enough in their field to have developed an adequate level of knowledge and experience.  
For patients to be eligible for this study, they needed to: i) be aged 16-17 years, ii) attend 
outpatient clinics at Leeds Regional CF centre, iii) have used an I-neb device for both mucolytics and 
antibiotics within the last two years, for at least two months. These criteria were chosen to fit with the 
questionnaires’ target audience, and to ensure that the individuals recruited had the experience, 
knowledge and maturity needed to understand and complete the survey. For the parent, the criteria 
were that they must i) have a child who satisfies the above criteria, ii) have capacity to consent to the 
study. 
 
Ethical approval and considerations 
Ethical approval was gained from the Proportionate Review Sub-committee of the NRES 
Committee York and Humber - Leeds West, in December 2018 (Appendix E). Consent was gained 
implicitly by participants choosing to complete the two survey rounds after reading the information 
sheet. Data was stored securely and confidentially in accordance with the Data Protection Act (1998). 
 
Measures 
The Beliefs about Medicines Questionnaire (BMQ) 
The original BMQ has two sections: BMQ-General and BMQ-Specific (Horne et al., 1999). 
The BMQ-General examines individuals’ perceptions of medications in general through two 
subscales: The General-Harm subscale, which assesses beliefs about how harmful medicines are, and 
the General-Overuse subscale which examines the concept of over-prescription. On the other hand, 
the BMQ-Specific section assesses perceptions of specific medications that have been prescribed for 
an individuals’ personal use. It is composed of two sub-scales: the Specific-Necessity scale examines 
patients’ perceptions of their personal need to adhere to their prescribed medication to control 
symptoms and maintain health, while the Specific-Concerns scale assesses patients’ beliefs 
concerning the likelihood of adverse reactions and consequences from taking their prescribed 
medication. Although these measures can be used in combination or separately, the BMQ-Specific 
questionnaire is often used alone to test the predictions of the Necessity-Concerns Framework; since 
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findings have shown that specific, rather than general, medication beliefs relate more closely to 
adherence behaviour (Horne et al., 1999). As such, only the BMQ-Specific was employed in this 
study. 
The BMQ-Specific consists of ten items, five of which examine patients' beliefs regarding the 
necessity of their medication to maintain their health (items: 1, 3, 5, 7, 10), and five, concerns about 
the potential negative consequences of taking their prescribed medication to their health (items: 2, 4, 
6, 8, 9) (Horne et al., 1999). These statements lie on a 5-point Likert Scale, from 1: ‘strongly disagree’ 
to 5: ‘strongly agree’. Responses are summed to produce separate sub-scale scores for the two 
dimensions (i.e. necessity and concerns), with total scores ranging from 5 to 25. Higher scores in 
either domain represent stronger necessity or concern beliefs regarding the medication in question. 
Scores that fall above the midpoint (i.e. 16 or above) are categorised as strong beliefs, as stated in the 
original paper by Horne et al. (1999). The necessity-concern differential represents the difference in 
scores (i.e. benefit-to-risk ratio) between the necessity and concern subscales. Higher necessity scores, 
relative to concern, produce a positive total, while a relatively higher concern to necessity score, a 
negative total. These total scores can range from -20 to +20. The BMQ is originally worded for 
completion by patients, but the statements have been edited for completion by parents (i.e. ‘my 
medicine disrupts my life’ becomes ‘my child’s medicine disrupts their life’) in a number of studies 
(e.g. Klok et al., 2012; Goodfellow et al., 2015; Sonney et al., 2017). The BMQ-Specific has been 
validated in adults (Horne et al., 1999), and in children as young as 7 years of age and their parents 
(Yilmaz, et al., 2012). The literacy level of the original BMQ-Specific is reported to be at the reading 
ability of 11- to 12-year-olds (Sonney et al., 2017), which is appropriate for this study's sample. 
 
Delphi Survey: Round One Questionnaires 
Clinician’s demographic questionnaire 
 A brief online demographics questionnaire was developed for clinicians for the Delphi survey 
and delivered in the first round. It collected the following information: clinicians’ gender, age, full 
name, email address and years of experience working in CF. Full names and email addresses were 
collected to allow data tracking and correspondence, while years working in CF was used to 
determine 'expert' status. 
 
CF-BMQ Specifics  
The initial CF-BMQ-Specific-Antibiotic and CF-BMQ-Specific-Mucolytic measures were 
presented in round one, which together consist of 21 items (Appendix F.1 to F.2). The CF-BMQ-A 
consisted of eleven items (four necessity beliefs, and seven concern), while the CF-BMQ-M ten items 
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(four necessity, six concern). The decision was made to not include the parent versions of either CF-
BMQ-Specifics in the Delphi survey, as the items are identical except for the change in subject ('me' 
to 'my child'). It was therefore considered that presenting all four questionnaires would increase 
participant burden, for little benefit. Instead, participants were informed of the existence of these 
questionnaires and asked to consider whether they could identify any necessity or concern beliefs 
which might apply to parents but not to their children.  
In the process of developing these questionnaires from the original BMQ-Specific, several 
changes were made by the research team. Modifications were made to item wording and/or items 
were removed or added, to increase the clarity and/or relevance of items, and thereby the validity of 
the questionnaires. The following items were re-worded to increase clarity: ‘My health, at present, 
depends on my medicines’ became ‘My health at present depends on me taking my nebulised 
medicines’; ‘My medicines are a mystery to me’ became ‘I don’t understand why I need to take my 
nebulised medication’, and ‘My medicines protect me from becoming worse’ became ‘My nebulised 
medication stops me from becoming worse’. The following item: ‘My medicines disrupt my life’ was 
made more specific: ‘Taking my nebulised medication disrupts my life’. It was considered by the 
clinicians within the research team that it is the act of taking nebulised medications that causes 
patients most disruption, and that the generic wording of the original item weakened its relevance. 
The following necessity item was removed from both questionnaires: ‘My life would be impossible 
without my nebulised medication’. This item was considered too strong for nebulised treatment, 
especially since mucolytics operate preventively, and these medications work within a treatment 
regimen to maintain health, rather than to cure symptoms. The following concern item was added to 
both questionnaires: ‘My nebulised medication causes unpleasant short-term side effects’, as nebuliser 
patients are known to report such concerns. Similarly, ‘Taking my nebulised medication is 
unpleasant’ was added to the antibiotics questionnaire alone, based on patient reports that nebulised 
antibiotics taste unpleasant. All items, like in the original BMQ-Specific, were placed on a 5-point 
Likert Scale, from 1: ‘strongly disagree’ to 5: ‘strongly agree’. 
 
Round one aim and format 
The overall aim of this round was to validate the initial CF-BMQ-Specific questionnaires by 
gaining further expert opinion on the importance of each item for assessing necessity or concern 
beliefs in antibiotic and mucolytic nebulised medication categories, and their views on the 
comprehensibility of each item. To this end, value and clarity ratings were requested for each item in 
both questionnaires. Ratings were placed on a 7-point Likert scale, from 1 ‘strongly disagree’ to 7 
‘strongly agree’. A wide scale was selected to allow greater data granularity but was limited to 7 
points, as research suggests that individuals find discrimination difficult beyond this (Streiner, 
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Norman & Cairney, 2015). After each item, a free text box was provided to allow participants to 
explain their rating and/or provide suggestions for rewording/rephrasing. A text box was also 
provided at the end of each questionnaire to allow panel members to provide suggestions for new 
necessity and/or concern belief items. Finally, it was considered that parents and adolescent patients 
may hold different necessity and concern beliefs. Therefore, the last section of the survey asked panel 
members to consider this and report such differences. 
 
Piloting round one 
This survey was piloted in line with good practice recommendations (e.g. Latour et al., 2009). 
Two academics and one member of the research team piloted the survey, and each was asked to give 
feedback regarding; i) their understanding of the individual items in the survey, ii)  their view on the 
readability of instructions and functionality of the survey (i.e. ease-of-use), and iii) the time taken to 
complete it. All participants found the format easy to follow and the questionnaire items clear, and 
reported completing the survey within 15-20 minutes, which is below the recommended round time of 
30 minutes (Okoli & Pawlowski, 2004). Participants recommended few changes, with just minor re-
wording and grammatical errors highlighted within participant instructions, with minor suggestions 
made as a result. 
 
Delphi Survey: Round Two Questionnaires  
Demographic questionnaire 
 In this round, the demographic form only requested participants' full names. Names were 
gathered in both rounds to allow tracking of data, with contact details already elicited in the first 
round. 
 
CF-BMQ-Specifics 
Like round one, round two presented the CF-BMQ-A and CF-BMQ-M (Appendix G.1 to 
G.2). However, in this round, they had been modified based on the data elicited in round one. 
Together, they comprised 23 items: 12 items in the CF-BMQ-A, and 11 in the CF-BMQ-M. Both 
questionnaires consisted of 5 necessity statements, with the remainder being concern items. 
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Round two aim and format 
The aim of the survey and format remained the same, though the section regarding parent 
beliefs was not included.  
 
Procedure for both Delphi survey rounds 
The Delphi survey was completed in two iterative rounds using the web-based platform 
‘Online Surveys’. Participants who met the study’s eligibility criteria were emailed a link to access 
round one of the survey, and were informed of the survey's closing date. 
The opening page of the round-one survey contained the participant information sheet and 
made participants aware that their consent would be taken implicitly through their completion of the 
survey. The following page requested basic demographic and career information, as previously 
described, after which brief instructions were provided. The CF-BMQ-A items were presented after 
this, and on the next page, the CF-BMQ-M items. For each item, in both questionnaires, participants 
were required to provide an importance and comprehensibility rating to maximise data collection, 
and, where they wished, comments to explain their rating and/or provide suggestions for re-wording. 
At the end of each questionnaire, participants were also asked to use free-text boxes to report any 
necessity and concern beliefs regarding the target nebulised medication category, which they 
considered important but which had not been addressed by the existing items. Following this, they 
were asked to provide their thoughts on any necessity and/or concern beliefs regarding nebulised 
medications that might be held by parents but not their children. Finally, the survey's last page 
thanked participants for taking part and reminded them that the researcher would email them a link to 
the second-round survey within the next four weeks. This data was then analysed to allow the two CF-
BMQ-Specifics to be revised ready for further evaluation in round two. 
Within a week of the first round's completion by all participants, participants were sent an 
email containing the link for round two, whose structure was largely identical to round one. The only 
change was the removal of the section requesting differences between parents and adolescents’ 
beliefs, as it was considered that little further benefit would be gained from repeating this question. 
The structure of both rounds of this Delphi survey can be viewed in Figure 2. 
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Figure 2: Flow diagram detailing the broad structure of the Delphi survey in round one (left) 
and round two (right). 
Each survey round remained open for a maximum of three weeks, and email reminders were 
sent on a weekly basis during this time to increase response rates, in line with research 
recommendations (Fan & Yan, 2010). The process of creating the final CF-BMQ-Specifics for 
patients and parents, and the steps of the Delphi survey, can be viewed in Figure 3. 
 
 
 
 
 
Delphi survey round one
Page one: Participant information and consent explained
Page two: Personal details (e.g. full name, email, gender, 
age, number of years working clinically in CF)
Page three: Instructions for the study
Page four: CF-BMQ-A items presented for evaluation
Page five: CF-BMQ-M items presented for evaluation
Page six: Considering additional necessity/concern beliefs 
for parents
Page seven: Thank you page and time-line information for 
round two
Delphi survey round two
Page one: Participant information and consent explained
Page two: Personal details (e.g. full name)
Page three: Instructions for the study
Page four: CF-BMQ-A items presented for evaluation
Page five: CF-BMQ-M items presented for evaluation
Removed
Page six: Thank you page
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Figure 3: Steps of the process used to develop the CF-BMQ Specifics. 
 
 
 
 
 
 
 
Aim: To develop initial drafts of the CF-BMQ-A and CF-BMQ-M for completion by 
patients and parents.
Research literature and the supervisory teams' clinical experience was used to refine 
the BMQ-Specific to nebulised mucolytic and antibiotic categories. 
Online Delphi survey round one developed and piloting completed.
Panel identified and recruited. Panel = 8 Physiotherapists.
Round 1 = 21 statements (11 antibiotic, 10 mucolytic)
Aim: Validate the patient CF-BMQ-A and CF-BMQ-M by gaining expert ratings on 
the value and clarity of each item, and suggestions for further items.
Results: Analysed the distribution of ratings on value and clarity and qualitative 
comments. The questionnaires were revised and the round two survey developed. 
Delphi round 2 = 23 statements (12 antibiotic, 11 mucolytic)
Aim: Validate the patient CF-BMQ-A and CF-BMQ-M by gaining expert ratings on 
the value and clarity of each item, and suggestions for further items.
Results: Analysed the distribution of ratings on value and clarity and qualitative 
comments.
Generation of the final CF-BMQ-A and CF-BMQ-M.
Wording revised in both to create parent versions. Four questionnaires created.
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Data analysis 
 
 Response, attrition rates and sample characteristics (e.g. age, gender, years working in CF) 
were examined across survey rounds. 
 
Measuring and assessing statistical consensus in Delphi surveys 
Currently, there is no universally accepted criterion for measuring or determining consensus 
in Delphi studies, and great contention exists in the literature regarding the best means to assess this 
(Landeta, 2006). For instance, while some authors attempt to increase the validity of results by 
proposing set analytical processes (e.g. Holey, Feeley, Dixon, Whittaker, 2007), others argue that the 
best means to measure and determine consensus is dependent on the purpose and design of each 
study, and that authors need to present rationales for their decisions (e.g. Jorm, 2015). Some also 
attempt to clarify what consensus is, and how it can be measured; Holey et al., (2007) describe how 
consensus is considered to be the same as agreement, and how it can be determined by: an aggregate 
of judgements; a move to a subjective level of central tendency, or by confirming stability in 
responses (i.e. the consistency of answers between a study’s successive rounds). 
Within the literature, percentage agreement levels, measures of central tendency and 
dispersion statistics, applied both individually and in combination, have been most commonly used to 
examine consensus (Diamond et al., 2014). However, the rationale for selection of these measures is 
often not reported. In recent years, reliance on one measure alone has been heavily criticised (e.g. 
Giannarou & Zervas, 2014), leading some authors to advocate the use of several complementary 
measures to improve the validity of results in Delphi surveys. Holey et al., (2007) for instance, 
consider consensus reached when the following occurs: an increase in percentage agreements; 
convergence of importance rankings; increase in Kappa values; a decrease in comments as rounds 
progressed; a smaller range of responses, and smaller standard deviation values. 
Delphi studies often use predetermined threshold values to gauge consensus, as these are 
considered to reduce response bias (Williams & Webb, 1994). However, these values are subjective 
and vary greatly; for instance, a review by Hasson, Keeney, McKenna (2000) found that accepted 
percentage of agreement values ranged from 51% to 80%. This has led some to argue that quantifying 
the degree of consensus is more important than reaching these values (Linstone & Turoff, 2011; von 
der Gracht, 2012). 
 
Measuring and assessing statistical consensus in this study 
Several descriptive statistics were calculated after each round for the items in both 
questionnaires in this study, to examine agreement levels. The accepted level of consensus was set at 
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a high level across these statistics, as the measures presented in this study had already been adapted 
by clinicians from CF services, and the sample consisted of a homogeneous panel, which led to the 
assumption that the panel would rate the questionnaire items favourably. It was therefore judged that a 
lower threshold would create difficulty in differentiating less-favoured items.  
 
i) Median, interquartile range and range 
 
The median, a measure of central tendency which represents the central value of a set of 
ordered data, was selected instead of the mean to assess the level of group agreement. The agreement 
data is ordinal in nature, and it was expected that the data would be negatively skewed (i.e. responses 
would be strongly positive across participants) rather than normally distributed across the range of 
responses, factors which contraindicate use of the mean. An increase in this value across rounds was 
considered to indicate increasing consensus, and the median consensus level was set at a threshold of 
6 ‘agree’ for both usefulness and clarity ratings.  
 
The range, and interquartile range (IQR) were used as measures of dispersion. The variance 
was not used, as it is considered less robust than the IQR in Delphi surveys (von der Gracht, 2012). 
The IQR represents the range in which the middle 50% of ratings occur, and provides a description of 
the average distribution of agreement, while the range indicates the degree of divergence. A decrease 
in the IQR and range across rounds was deemed indicative of increasing group consensus. The IQR 
consensus level was set at 2, rather than 1, as a value of 1 is only considered appropriate for 4- or 5-
point Likert scales (von der Gracht, 2012). Thresholds were not specified for the range, as it was used 
to complement the IQR. 
 
ii) Percentage of agreement 
 
The percentage of agreement values was used to complement the mean, it assessed the 
percentage of responses that met or exceeded the mean consensus cut-off value of 6. An increase in 
this value across rounds was considered to indicate increasing consensus, with the consensus 
threshold set as ≥70%. 
iii) Number of comments 
  
The total comments made for each item were summed. A decrease in constructive comments 
across round was considered indicative of increasing group consensus, as reported in Holey et al.’s 
(2007) study. 
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Item-specific comment analysis  
Following each round, the item-specific comments were collated for each item and examined 
individually. A basic content analysis was completed on these data, as outlined in Graneheim and 
Lundman (2004).  
 
Additional item comment analysis 
 Comments regarding additional necessity or concern beliefs were collated after each round, 
and, again, a basic content analysis was completed on this data, as outlined in Graneheim and 
Lundman (2004). 
 
Decision making from item-specific feedback 
Decisions on whether to retain, revise or remove items were made on a case-by-case basis 
after both rounds, using both the statistical rating summaries (for both usefulness and 
comprehensibility) and item-specific comments. Qualitative data was prioritised in the analysis and 
was used to guide and provide context for item amendments or removals. It was considered for every 
item regardless of whether consensus had been met statistically. Indeed, in instances where statistical 
summaries and item-specific comments were discrepant (i.e. high values, but negative feedback), 
comments were prioritised. Item-specific comments were, however, not implemented where 
contradictions existed, or where changes could reduce an item’s clarity or modify its nature without 
strong justification. For items to meet consensus, high scores needed to be paired with comments that 
supported or did not strongly question their value or clarity. Throughout the process of refining and 
removing items from the original questionnaire, significant caution was applied, as this study sought 
simply to tailor the questionnaire to nebulised medications, rather than reinvent it. To support this 
process, all amendments and item removals were discussed with a member of the supervisory team. 
 
Decision making from additional item feedback 
The addition of new items for round two was driven by the additional item comments in 
round one, while additions to the final questionnaire were based on comments and statistical 
summaries from round two. The same procedures were applied. 
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Chapter 3: Study One Results 
 
Participants 
Response rates  
In total, 8 physiotherapists registered interest in this Delphi survey from a potential pool of 
240. All of these clinicians completed the survey’s first round, while 7 completed the second, 
producing a 100% response rate for round one and an 87.5% response rate for round two. This meets 
the minimal recommended participant level of 7 (Linstone, 1978), and exceeds the minimal accepted 
attrition rate of 70% (Keeney et al., 2010). 
 
Sample demographics 
Demographic information for rounds one and two is summarised in Table 1. This table shows 
that although all participants were female, varied age ranges and geographical locations were 
represented. All participants reported working within CF for at least two years, with a large majority 
working for at least 10 years (e.g. round 1: 75%, round 2: 71.4%); confirming the strong clinical 
expertise of this sample. 
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Table 1: Participant demographics across the two rounds. 
Demographics  Round One Round Two 
 
Gender  Female: 8 (100%) Female: 7 (100%) 
Age 22-32 1 (12.5%) 1 (14.3%) 
33-43 2 (25%) 1 (14.3%) 
3 (42.9%) 44-54 3 (37.5%) 
55-65 2 (25%) 2 (28.6%) 
 65+ - - 
Region of work Scotland 2 (25%) 2 (28.6%) 
Yorkshire 2 (25%) 2 (28.6%) 
East of England 1 (12.5%) 1 (14.3%) 
North West 1 (12.5%) 1 (14.3%) 
Greater London 1 (12.5%) 1 (14.3%) 
 South East 1 (12.5%) - 
Years of experience 1-2 - - 
2-5 1 (12.5%) 1 (14.3%) 
5-10 1 (12.5%) 1 (14.3%) 
 10+ 6 (75%) 5 (71.4%) 
Note: Years of experience represents the number of years spent working clinically within 
Cystic Fibrosis.  
 
Delphi survey: round one results  
Aim of round one 
 Round one aimed to gain the opinion of an expert group on the value and clarity of items in 
the CF-BMQ-A and CF-BMQ-M, and their recommendations for new items.  
 
Statistical summary item-specific 
Participants rated 21 statements, 11 items in the CF-BMQ-A and 10 in the CF-BMQ-M, on 
two dimensions: usefulness and comprehensibility. Descriptive statistical summaries for both ratings 
were produced for every item, and can be viewed in Table 2. These include: the percentage of 
agreement score and median, which represent the level of group agreement, the IQR which reflect the 
degree of group consensus, and the range which highlights dispersion of opinion. 
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Table 2: Round one importance and comprehensibility ratings for the CF-BMQ-A and CF-BMQ-M. 
CF-BMQ-A Importance ratings Comprehensibility ratings  
Item  Median (IQR) Range % Agreement Median (IQR) Range % Agreement 
1. My health at present depends on me taking my nebulised antibiotics (N) 6 (1.25) 2 75% 5.5 (1.25) 4 50% 
2. Having to take nebulised antibiotics worries me (C) 6 (1) 5 87.5% 6.5 (1.25) 3 75% 
3. I sometimes worry about long-term effects of taking my nebulised 
antibiotics (C) 
6 (1) 2 87.5% 6 (1) 2 87.5% 
4. Without my nebulised antibiotics I would be very ill (N) 6 (1.5) 5 62.5% 6 (1.25) 4 75% 
5. I don’t understand why I need to take my nebulised antibiotics (C) 7 (0.25) 1 100% 7 (0.25) 1 100% 
6. My health in the future will depend on my nebulised antibiotics (N) 6 (1) 2 87.5% 6 (0.25) 2 87.5% 
7. Taking my nebulised antibiotics disrupts my life (C) 7 (0.25) 1 100% 7 (0) 1 100% 
8. I sometimes worry about becoming too dependent on my nebulised 
antibiotics (C) 
6 (2.25) 4 62.5% 5.5 (1.25) 3 50% 
9. My nebulised antibiotics stop me from becoming worse (N) 7 (1.25) 3 75% 6 (1.25) 3 75% 
10. Taking my nebulised antibiotics is unpleasant (C) 6 (1.25) 2 75% 6 (2.25) 3 62.5% 
11. My nebulised antibiotics cause unpleasant short-term side-effects (C) 6 (1.25) 3 75% 5.5 (2.25) 4 50% 
CF-BMQ-M        
1. My health at present depends on me taking my nebulised mucolytics (N) 6.5 (1.25) 2 75% 5.5 (2) 4 50% 
2. Having to take nebulised mucolytics worries me (C) 6 (1.25) 4 75% 6 (1.25) 3 62.5% 
3. I sometimes worry about long-term effects of taking my nebulised 
mucolytics (C) 
6 (1) 1 62.5% 6 (1) 2 62.5% 
4. Without my nebulised mucolytics I would be very ill (N) 6 (0.25) 2 75% 6 (0.25) 2 100% 
5. I don’t understand why I need to take my nebulised mucolytics (C) 7 (0) 4 87.5% 7 (0) 3 87.5% 
6. My health in the future will depend on my nebulised mucolytics (N) 6.5 (1) 2 87.5% 6 (0.5) 3 75% 
7. Taking my nebulised mucolytics disrupts my life (C) 7 (0.25) 2 87.5% 7 (0) 4 87.5% 
8. I sometimes worry about becoming too dependent on my nebulised 
mucolytics (C) 
5 (1.25) 2 25% 5 (1.25) 2 37.5% 
9. My nebulised mucolytics stop me from becoming worse (N) 7 (1) 1 100% 6 (1) 2 87.5% 
10. My nebulised mucolytics cause unpleasant short-term side-effects (C) 6 (1.25) 2 75% 5.5 (1.5) 3 50% 
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In general, usefulness ratings suggested that participants considered items in both 
questionnaires important. Only 19% (4/21) of items (CF-BMQ-A necessity item 4 and concern item 8, 
and CF-BMQ-M concern items 3 and 8) failed to reach consensus across the three statistical measures 
Within median ratings, all items scored between 6 and 7, with only item 8 in the CF-BMQ-M failing 
to reach consensus by scoring 5. Regarding percentage of agreement, although all four items did not 
reach the consensus threshold, all but item 8 in the CF-BMQ-M (which scored just 25%) came close, 
with 62.5% of respondents rating these items as useful. Little deviation occurred within item 
usefulness ratings across the questionnaires. In the CF-BMQ-A, IQR item ratings ranged from 0.25 to 
2.25, with the range itself averaging just 2.7 across items. Six items (1, 4, 9, 8, 10, 11) exceeded an 
IQR value of one, of which item 8 also exceeded the consensus threshold of two. In the CF-BMQ-M, 
IQR ratings were less variable, ranging between 0 and 1.25 across items, with the range itself 
averaging just 2.2. Only four of these items (1, 2, 8, 10) exceeded an IQR value of one, and none met 
or exceeded a value of two. 
 
Overall, item clarity ratings were lower and more variable than usefulness ratings across both 
questionnaires. In total, 43% (9/21) of items (CF-BMQ-A necessity item: 1 and concern items: 8, 10, 
11, and CF-BMQ-M necessity item 1 and concern items: 2, 3, 8, 10) failed to reach consensus across 
the three statistical measures. Median ratings ranged between 5.5 to 7 for the CF-BMQ-A items, and 5 
to 7 for the CF-BMQ-M items, with 3 items in each questionnaire failing to reach the median 
consensus threshold of 6. All 9 items failed to reach the percentage of agreement threshold. Most 
notably, five were rated as clear by just 50% of respondents (CF-BMQ-A items 1, 8, 11, and CF-
BMQ-M items 1, 10), and item 8 in the CF-BMQ-M was rated clear by just 37.5%. IQR values across 
items for the CF-BMQ-A ranged between 0 and 2.25, with the range itself averaging 2.7. Seven items 
(1, 2, 4, 8, 9, 10, 11) exceeded an IQR value of one, of which items 10 and 11 exceeded a value of 
two. CF-BMQ-M IQR values ranged between 0 and 2 across items, with the range itself averaging 
2.8. Four items (1, 2, 8, 10) exceeded a value of one, of which only item 1 met an IQR value of two. 
 
Round one: item-specific qualitative feedback 
During the first round, 49 item-specific comments were made by participants across both 
questionnaires. However, three of these comments were not considered relevant to the value or clarity 
of these items. The first explained why a patient may not hold a certain belief, while the remaining 
statements highlighted that if patients completed the questionnaires they would not understand the 
reference to medication categories in the items, since they are only aware of their medication’s names. 
Of the remaining 46 items, 27 were reported in the CF-BMQ-A (13 within necessity-belief items, and 
14 within concern), and 19 in the CF-BMQ-M (7 necessity, 12 concern). These comments were 
placed within four categories: constructive feedback on item relevance, meaning, wording, or positive 
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feedback. The frequency of these comments across items within both questionnaires can be seen in 
Table 3. 
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Table 3: Item-specific qualitative feedback for round one. 
CF-BMQ-A Comment categories   
Item and belief type: Necessity (N) or Concern (C) Item 
relevancy 
Item wording Item 
meaning 
Positive 
feedback 
Total 
1. My health at present depends on me taking my nebulised antibiotics (N) - 2 2 - 4 
2. Having to take nebulised antibiotics worries me (C) - - 2 - 2 
3. I sometimes worry about long-term effects of taking my nebulised antibiotics (C) - 1 - - 1 
4. Without my nebulised antibiotics I would be very ill (N) - 4 - - 4 
5. I don’t understand why I need to take my nebulised antibiotics (C) - - - 1 1 
6. My health in the future will depend on my nebulised antibiotics (N) - 1 2 - 3 
7. Taking my nebulised antibiotics disrupts my life (C) - 1 - - 1 
8. I sometimes worry about becoming too dependent on my nebulised antibiotics (C) 1 1 - - 2 
9. My nebulised antibiotics stop me from becoming worse (N) - 2 - - 2 
10. Taking my nebulised antibiotics is unpleasant (C) - 1 2 - 3 
11. My nebulised antibiotics cause unpleasant short-term side-effects (C) - 4 - - 4 
  Total: 1 17 8 1 27 
CF-BMQ-M 
 
     
1. My health at present depends on me taking my nebulised mucolytics (N) - 2 1 - 3 
2. Having to take nebulised mucolytics worries me (C) 1 - - - 1 
3. I sometimes worry about long-term effects of taking my nebulised mucolytics (C) 1 1 - 1 3 
4. Without my nebulised mucolytics I would be very ill (N) - 1 - - 1 
5. I don’t understand why I need to take my nebulised mucolytics (C) - - - 1 1 
6. My health in the future will depend on my nebulised mucolytics (N) - 1 1 - 2 
7. Taking my nebulised mucolytics disrupts my life (C) - - - - 0 
8. I sometimes worry about becoming too dependent on my nebulised mucolytics (C) 2 1 - - 3 
9. My nebulised mucolytics stop me from becoming worse (N) - 1 - - 1 
10. My nebulised mucolytics cause unpleasant short-term side-effects (C) 1 3 - - 4 
  Total: 5 10 2 2 19 
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Table 3 shows that while the relevance of just one item (item 8) was questioned in the CF-
BMQ-A in one comment, the relevance of four items (items: 2, 3, 8 and 10) were questioned in 5 
comments in the CF-BMQ-M. Importantly, item 3 in the CF-BMQ-M, and  item 8 in both 
questionnaires had also failed to reach consensus on usefulness ratings. 
In total, 27 comments were made regarding item wording across both questionnaires; 17 
across 9/11 items (82% of items) in the CF-BMQ-A, and 10 across 7/10 items (70% of items) in the 
CF-BMQ-M. Most notably, within the CF-BMQ-A, 47% of these comments were made regarding 
items 4 and 11, and for the CF-BMQ-M, 30% for item 10 (which is the equivalent of item 11 in the 
CF-BMQ-A). This category included comments which questioned item wording explicitly, and/or 
which presented rewording suggestions which did not change item meaning. Ten comments were 
made in relation to item meaning across both questionnaires; four items (1, 2, 6, 10) were questioned 
by 8 comments in the CF-BMQ-A, and two items (1, 6) by two comments in the CF-BMQ-M. This 
category included comments which explicitly reported problems with item meaning, suggested 
statements which changed item meaning, or which made an item more specific. Positive comments 
were made for item 5 in both questionnaires, and item 3 in the CF-BMQ-M. Although item 5 only 
received this comment, item 3 also received comments which questioned the relevance and wording 
of this item. Comments related to item wording, meaning and positive feedback did not clearly relate 
to quantitative measures. 
It is important to note that significantly more wording and meaning comments were made 
regarding the CF-BMQ-A, despite the questionnaires being identical in wording. It was considered 
that this resulted from participants not wishing to repeat themselves across the questionnaires, since 
all participants assessed the CF-BMQ-A before the CF-BMQ-M. It was therefore considered that 
comments regarding item wording and meaning in either questionnaire applied to the other. 
 
Item changes from item-specific feedback in round one 
 As a result of the item-specific statistical and qualitative feedback, 8 items were revised in 
each questionnaire (representing 73% of CF-BMQ-A items, and 80% of CF-BMQ-M items), and 
three items removed entirely across both questionnaires. 
 
Item revisions 
Revisions ranged from minor wording adjustments to language changes which increased 
clarity or altered meaning. These changes and their rationale will now be presented. The most 
substantial amendments were made to item 1: ‘My health at present depends on me taking my 
nebulised medications’, and its future equivalent, item 6 ‘My health in the future will depend on my 
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nebulised medications’. For item 1, dissatisfaction arose in clarity ratings and comments across both 
questionnaires, while for item 6, dissatisfaction was only represented within comments. Importantly, 
several of the comments regarding item 1 highlighted how nebulised medications are just one 
component of maintaining health in CF, causing disagreement with this item to reflect either: a 
patients’ belief that nebulised medication is not important for their current health, or a recognition that 
their health depends on several complementary treatments. To overcome this, the item was modified 
to: ‘To be healthy now, I need to take my nebulised medications’. This statement continues to reflect 
the core meaning of the original statement (i.e. personal need for a treatment to maintain current 
health), with the word ‘need’ used to place a strong but non-exclusive focus on this treatment. Similar 
issues also arose regarding item 6, alongside further ambiguity concerns, i.e. that this item could be 
understood as meaning: ‘taking nebulised medications in the future will improve my future health’, 
rather than: ‘taking my medication now will improve my future health’ (the intended meaning). The 
former interpretation is problematic since it would bear no theoretical relation with present-day 
adherence behaviours. To remedy both problems, item 6 was modified to: ‘To be healthy in the future, 
I need to take my nebulised medications now’. 
As a result of dissatisfaction in clarity ratings and comments, the following two items: 
‘Without my nebulised medications I would be very ill’ and ‘My nebulised medications cause 
unpleasant short-term side-effects’ underwent moderate revisions. Reports for the first item expressed 
unease with the phrase ‘very ill’ and its impact on patients. This was amended to: ‘Without my 
nebulised medications, my health would be much worse’. The strength of the original statement was 
retained through inclusion of the word ‘much’. Comments on the second item suggested that patients 
would struggle to understand the phrases ‘short-term’ and ‘side-effects’. To support understanding, 
examples were added, and the item was modified to: ‘My nebulised medications can cause unpleasant 
side-effects (e.g. bad taste, coughing, feeling sick)’. 
Minor changes were made to four items in response to clarity ratings and/or comments:   
i) ‘Having to take nebulised medications worries me’ became ‘Having to take my nebulised 
medications worries me’ 
ii) ‘I sometimes worry about long-term effects of taking my nebulised medications’ became ‘I 
sometimes worry about the long-term effects of taking my nebulised medications’ 
iii) ‘My nebulised medications stop me from becoming worse’ became ‘My nebulised 
medications stop my health from becoming worse’ 
vi) ‘Taking my nebulised antibiotics disrupts my life’ was modified to ‘Taking my nebulised 
antibiotics gets in the way of my life’. 
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Finally, one item was not modified, despite receiving clarity-related feedback: ‘Having to 
take my nebulised medications worries me’. Participants’ comments queried whether this item could 
be made more specific. However, it was considered that this would change the question’s nature 
which is intentionally broad. 
 
Item removal 
Two items were removed from the CF-BMQ-A, and one from the CF-BMQ-M, after 
examination of usefulness ratings and related comments. Table 4 presents these items alongside a 
summary of the reasons for their removal.  
 
Table 4: Items removed across the CF-BMQ-A and CF-BMQ-M following round one feedback 
 Item Reason for removal 
Both 
questionnaires 
Item 8 – ‘I sometimes worry 
about becoming too 
dependent on my nebulised 
medications’ – an original 
concern belief 
Item failed to achieve statistical consensus for 
value and clarity on both questionnaires and 50% 
of relevancy comments made across the 
questionnaires critiqued this item. 
 
CF-BMQ-A 
only 
Item 10 – ‘Taking my 
nebulised antibiotics is 
unpleasant’ – a concern 
belief generated from the 
research team. 
Item failed to achieve statistical consensus for 
clarity and comments critiqued the items 
vagueness. Most importantly, once item 11 (side-
effects) was revised from round one feedback, 
substantial overlap existed with these items. 
 
 
Several items were, however, retained despite statistical and/or qualitative feedback 
questioning their relevance. Table 5 presents these items alongside the rationale for why they were 
retained. 
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Table 5: Items retained from the CF-BMQ-M despite feedback questioning item relevance. 
 Item Reason retained 
CF-BMQ-M Item 3 – ‘I sometimes worry 
about the long-term effects 
of taking my nebulised 
mucolytics’ – an original 
concern belief. 
Although this item did not reach statistical 
consensus, it only received one comment. Although 
this belief may be less probable within this 
medication than antibiotics, where it is held it was 
considered that it would be highly likely to 
influence adherence behaviour. 
 Item 2 – ‘Having to take 
nebulised mucolytics worries 
me’ – an original concern 
belief. 
This item received one comment. Again, although 
clinicians may not perceive that individuals worry 
about these medications. It is likely that if they do, 
such worries will influence adherence behaviour. 
 Item 10 – ‘My nebulised 
mucolytics cause unpleasant 
short-term side-effects’ – an 
original concern belief. 
This item received one comment. Although 
mucolytics are less likely to cause side-effects, 
where side-effects do occur or where it is 
considered that they could occur, they are no less 
likely to influence adherence behaviour than 
antibiotics. 
CF-BMQ-A Item 4 – ‘Without my 
nebulised antibiotics I would 
be very ill’ – an original 
concern belief. 
This item did not reach statistical consensus and 
received four qualitative comments. They however, 
suggested that it was the wording of the item that 
dissatisfied clinicians, rather than item usefulness. 
 
Round one: additional item qualitative feedback 
Addition of belief items to the CF-BMQ-A and CF-BMQ-M 
At the end of the questionnaires, participants were asked to report any necessity or concern 
beliefs for nebulised medications which they considered to be missing from the existing questionnaire 
items. In total, 11 comments were made across both questionnaires, although four of these were 
general beliefs related to completing treatments, rather than necessity or concern beliefs regarding 
medications. From these comments, three new items were developed, two of which were included in 
both questionnaires, and one in the CF-BMQ-A alone. These comments, and their categorisation and 
development into items for the round 2 questionnaires, can be viewed in Table 6. 
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Table 6:   Round one categorisation of patient feedback for new items.
Version Necessity item suggestions  Round 2 inclusion? Concern item 
suggestions  
Round 2 inclusion? More general 
beliefs 
Round 2 inclusion? 
CF-
BMQ-A 
I don't believe my nebulised 
antibiotics work for me. 
No. Overlap with existing 
item: ‘To be healthy now, I 
need to take my nebulised 
Antibiotics’ 
Increasing resistance to 
antibiotics. 
Yes. ‘I sometimes worry that 
taking my nebulised 
antibiotics now will mean that 
they won't work as well in 
future’ 
Time taken to take 
nebulised 
antibiotics. 
No. 
 I only need to take my 
nebulised antibiotics regularly 
if I feel unwell. 
 
Something around the 
frequency of use e.g. I think 
taking some of treatment is 
better than none at all. 
Yes.  ‘I only need to take 
my nebulised Antibiotics 
when I feel unwell’ 
 
  Fitting in with other 
treatments. 
No. 
CF-
BMQ-M 
I don't need to take my 
nebulised mucolytics regularly 
if I feel well. 
 
I only need to take my 
nebulised mucolytic if I am 
going to do my physiotherapy. 
 
Something around the 
frequency of use e.g. I think 
taking some of treatment is 
better than none at all. 
Yes. ‘I only need to take 
my nebulised Mucolytics 
when I feel unwell’ 
 
  Time taken to take 
nebulisers. 
No. 
     Visibility of 
nebulisers in front 
of friends. 
Yes, for both 
questionnaires. ‘Taking 
my nebulised medications 
is embarrassing’. 
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Importantly, the inclusion of the items: ‘I only need to take my nebulised medications 
regularly if I feel unwell’ and ‘Taking my nebulised medications is embarrassing’, extends the nature 
of this questionnaire beyond the BMQ-Specific. The first item broadens the original definition of 
necessity beliefs, as it considers not only if a medication is needed to maintain or improve current 
health, but also when it is taken. Such timing-related beliefs are an important consideration in 
medications that can be prophylactic in nature within a health condition that can be asymptomatic. 
The second item is considered to extend the definition of concern by moving from concerns regarding 
the medication itself, to the medication delivery system. This was considered important, as the I-
nebuliser delivery system is clearly visible when in use and requires steady breathing to work. 
 
The decision was made to not include the other more general beliefs related to completing 
nebulised treatments i.e. time and fitting in with other treatments, as time is not a belief specific to 
medication categories, and does not in itself offer an explanation for poor adherence, while 
prioritisation of different treatments was too broad for this study’s focus. 
 
Addition of belief items to the parent questionnaire versions 
Participants were asked to report necessity and concern beliefs for nebulised medications that 
they considered only a parent would hold. Although 10 comments were made, the majority were 
general concerns regarding health and treatment, with just 4 comments relating specifically to 
nebulised medications. These comments and their categorisation can be viewed in Table 7.  
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Table 7: Round one suggestions for new items in the parent versions of the CF-BMQ-A and CF-BMQ-
M.  
Necessity and concern beliefs 
for nebulised medications 
Beliefs regarding using 
nebulisers  
General health and 
treatment beliefs 
‘Will the nebulised medication 
cause resistance’ (concern). 
‘That the equipment takes a 
long time to clean and may be 
a source of infection’. 
‘In my experience, the main 
concern from parents is their 
child's adherence’. 
 
‘Will I as the parent develop 
resistance’ (concern). 
‘My child would not take their 
nebulised medication if I did 
not prepare it for them’. 
‘Parents are more likely to 
have long term implication 
concern beliefs regarding lung 
function, transplantation etc 
that patients may not yet be 
aware of’. 
‘My child does not understand 
why they need to take 
nebulised …’ (necessity). 
‘Perhaps concerns relating to 
the child’s ability to do the 
treatment alone / dependency 
on the parent to do the 
treatment’. 
‘What happens if my child 
can’t take all or any of the 
medications?’ 
 
‘That antibiotic nebulisers may 
make the child wheezy or their 
wheeze worse’ (concern). 
  
 
Within the items concerning nebulised medications, only the item ‘Will I, as the parent, 
develop resistance?’ was considered potentially exclusive to parents, but it was also considered 
unlikely to be held in the first place. The number of general comments resulting from this question 
suggests that participants had difficulty answering it, which in turn suggests that the patient 
questionnaires would sufficiently capture parents’ necessity and concern beliefs regarding these 
medications, once re-worded. 
 
Delphi survey: round two results 
Aim of round two 
 Round two aimed to gain opinion on the new items and to gain increased consensus on the 
value and clarity of revised items in the CF-BMQ-A and CF-BMQ-M, from the same expert group, 
and any further recommendations for new items. 
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Statistical summary item-specific 
Participants rated 23 statements, 12 in the CF-BMQ-A and 11 in the CF-BMQ-M, on the 
same dimensions of importance and comprehensibility. Descriptive statistical summaries for both 
ratings were produced for every item, and can be viewed in Table 8. 
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Table 8: Round two importance and comprehensibility ratings for the CF-BMQ-A and CF-BMQ-M. 
CF-BMQ-A Importance ratings Comprehensibility ratings 
Item and belief type: Necessity (N) or Concern (C) Agreement 
% 
Median 
(IQR) 
Range Agreement % Median 
(IQR) 
Range 
1. To be healthy now, I need to take my nebulised antibiotics (N) 85.8 7 (1) 2 85.8 6 (0.5) 2 
2. Having to take my nebulised antibiotics worries me (C)  71.5 6 (0.5) 4 71.5 6 (1.5) 4 
3. I sometimes worry about the long-term effects of taking my nebulised antibiotics (C) 85.8 6 (1) 2 85.8 6 (0.5) 2 
4. Without my nebulised antibiotics my health would be much worse (N) 85.8 6 (1) 2 85.8 6 (1) 2 
5. I don’t understand why I need to take my nebulised antibiotics (C) 100 7 (0.5) 1 100 7 (0.5) 1 
6. To be healthy in future, I need to take my nebulised antibiotics now (N) 71.5 7 (1.5) 2 71.5 6 (1.5) 2 
7. Taking my nebulised antibiotics gets in the way of my life (C) 100 7 (0) 1 100 7 (0) 1 
8. I sometimes worry that taking my nebulised antibiotics now will mean that they won't work 
as well in future (C) 
85.8 7 (0.5) 2 85.8 6 (1) 2 
9. My nebulised antibiotics stop my health from becoming worse (N) 100 7 (1) 1 100 7 (1) 1 
10. My nebulised antibiotics can cause unpleasant side-effects (e.g. bad taste, coughing, feeling 
sick) (C) 
100 7 (0.5) 1 100 7 (0.5) 1 
11. Taking my nebulised antibiotics is embarrassing (C) 57.2 6 (2) 5 85.8 6 (1) 2 
12. I only need to take my nebulised antibiotics when I feel unwell (N) 85.8 7 (1) 2 100 6 (1) 1 
CF-BMQ-M       
1. To be healthy now, I need to take my nebulised mucolytics (N) 85.8 7 (1) 2 71.5 7 (1.5) 2 
2. Having to take my nebulised mucolytics worries me (C) 85.8 6 (0.5) 4 71.5 6 (1.5) 3 
3. I sometimes worry about the long-term effects of taking my nebulised mucolytics (C) 57.2 6 (2) 2 71.5 6 (1) 2 
4. Without my nebulised mucolytics my health would be much worse (N) 85.8 7 (1) 2 71.5 6 (1) 2 
5. I don’t understand why I need to take my nebulised mucolytics (C) 85.8 7 (0) 2 100 7 (0) 1 
6. To be healthy in future, I need to take my nebulised mucolytics now (N) 85.8 7 (1) 2 71.5 6 (1.5) 2 
7. Taking my nebulised mucolytics gets in the way of my life (C) 100 7 (0) 1 100 7 (0) 1 
8. My nebulised mucolytics stop my health from becoming worse (N) 100 7 (1) 1 100 6 (1)  1 
9. My nebulised mucolytics can cause unpleasant side-effects (e.g. bad taste, coughing, feeling 
sick) (C) 
85.8 7 (0.5) 2 100 7 (0.5) 1 
10. Taking my nebulised mucolytics is embarrassing (C) 71.5 6 (1.5) 5 100 6 (1) 1 
11. I only need to take my nebulised mucolytics regularly when I feel unwell (N) 85.8 6 (1) 3 85.8 6 (1) 3 
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In round two, item usefulness ratings had improved from round one across both 
questionnaires. Only 8% (2/23) of items (CF-BMQ-A concern item 11 and CF-BMQ-M concern item 
3) failed to reach consensus across the three statistical measures. Importantly, CF-BMQ-M item 3 had 
also failed to reach consensus in round one, while CF-BMQ-A item 11 had only been introduced in 
this round. All items’ median ratings were between 6 and 7 across both questionnaires, and in 
percentage of agreement, all scored above 70%, apart from the two failed items above, which each 
scored 57.2%; highlighting that only a small majority rated these items as useful. Overall, less 
deviation occurred within item usefulness ratings than in round one. In the CF-BMQ-A, IQR values 
ranged from 0 to 2, with the range itself averaging just 2. Just two items: 6 and 11, exceeded an IQR 
value of one, with item 11 meeting the consensus threshold value of two. Similarly, the CF-BMQ-M 
IQRs ranged between 0 and 2, with the range itself averaging 2. Again, just two items (3 and 10) 
exceeded a value of one, with item 3 meeting the consensus threshold value of two. 
 
Item clarity ratings were significantly improved from round one; all items reached consensus 
across all three statistical measures. Greater consistency within ratings was also achieved; IQR item 
ratings across both questionnaires ranged from just 0 to 1.5, with the range averaging 1.8 for the CF-
BMQ-A, and 1.7 for the CF-BMQ-M. Also, only 5 items (CF-BMQ-A items 2, 6; CF-BMQ-M items 
1, 2, 6) exceeded an IQR value of one.  
 
Round two: item-specific qualitative feedback 
During the second round, 27 item-specific comments were made by participants across both 
questionnaires. However, eight of these comments were not considered relevant to the value or clarity 
of the items, as they provided general feedback or reflected participant misunderstandings of the 
items’ or questionnaires’ purpose. For instance, general feedback raised the problem of using 
medication categories rather than names as highlighted in round one, while another raised an ethical 
concern: ‘Could asking about potential concerns cause increased concern in patients?’. Regarding 
misunderstandings, one participant reported that the following item: ‘I only need to take my nebulised 
antibiotics when I feel unwell’, is not applicable to patients who take antibiotics on a continuous basis 
regardless of their infection status. It is possible that this participant interpreted this item as: ‘I only 
need to take my nebulised antibiotics when I am unwell’. Surprisingly, other comments suggested 
declaring adherence behaviour within belief statements; for instance, one participant suggested 
adding: ‘...and this is why I don’t take them regularly’ to an item. 
Of the remaining 19 comments, 8 related to the CF-BMQ-A (6 for necessity items, 2 for 
concerns), and 11 for the CF-BMQ-M (7 necessity, 4 concern). Again, these comments were placed 
within four categories: constructive feedback on item relevance, meaning, wording, or positive 
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feedback. The frequency of these comments across items within both questionnaires can be seen in 
Table 9. 
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Table 9: Item-specific qualitative feedback for round two items.
CF-BMQ-A Comment categories   
Item and belief type: Necessity (N) or Concern (C) Item relevancy Item wording Item meaning  Positive feedback Total  
1. To be healthy now, I need to take my nebulised antibiotics (N) - 1 1 - 2 
2. Having to take my nebulised antibiotics worries me (C) 1 - - - 1 
3. I sometimes worry about the long-term effects of taking my nebulised antibiotic (C) - - - - 0 
4. Without my nebulised antibiotics my health would be much worse (N) - 1 - - 1 
5. I don’t understand why I need to take my nebulised antibiotics (C) - - - - 0 
6. To be healthy in future, I need to take my nebulised antibiotics now (N) - - 1 1 2 
7. Taking my nebulised antibiotics gets in the way of my life (C) -                - - - 0 
8. I sometimes worry that taking my nebulised antibiotics now will mean that they won't work as well in future (C) - - - - 0 
9. My nebulised antibiotics stop my health from becoming worse (N) - 1 - - 1 
10. My nebulised antibiotics can cause unpleasant side-effects (e.g. bad taste, coughing, feeling sick) (C) - - - - 0 
11. Taking my nebulised antibiotics is embarrassing (C) - - 1 - 1 
12.  I only need to take my nebulised antibiotics when I feel unwell (N) - - - - 0 
  Total:               1 3 3 1 8 
CF-BMQ-M 
 
     
1. To be healthy now, I need to take my nebulised mucolytics (N) - 2 - - 2 
2. Having to take my nebulised mucolytics worries me (C) 1 - - - 1 
3. I sometimes worry about the long-term effects of taking my nebulised mucolytics (C) - - - - 0 
4. Without my nebulised mucolytics my health would be much worse (N) - 2 - - 2 
5. I don’t understand why I need to take my nebulised mucolytics (C) - - - - 0 
6. To be healthy in future, I need to take my nebulised mucolytics now (N) - - - 1 1 
7. Taking my nebulised mucolytics gets in the way of my life (C) - - - - 0 
8. My nebulised mucolytics stop my health from becoming worse (N) - 2 - - 2 
9. My nebulised mucolytics can cause unpleasant side-effects (e.g. bad taste, coughing, feeling sick) (C) 1                - 1 - 2 
10. Taking my nebulised mucolytics is embarrassing (C)                1 - - - 1 
11. I only need to take my nebulised mucolytics when I feel unwell (N)                - - - - 0 
  Total:               3 6 1 1 11 
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Overall, Table 9 shows the substantial reduction in comments between rounds one and two, 
from a constructive comment total of 43 in round one, to just 17 in round two. Regarding item 
relevance, one concern item (item 2) was questioned in the CF-BMQ-A by one comment, and three 
concern items (2, 9, 10) by 3 comments for the CF-BMQ-M. Interestingly, despite this feedback all of 
these items had achieved statistical consensus.  
In total, only 9 comments were made regarding item wording across both questionnaires. In 
the CF-BMQ-A, 3 comments were made across 3 necessity items (1, 4, 9), and in the CF-BMQ-M, 6 
comments were made across the equivalent 3 necessity items (1, 4, 8). Regarding item meaning, 3 
items (1, 6, 11) attracted 3 comments in the CF-BMQ-A, while only one comment questioned one 
item (item 9) in the CF-BMQ-M. Positive comments were made for item 6 in both questionnaires, 
despite item 6 in the CF-BMQ-A also receiving a comment which questioned item meaning. 
Comments related to item wording, meaning and positive feedback did not clearly relate to 
quantitative measures. 
 
Item changes from item-specific feedback in round two 
In this round, item-specific statistical and qualitative feedback led to no revisions or removals 
for any item.  
 
Item revisions 
As previously described, all items met statistical consensus for clarity, and just 13 comments 
were made regarding item meaning or wording over both questionnaires. Although these comments 
were examined, it was considered from this feedback that no further revisions were needed. For 
instance, ‘Without my nebulised medications, my health would be much worse’ received comments 
questioning the need for language as strong as ‘much worse’. However, it was recognised that 
weakening the language of this item would likely reduce the variability of responses to it, on the 
continuum of ‘strongly disagree’ to ‘strongly agree’. Similarly, for the item ‘My nebulised 
medications can cause unpleasant side-effects (e.g. bad taste, coughing, feeling sick)’, one comment 
highlighted that the wording did not differentiate between whether an individual has experienced side-
effects first-hand, or simply has knowledge that they could occur. However, for the purposes of this 
item, such a distinction makes no difference, as both possibilities could be considered valid concerns 
about a treatment 
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Item removal  
Despite statistical and/or qualitative feedback questioning the usefulness of several items, 
none were removed. Table 10 presents these items alongside a brief rationale for why they were 
retained. 
 
Table 10: Items removed across the CF-BMQ-A and CF-BMQ-M following round one feedback. 
 Item Reason retained 
Both Item 11 in the CF-BMQ-A and 
item 10 in the CF-BMQ-M – 
‘Taking my nebulised 
medications is embarrassing’ – a 
concern item generated from 
round one. 
Although the item failed to reach statistical consensus in 
the CF-BMQ-A, it achieved statistical consensus on the 
CF-BMQ-M, and only received one comment which 
questioned its relevance across both questionnaires.  
 Item 2 – Having to take my 
nebulised medications worries 
me – an original concern item. 
Only one comment in each questionnaire questioned the 
relevance of this item 
CF-
BMQ-
M 
Item 3 – ‘I sometimes worry 
about long-term effects of taking 
my nebulised mucolytics’ – an 
original concern item. 
Again, this item did not reach consensus statistically. 
The rationale for retaining this item despite this was 
explained in round one. 
 Item 9 – ‘My nebulised 
mucolytics cause unpleasant 
short-term side-effects’ – an 
original concern item. 
Only one comment questioned the relevance of this 
item. The rationale for retaining this item was explained 
in round one. 
 
Round two: additional item qualitative feedback 
Addition of belief items to the CF-BMQ-A and CF-BMQ-M 
Again, at the end of the questionnaires, participants were asked to report any necessity or 
concern beliefs for nebulised medications that they considered to be missing from the existing items. 
Only one comment was made in this round; ‘Ask questions about time taken to take nebulised 
antibiotics’, however this item was not considered for inclusion due to reasons previously discussed. 
The lack of comments in this section suggests that the panel were satisfied with the questionnaire 
items by round two. 
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Final questionnaire  
The final CF-BMQ-A and CF-BMQ-M are identical in item content, with each containing 5 
necessity and 7 concern beliefs (see Appendix H.1 to H.2). 
 
 Importantly, it was decided that item 8 developed after round one for the CF-BMQ-A alone: ‘I 
sometimes worry that taking my nebulised medications now will mean that they won't work as well in 
future’ should also be included in the mucolytic questionnaire. It was considered reasonable that this 
belief could be held regarding mucolytics, even if the development of such tolerance is not medically 
founded.  
 
Assessment of reading level  
The Flesch-Kincaid Grade level was used to calculate the reading level of the questionnaires. 
The original BMQ-Specific scored 4.8, while the CF-BMQ-Specific a slightly increased score of 5.1. 
Nonetheless this tool placed the reading level of both questionnaires at the US 5th grade, suggesting 
that 10- and 11-year olds would be able to understand the language used in the questionnaires.  
To further ensure the readability of the final questionnaires, they were piloted with 8 children 
(3 = male and 5 = female) aged between 11 and 12 years. They were asked to indicate whether there 
were any words or sentences that they found harder or impossible to understand in the CF-BMQ-
Specific. The first two children to consider the questionnaires indicated that they found item 8 (‘I 
sometimes worry that taking my nebulised medication now will mean that they won’t work as well in 
future’) more difficult to understand. They reported experiencing difficulty with the phrasing ‘now 
will’ and the length of the sentence. In response, the item was amended to: ‘I sometimes worry that if I 
take my nebulised medications now, they won't work as well in future’. This item was then included in 
the questionnaire and individuals were asked to choose their preferred phrasing; 4 of the 6 of these 
children chose the revised wording. 
 
Item content of the original and final questionnaires 
The original BMQ-S items and the final adapted items for the CF-BMQ-S can be viewed in 
Table 11 below.  
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Table 11: Original BMQ-S items and final adapted items for the CF-BMQ-S. 
 Original BMQ-S   Final CF-BMQ-S items 
 Item and belief type: Necessity (N) or Concern (C) 
 
1. 
 
My health, at present, depends on my 
medications (N) 
 
1. 
 
To be healthy now, I need to take my 
nebulised medications (N) 
2. Having to take medications worries me (C) 2. Having to take my nebulised medications 
worries me (C) 
3. My life would be impossible without my 
medications (N) 
3. I sometimes worry about the long-term effects 
of my nebulised medications (C) 
4. I sometimes worry about the long-term 
effects of my medications (C) 
4. Without my nebulised medications my health 
would be much worse (N) 
5. Without my medications I would be very 
ill (N) 
5. I don’t understand why I need to take my 
nebulised medications (C) 
6. My medications are a mystery to me (C) 6. To be healthy in future, I need to take my 
nebulised medications now (N) 
7. My health in the future will depend on my 
medications (N) 
7. Taking my nebulised medications gets in the 
way of my life (C) 
8. 
9. 
My medications disrupt my life (C) 
I sometimes worry about becoming too 
dependent on my medications (C) 
8. I sometimes worry that taking my nebulised 
medications now, means that they won’t work 
as well in future (C) 
10. My medications protect me from becoming 
worse (N) 
9. My nebulised medications stop my health 
from becoming worse (N) 
  10. My nebulised medications can cause 
unpleasant side-effects (e.g. bad taste, 
coughing, feeling sick) (C) 
  11. Taking my nebulised medications is 
embarrassing (C) 
  12. I only need to take my nebulised medications 
when I feel unwell (N) 
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Chapter 4: Study One Discussion 
 
Review of study one  
This study adapted the BMQ-Specific – a generic measure used to assess necessity and 
concern beliefs in medications across health conditions – for use specifically with nebulised antibiotic 
and mucolytic medications in CF. It consisted of two phases. First, two draft questionnaires were 
developed from the BMQ-Specific by the researcher and supervisory team: one for nebulised 
antibiotics and the other for nebulised mucolytics. Following this, a modified Delphi survey was used 
to gain consensus from a panel of experts regarding the usefulness and clarity of items in both 
questionnaires, and to elicit recommendations for new items, over two rounds. The findings from the 
first round were used to revise the content of the questionnaires for round two, and the findings from 
round two were used to inform the content of the final form of the questionnaires. 
 
 
Summary of findings 
As previously discussed in Chapter 3, the draft questionnaires were constructed by the 
research team from the original BMQ-S, with several changes made to increase the clarity and/or 
relevance of items to nebulised antibiotics and mucolytics specifically. This included four items being 
reworded, one necessity item being removed from each questionnaire, and two new concern items 
being developed, both of which were added to the antibiotics questionnaire, and one to the mucolytics 
questionnaire. These changes were made as a result of discussion based on the team’s clinical 
experience, and after consideration of the relevant research literature, with full consensus gained 
within the team before alterations were made.  
 
In relation to the Delphi survey, positive consensus on the value and clarity of items in both 
questionnaires was gained by round two. In round one, although initial consensus was positive 
regarding the value of items in both questionnaires, findings regarding clarity were more variable. 
Only 19% (4/21) of items failed to achieve statistical consensus for value, but almost half of items 
(43%) did not attain this for clarity, and six times more item-specific feedback comments were given 
for clarity than value (6 vs. 37). As a result, for the second round, three concern items (two from the 
CF-BMQ-A and one from the CF-BMQ-M) were removed, and eight items (four necessity and four 
concern) were identically revised in each questionnaire, leaving just one unaltered item in each. 
Although these revisions were widespread, most were minimal in scope, and just one original BMQ-
Specific item was removed entirely from each questionnaire. Seven suggestions were given for new 
items, leading to one necessity item and two concern items being generated; one of each was added to 
the CF-BMQ-M, and all three to the CF-BMQ-A. 
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As hoped, these changes led to improved consensus after round two; only two items failed to 
reach statistical consensus for value (one on each questionnaire, including a newly-added concern 
item), and all items attained consensus for clarity. Additionally, only four item-specific comments 
were made regarding value, and thirteen for clarity. Only one suggestion for a new item was made in 
this round, suggesting increased satisfaction with the items available. Importantly, no removals, 
additions or even minor revisions were made in either questionnaire as a result of round-two 
feedback. This decision was made due to the already strong positive consensus after round two; it was 
determined that any changes made at this point might be equally likely to reduce consensus, with no 
further Delphi survey round available to examine this. Also, most of these comments were considered 
minor or to represent dissenting views, so did not provide strong justification to make further changes. 
Possible reasons for such a quantity of comments despite high quantitative consensus, will be 
considered later in the discussion. Additionally, the two items which had failed to reach consensus 
were also retained, for reasons which will also be discussed later. 
 
The lack of consensus regarding item clarity after the first round was surprising. It had been 
expected that a high level of positive agreement would be gained immediately from the panel 
regarding both the value and clarity of items, since the BMQ-Specific is a well-developed and 
validated measure and the research team had already adapted it to nebulised CF medication 
categories. Consequently, most of the changes highlighted above were made as a result of such less 
favourable feedback to improve item clarity. It was expected that the majority of these comments and 
subsequent item changes would focus on problems in relation to their adaptation to nebulised 
medications and/or CF – however, most related to the general wording of items, including 
grammatical errors, ambiguity, and concerns regarding language complexity. This suggested that the 
panel was actually highlighting clarity problems in the original wording of items in the BMQ-
Specific, independent of the illness and medications of interest. Importantly, the improved 
quantitative and qualitative results for several items in the second round following these changes, 
support this view.  
 
Interestingly, perceived value was rated less favourably overall for concern than necessity 
items in both rounds. Indeed, three of the four items which failed to achieve consensus for value in 
round one were concerns, as were both such items in round two. Qualitative findings showed a similar 
pattern; all comments which critiqued item relevance were for concern items, across both rounds. 
These findings suggest that concern items were considered by the panel to be of less value than 
necessity items. Most of these comments were reported for the CF-BMQ-M, which shows that the 
panel’s views of the value of concern beliefs differed between the two medication categories. 
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Importantly, this finding supports this study’s novel decision to create two questionnaires to 
differentially assess beliefs between the nebulised medication categories 
 
In the second round, more item-specific comments were made that were not relevant to the 
survey questions, than in the first round (8 vs. 3). In round one, such comments were mostly relevant, 
but related to the questionnaires generally, rather than to specific items. However, those from round 
two seemed instead to indicate that specific items, as well as the questionnaires’ purpose, were being 
misunderstood in places. Arguably, if this was due to misunderstanding the survey itself, such issues 
would have arisen similarly in both rounds. Instead, it may simply be that participants felt a continued 
wish to suggest helpful changes as they had done in the first round, but had greater difficulty 
generating relevant comments due to the improved questionnaire items. This hypothesis seems 
reasonable, considering the large number of otherwise useful comments in both rounds, and the fact 
that piloting was favourable. 
 
 
Developing the final questionnaires 
It was originally planned that any item failing to reach consensus in either questionnaire 
would be removed from it – however, it was recognised that entirely omitting certain items from one 
questionnaire alone would prevent direct examination of differences in beliefs between the two 
medication categories in the second study. The two final questionnaire items were therefore made 
identical in content, a decision which also partially underpinned the lack of changes to the 
questionnaires following round two. In practice, this meant that the two items which had failed to 
reach statistical consensus for value following round two in either questionnaire, were retained in 
both. This decision also led to one item being added to the final version of the CF-BMQ-M which had 
originally been developed by the research team for the CF-BMQ-A alone. The reasons for retaining 
these items, rather than simply removing them from both questionnaires, will now be examined in 
detail. 
 
The first item which had failed to achieve consensus on value: “Taking my nebulised 
medications is embarrassing” was a new item suggested in round-one feedback by a panel member. It 
was expected to perform well in round two since both published research (see Dziuban et al., 2007; 
Hogan et al., 2015 as discussed in the introduction), and the supervisory team’s clinical experience, 
had highlighted the relevance of embarrassment as a barrier to adherence in nebulised medications. 
Surprisingly, however, it failed statistical consensus for value on the CF-BMQ-A, and only 
marginally reached consensus on the CF-BMQ-M. One possible explanation for the poorer 
performance of this item is a design flaw in the survey instructions. When this item was developed, it 
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was recognised that it extended the nature of the BMQ-Specific, by potentially allowing consideration 
of both the medication itself, and its delivery method. However, the survey instructions asked the 
panel to consider the value and clarity of beliefs relating to the medications in isolation, arguably 
potentially leading panel members to discount the delivery device. Another potential explanation is 
that the panel members were all physiotherapists, to whom concerns relating to emotions surrounding 
medications arguably have reduced pertinence compared to other professionals such as psychologists. 
In view of these considerations, the decision was made to retain the item for both questionnaires. 
 
The second, an original BMQ-Specific item, “I sometimes worry about the long-term effects 
of taking my nebulised medications”, failed on the CF-BMQ-M, an outcome which could be easily 
justified by the fact that mucolytics are less likely than antibiotics to cause long-term detrimental 
effects to health. However, as considered in the introduction, patients often hold scientifically 
incorrect beliefs regarding their medications, the frequency of which healthcare professionals can 
underestimate, so, as described above, it was considered of interest to retain this item in both 
questionnaires. The same rationale also underpinned the decision to include the following item which 
had been developed for the CF-BMQ-A alone “I sometimes worry that taking my nebulised 
medications now will mean that they won't work as well in future” in the CF-BMQ-M, despite such 
beliefs about resistance not being reported by patients in regards to mucolytics. 
 
Finally, it is also important to note that some of the item additions and/or rephrasing of 
original items for the final questionnaires extended their nature beyond the original BMQ-Specific. 
The necessity item – “I only need to take my nebulised medications regularly if I feel unwell” – was 
developed from round-one feedback, and broadens the original definition of necessity by considering 
not only if a medication is needed to maintain or improve current health, but also when it needs to be 
taken. Timing-related beliefs are an important consideration with CF medications, as they are 
generally only effective when taken regularly. Both concern items – “Taking my nebulised 
medications gets in the way of my life” (an original but modified BMQ-Specific item), and “Taking 
my nebulised medications is embarrassing” (generated from round-one feedback, as discussed above) 
– extend the original focus of concerns by now including the word ‘taking’, which, as discussed 
above, includes not only the medication, but its delivery system. These changes were considered 
important as, theoretically, the nature of the I-nebuliser device itself is highly likely to impact 
adherence behaviour, especially as it can be highly visible and time-consuming to use and clean. In 
other treatments in CF, and indeed in other illnesses, where the BMQ has been used, the delivery 
mechanism of a treatment may not have been as pertinent an issue. However, examination of delivery 
devices could be an interesting extension for this model and subsequent research. 
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Study one strengths and limitations 
 Several strengths and limitations exist in this study, the most significant of which will now be 
considered. The first key strength of this study lies in its originality; it presents the first known 
attempt to adapt the BMQ-Specific to both nebulised medication categories in CF, and to complete 
such adaptations through a process driven by gaining consensus from a group of experts. Importantly, 
this represents a more systematic means of tailoring the BMQ-S to specific medications, than those 
undertaken in several previous studies; for instance, that of Bucks et al. (2009), who simply describe 
the method for refining questionnaires as a ‘discussion with the team’. This study not only potentially 
provides the foundation for a measure to assess beliefs in nebulised medication categories in CF, but 
also suggests a method for future researchers to use when tailoring the BMQ-Specific to other 
treatments. 
 
Participants  
Response numbers for this study were surprisingly low. No ‘experts by experience’ (CF 
patients using these medications, or their parents) were successfully recruited, despite four patients 
and parents being approached; also, only eight clinicians agreed to participate. This lack of interest 
was unexpected, especially considering that the clinicians approached were all members of a 
nationwide CF special-interest group. Despite this, at least 7 participants took part in both rounds. 
This is the minimal level required for Delphi surveys (Linestone, 1978), but falls below the range of 
10-15, more recently advocated by several authors as optimal in ensuring the reliability of group 
judgements (e.g. Skulmoski et al., 2007). The panel itself was also limited to just one group 
(physiotherapists); such homogeneity is considered by several authors to limit the range of elicited 
viewpoints, and thereby the validity and generalisability of developed questionnaires (e.g. Linstone & 
Turoff, 2002). However, this panel represented physiotherapists of various ages, levels of clinical 
experience, and national locations. Clinical psychologists from the supervisory team were also 
involved in supporting the initial development and revisions of these questionnaires. These factors, 
taken together, will have widened perspectives. A further strength of this study lies in the clinical 
experience of the panel, supervisors, and wider research team; most panel members had at least 10 
years of clinical experience in CF, the wider research team at least 5 years’ experience each, and the 
supervisory team of clinicians over 20 years’ experience each. This suggests that all individuals 
involved in this research were well-placed to give their clinical opinion on the questionnaires. 
Despite the small sample, attrition between the rounds was minimal (N=1) and participants 
provided a high volume of feedback, suggesting that those who participated were knowledgeable and 
interested, factors considered to increase the content validity of Delphi surveys (Goodman, 1987). The 
use of quasi-anonymity in this study is likely to have contributed to this strong retention and 
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participant input. Research has shown that quasi-anonymity supports retention compared to full 
anonymity, by allowing the use of personalised correspondence, including reminder emails (e.g. 
Sánchez-Fernández, Muñoz-Leiva, & Montoro-Ríos, 2012), and that it increases accountability, and 
therefore, participants’ motivation and due consideration (Goodman, 1987). Although this can, in 
turn, lead participants to be more cautious and rate items more favourably (McKenna, 1994), this did 
not appear to occur in this study; item-specific constructive feedback was commonplace, even where 
ratings were already favourable. Importantly, quasi-anonymity also allowed examination of the 
feedback of the individual who left the study after the first round. This feedback was very favourable, 
showing that the increased consensus in round two was not attributable to their dropping out.  
Ultimately, regardless of specific limitations, it is important to recognise that Delphi surveys 
are, by their nature, limited in reliability – they simply represent the views of a subset of individuals at 
a single point in time, so it would be scientifically untenable and overstated to claim that one group 
can represent generalisable expert opinion. In recent years, some Delphi surveys in the literature have 
begun to address this by correlating findings between independent expert groups (e.g. Garnett, Crane, 
West, Brown & Michie, 2015). This study did not have the capacity to do this, so the generalisability 
of findings to another group is unknown.  
 
Survey design 
Although certain features of the survey design may have been advantageous in promoting 
retention, these same features may arguably have limited it. For instance, within this Delphi survey, 
rather than being presented with a summary of their individual and group responses for each item 
after the first round, panel members were instead given updated questionnaires developed from the 
group feedback. While this will have reduced the time-burden, it also prevented participants from 
considering the specific ratings and comments of other members in relation to their own responses, 
potentially limiting opportunities to understand others’ perspectives, and/or change their own views as 
a result. Without such feedback, it is likely that some respondents had difficulty in understanding why 
their suggestions had, or had not, been implemented between rounds, and in recalling what their 
previous responses had been. This may explain why certain comments were repeated across rounds, 
and why dissenting opinions were still reported. Overall, this is likely to explain why comments 
appeared less useful and/or relevant in round two. 
It is also important to note more general difficulties with the surveys themselves; the 
questionnaires were presented to all panel members in the same order across both rounds (CF-BMQ-
A first, CF-BMQ-M second). As discussed in the results section, this order-effect is assumed to have 
underpinned the significantly higher number of clarity-related comments made for the CF-BMQ-A 
than the identically-worded CF-BMQ-M in round one. However, this discrepancy did not occur in 
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round two, or in value-related comments in either round (since the value of items requires a fresh 
appraisal between medications while clarity does not). This suggests that such effects were likely 
minimal, since genuine order-effects (e.g. fatigue) would have affected both kinds of comments 
equally. Also, a proportion of irrelevant comments provided in both rounds can  be attributed to 
participants finding the survey format constraining; although participants were able to comment on 
individual questionnaire items, a space for more general comments regarding the questionnaire as a 
whole was not provided, leading some respondents to place them within item-specific spaces. This 
factor is also likely to have limited respondents’ ability to provide overall impressions of the 
questionnaires, some of which feedback did indeed prove useful when provided. 
 
Conclusion 
Overall, despite the limitations arising from the application of the Delphi method, both in this 
study specifically, and more generally, it provided an effective means to draw together the opinion of 
a group of experts, and gain consensus on the developed questionnaires, in a more robust way than 
many similar previous studies. Ultimately, the adaptation of the BMQ-Specific to assess necessity and 
concern beliefs within nebulised medication categories in CF was completed in order to examine 
whether these questionnaires can predict adherence behaviour to these medications more effectively 
than the original measure. This is examined through study two. 
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Chapter 5: Study Two Method 
Predicting adherence behaviour from medication beliefs 
Design 
 A  longitudinal design was used to examine the relationship between medication beliefs and 
adherence behaviour to nebulised medications in CF. Participants were provided with a series of 
questionnaires by their physiotherapist, which collected information regarding their beliefs about their 
nebulised medication(s), illness perceptions, and sociodemographic and health factors. Although other 
data-collection methods and designs were considered, they were deemed less suitable. For instance, 
while postal or online questionnaires might have reduced the time burden placed upon the 
physiotherapy teams, they often lend themselves to small and biased samples, especially when sample 
sizes are limited (Sax, Gilmartin & Bryant, 2003). Also, although a longer longitudinal design would 
have allowed examination of the stability of beliefs and adherence behaviour over a period of time, 
and thereby of the self-regulatory aspect of the Necessity Concerns Framework, this was not deemed 
possible due to the project’s time constraints. 
The specific version(s) of the medication-belief questionnaires (i.e. BMQ-Specifics and CF-
BMQ-Specifics) that participants (i.e. patients and parents) completed were determined by the 
patients’ I-nebuliser prescription. This created three possible groups; those prescribed only mucolytics 
or antibiotics through the I-nebuliser device, and those prescribed both. The first groups were named 
‘antibiotic-only’ or ‘mucolytic-only’, while the dual group was named the ‘combined group’. It is 
important to note that some individuals were prescribed more than one medication within a 
medication category through the I-nebuliser device. In these instances, one medication was 
nominated, rather than participants completing a BMQ-Specific and CF-BMQ-Specific questionnaire 
for each individual medication within a category, as it was considered that this would lead to high 
repetition and burden for certain participants. Equally, asking participants to complete just one 
questionnaire for multiple medications was thought to be inappropriate, since there is no reason to 
assume that participants would hold the same necessity and concern beliefs about different 
medications, even within the same medication category. In all such cases, selection of which 
medication to nominate was based on which would afford the most reliable adherence data. Where no 
clear advantage existed, participants chose the medication. Also, as the questionnaires are very similar 
in nature, their order of completion was counterbalanced within the groups, to reduce order effects. 
 Objective adherence data was collected from patients’ I-nebuliser devices at their next clinic 
appointment, which usually occurred six to eight weeks after questionnaire completion. Adherence 
data was collected prospectively, rather than retrospectively, as assessing the predictive validity of the 
belief measures in this study for future behaviour was of higher interest to clinicians. This timeframe 
was considered sufficient to provide a stable and representative measure of a patient’s adherence 
88 
 
while fitting within the time constraints of this study. Although it could be argued theoretically that 
participation in this study (i.e. completion of questionnaires and knowledge about I-neb data being 
collected) could influence subsequent adherence behaviour, when it is considered that I-neb data is 
routinely monitored in these services, and the importance of adherence routinely advocated, such 
effects were considered unlikely.  
 
Participants 
Recruitment 
 Convenience sampling was used to recruit adolescent patients and their parent or guardian 
(hereafter referred to simply as ‘parents’) to the study. Patients and parents were approached at their 
local paediatric CF centre, during either routine outpatient appointments or inpatient discharge 
appointments, after the patient’s eligibility had been assessed by their physiotherapist. If eligible, 
patients and parents were informed of the study’s purpose and procedure by their physiotherapist, 
provided with an information sheet each (see Appendix I.1 to I.2), and given the opportunity to ask 
questions. They were informed that they could make their decision on whether to take part within that 
appointment, or at their next outpatient routine appointment, but that the study would close after this.  
 Based on the theoretical and empirical literature, a moderate effect size was anticipated for 
this study (e.g. Horne et al., 1999; Bucks et al., 2009). A power analysis using G*power (Erdfelder, 
Faul & Buchner, 1996) calculated that to complete a multiple linear regression analysis with 2 to 4 
predictors, a moderate effect size, and an alpha level of 0.05, a minimum sample of 23 would be 
needed to achieve a power of .80, and for correlations, a minimum sample size of 34. Clinician review 
of caseloads at the three paediatric CF centres suggested that each site would be able to recruit at a 
minimum 10 patients and 10 parents over a three-month period, equating to 30 patients and 30 
parents. Therefore, this minimum sample size would allow reliable statistical analysis to be completed 
for regression analysis, and potentially for correlational analysis if this minimum sample size was 
exceeded. 
 
Inclusion and exclusion criteria 
For patients to be eligible for this study, they needed to: i) be aged between 12 to 17 years, ii) 
attend outpatient clinics at Leeds, Sheffield or Liverpool Paediatric CF centres, and iii) be taking 
nebulised mucolytic and/or antibiotic medications on a set-prescription basis through a I-nebuliser 
device. A set-prescription basis was required, since these medications can, on occasion, be prescribed 
on a PRN basis (i.e. as-needed), which would prevent calculation of adherence. Patients were 
excluded from the study if they: i) completed an inpatient stay during the data collection period, as 
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research has shown that hospital stays increase nebuliser adherence rates (Abbot & Gee, 1998), ii) 
were due to transition to adult care, as this would prevent follow-up, iii) were due to stop their I-neb 
treatment imminently, iv) appeared distressed in clinic, v) could not provide consent, vi) had a 
learning disability, as the measures have not been validated in this population, or vii) if they had a 
recorded lung function of FVB1 < 30% and were awaiting transplant. For parents to participate, they 
needed: i) a child who satisfies the above criteria, ii) capacity to consent to the study. 
 
Ethical approval and considerations 
Ethical approval was gained from the Proportionate Review Sub-committee of the NRES 
Committee York and Humber - Leeds West, in December 2018. Potential ethical issues of note will 
now be described. Firstly, while all participants provided informed consent to take part in the study, 
they were able to begin the study soon after being informed of it. Although this could theoretically 
have prevented participants from fully considering their participation, it was considered that the low 
risk and routine nature of this study, alongside the fact that outpatient appointments are 6-8 weeks 
apart, made this a practical option. Though adherence is a sensitive topic, it was not considered that 
this research would cause increased distress to participants or increased risk, since these discussions, 
and responding to risks that arise from low adherence, represent routine practice in outpatient clinics 
in these services. Finally, although data was stored securely and confidentially in accordance with the 
Data Protection Act (1998), it was only pseudo-anonymised rather than fully anonymised, through 
clinicians creating patient identifiers at their CF centres. It was considered that this would be 
important to allow data-checks, due to the potential complexity of some patients’ adherence data. 
One amendment was made following completion of study one, as a result of the CF-BMQ-
Specific questionnaires being adapted. Ethical approval was gained from the Proportionate Review 
Sub-committee of the NRES Committee York and Humber - Leeds West, on 03/06/19 (see Appendix 
J).  
 
Site recruitment and management 
The researcher made contact with clinicians at the Liverpool and Sheffield sites, and site 
visits were completed to discuss the study’s feasibility, including data-collection strategies and data-
storage facilities. Once research and development approval were gained, study documentation was 
provided to all three sites, and communication was maintained throughout the study’s recruitment 
phase. 
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Measures 
Sociodemographic questionnaire  
A brief sociodemographic questionnaire for parents was developed for the study. It collected 
the following details: parents’ gender, age, ethnicity, religion, marital status, family composition (i.e. 
number of adults / children in the household), home postcode, occupation, and education level (see 
Appendix K). The final three items were collected as a means to determine socioeconomic status. 
 
Patient demographic and health status questionnaire 
A demographic and health status questionnaire was developed for completion by clinicians. 
This included the following patient information: age, gender, current FEV1%, number of inpatient 
admissions within the last year, and their nebulised medication prescription during the data collection 
period (see Appendix L). 
 
The Beliefs about Medicines Questionnaire-Specific (BMQ-Specific) 
The original BMQ-Specific has been described within the method chapter for Study 1 (see 
Chapter 2). In Study 2, four versions of this standard questionnaire were developed, one for each 
medication category (i.e. antibiotics and mucolytics) for completion by both participant types (i.e. 
patients and parents). First, the wording of the items was adapted by substituting ‘nebulised antibiotic’ 
or ‘nebulised mucolytic’ for the word ‘medication’ (e.g. the original BMQ item: ‘my medicine 
disrupts my life’ became either ‘my nebulised antibiotics disrupt my life’, or my nebulised mucolytics 
disrupt my life’) (see Appendix M.1 to M.2). The BMQ-Specific is designed to be adapted in this 
manner for the specific medication of interest. To accommodate the change in respondent, items were 
altered from first person (patient perspective) to third person (parent perspective). For example, ‘my 
nebulised antibiotics disrupts my life’ became ‘my child’s nebulised antibiotics disrupts their life’) 
(see Appendix N.1 to N.2). 
 
The Cystic Fibrosis Beliefs about Medicines Questionnaire-Specific (CF-BMQ-Specific) 
 The CF-BMQ-Specific refers to two questionnaires that were developed in Study 1 to assess 
necessity and concern beliefs for nebulised medication categories in CF. The first, the CF-BMQ-A, 
was tailored to antibiotics, while the second, the CF-BMQ-M, to mucolytics. Importantly, although 
these questionnaires were developed separately for each nebulised medication category, the content of 
the final items were made identical (except for the substitution of ‘antibiotics’ vs. ‘mucolytics’). 
These questionnaires were also adapted to be completed by parents in the same manner as for the 
91 
 
BMQ-Specific, described above. The four versions of the BMQ-Specific and CF-BMQ-Specific for 
this study can be seen in Table 12 below: 
 
Table 12: The BMQ-Specific and CF BMQ-Specific divided into four versions by nebulised 
medication category and respondent. 
  Respondent 
  Child Parent 
BMQ-
Specific 
Mucolytic BMQ-Specific child 
mucolytic 
BMQ-Specific parent 
mucolytic  
Antibiotic BMQ-Specific child 
antibiotic 
BMQ-Specific parent 
antibiotic 
CF 
BMQ-
Specific 
Mucolytic CF BMQ-Specific child 
mucolytic 
CF BMQ-Specific parent 
mucolytic 
Antibiotic 
 
CF BMQ-Specific child 
antibiotic 
CF BMQ-Specific parent 
antibiotic 
 
Brief Illness Perception Questionnaire (B-IPQ) 
The Brief Illness Perception Questionnaire (B-IPQ) is a 9-item measure that has been 
designed to quickly assess cognitive and emotional representations of illness (Broadbent et al., 2006). 
It was developed from the Illness Perception Questionnaire-Revised, which has over 80 items and 9 
subscales, by reducing each of these sub-scales to just one item. Five of the B-IPQ items assess 
cognitive representations of illness perceptions: consequences, timeline, personal control, treatment 
control, and identity; while two items assess emotional representations: concerns and emotional 
impact. These cognitive and emotional perceptions are measured on a single scale of 0-10, with higher 
scores indicating increased negative impact of the illness on that domain of an individual’s life. The 
final two items examine their degree of understanding and perceived causal factors of the illness. The 
B-IPQ has been validated for use in adults (Broadbent et al., 2006) and has been adapted for use with 
parents and children (Sonney et al., 2017). The literacy level of this measure has been reported to be 
at the reading ability of 9- to 10-year-olds (Sonney et al., 2017), which is appropriate for this study’s 
target sample. 
For this study, the questionnaire was edited in several ways. First, the wording of the items 
was adapted to the participant group, by substituting ‘CF’ for the word ‘illness’ (i.e. ‘How much does 
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your illness affect your life?’ became ‘How much does your CF affect your life?). This measure is 
designed to be adapted in this manner (see Appendix O.1 to O.2). The phrasing of the items was again 
altered for completion by parents as well as patients (i.e. ‘How much does your CF affect your life?’ 
became ‘How much does your child’s CF affect their life?). Finally, the decision was made to remove 
the final item from this questionnaire which considers cause, since it is considered of little relevance 
to genetic illnesses (Olsen, Berg & Wieb, 2008). 
 
Measuring and calculating medication adherence 
 Adherence data for this study was collected through I-nebuliser devices. As described in 
detail in the introduction, these devices provide a ‘gold standard’ means to record adherence 
behaviour, through adaptive aerosol delivery and data-recording technology. These devices record 
both the date and time that medication is taken, and the dose inhaled, allowing information on how 
and when the device was used to be compared with prescription data, and adherence behaviour to be 
objectively calculated. 
The richness of data provided by the I-nebuliser device allows adherence to be defined and 
calculated in several ways. First, an overall measure of adherence can be determined by calculating 
the percentage of times that the nebuliser was taken over the number of times it was prescribed over a 
set period of time. This calculation can lead to a value above 100% if the patient uses the dose more 
than prescribed. Second, one can determine how consistently the medication was taken, by calculating 
the percentage of days that each patient fully adhered to their medication. Third, a minimum standard 
measure can be determined by calculating the percentage of days that the device was used at least 
once. Most studies relating to the I-nebuliser device have defined and calculated adherence using the 
first measure alone (e.g. McNamara, 2009; Daniels et al., 2011; Ball et al., 2013), though others have 
used a combination of these measures (e.g. Latchford et al., 2008). To allow comparison to previous 
research adherence was calculated using the first measure in this study. 
It is important to note that I-nebuliser devices code the dose successfully completed into three 
tiered categories: full, partial and none. ‘Full’ indicates that ≥75% of the dose has been successfully 
taken, while ‘partial’ indicates between 25% and 75%, and ‘none’ < 12.5%. For this study, the binary 
measure ‘medication adhered to’ was chosen to include such ‘partial’ recordings. This decision was 
made as clinicians report that a partial dose often represents a problem or malfunction with the device 
rather than a failure to adhere by the patient, while ‘none’ is considered to represent non-adherence, 
where patients activate the device, but do not complete it appropriately. 
Unfortunately, I-nebuliser recordings do not discriminate between different medications taken 
with the same device, preventing adherence behaviour from being calculated for individual 
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medications. To overcome this difficulty, where patients took more than one medication through the 
same I-nebuliser device, clinicians elicited patients’ typical patterns of medication use for each 
medication and used these to retrospectively identify which activations belonged to which medication. 
For instance, nebulised mucolytics are usually taken by patients at the start and end of each day, while 
nebulised antibiotics are typically taken in the afternoon. In instances where patterns were harder to 
discriminate, or varied over time, clinicians examined this data with patients to manually match it to 
the medication of interest. Importantly, this method of manually examining adherence data is 
routinely used in clinical practice, and while it is unlikely to be fully accurate, is the best method 
currently available for such cases. Also, some patients’ prescriptions changed during the data-
collection period (e.g. the dose frequency was modified, or treatment paused or ended). To 
accommodate this, prescription changes within the data-collection period were recorded, and 
adherence calculated accordingly. 
 
Procedure 
After being informed of the study, patients and parents who wished to participate were asked 
to complete the appropriate consent or assent form (see Appendix P.1 to P.3). Patients aged less than 
16 years old completed the assent form, and required the consent of their parents to take part. 
Participants were given the option to start the study at the appointment where the study was 
introduced, or at their following outpatient appointment. In the appointment where participants started 
the study, hereafter referred to as baseline, both patients and parents were asked to complete several 
questionnaires. Physiotherapists acted as field researchers for this study and administered these 
questionnaires at a time convenient to the running of the clinics. They provided participants with an 
overview of the different questionnaires, explained that they needed to be completed independently 
(i.e. without parents’ help in selecting answers, though they could clarify meaning), and encouraged 
questions. First, participants were asked to complete their appropriate version of the BMQ-Specifics 
and CF-BMQ-Specifics. Patients and parents within the ‘antibiotic-only’ or ‘mucolytic-only’ groups 
were given one BMQ-S questionnaire and one CF-BMQ-S questionnaire for their medication 
category, while those in the ‘combined’ group completed two BMQ-S questionnaires, and two CF-
BMQ-S questionnaires, one each for each medication category. Before completing these 
questionnaires, patients and parents were made aware of which specific medication they were 
completing each medication belief questionnaire for, if appropriate. For each item in these 
questionnaires, participants were asked to rate how much they agreed with each belief statement (on a 
scale from 1: strongly agree to 5: strongly disagree). All participants were then asked to complete the 
patient or parent version of the B-IPQ, which again asked them to rate their agreement with the illness 
perception items (on a scale of 0 to 10). Finally, patients were asked to complete a questionnaire 
seeking to assess the accessibility and usability of the CF-BMQ-Specific questionnaire (see Appendix 
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Q). They were asked to rate how well they understood the questionnaire items, and how well they 
liked them, and to report any items that they did not understand or like. Parents were asked to 
complete a short sociodemographic questionnaire for themselves. On average, each questionnaire took 
approximately 5 minutes to complete. Therefore, patients and their parents in the ‘mucolytics-only’ or 
‘antibiotics-only’ groups spent approximately 20 minutes completing these questionnaires, while 
those in the ‘combined’ group took approximately 30 minutes.  Participants were thanked for their 
participation and reminded that the next part of the study would require access to their I-nebuliser 
device at their next outpatient appointment. 
At patients’ next routine outpatient appointment, named the follow-up session, which occur 
on average at 6- to 8-week intervals at the sites, patients’ I-nebuliser data was downloaded by their 
physiotherapist. This data was then visually displayed through Insight software (Philips, Chichester, 
UK) and reviewed with patients and parents, to consider adherence levels and patterns, and data 
anomalies. Importantly, this method of examining the data represents routine practice at all three 
centres. Participants were then debriefed, thanked for their participation, and asked if they would like 
to receive a summary of the study’s findings. Following this, clinicians reviewed patients’ medical 
notes to complete the patient health and demographics form (see Appendix R). All data collection for 
this study took place between July 2019 and November 2019. 
 A visual representation of the procedure for phase 2 across the three nebulised medication 
categories can be seen in Table 13. 
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Table 13: The procedure in phase 2 for baseline and follow-up for each medication group, for 
patients, parents and clinician. 
  Mucolytics-only Antibiotics-only Combined 
 
 
  Patient Parent Patient Parent Patient Parent Clinician 
Baseline 
 
Consent forms ✓ ✓ ✓ ✓ ✓ ✓  
BMQ-Specific  
(Child version) 
✓  ✓  ✓✓   
 
BMQ-Specific 
(Parent version) 
 ✓  ✓  ✓✓ 
 
CF-BMQ-Specific 
(Child version) 
✓  ✓  ✓✓  
 
CF-BMQ-Specific 
(Parent version) 
 ✓  ✓  ✓✓ 
 
B-IPQ (Child 
version) 
✓  ✓   ✓ 
 
B-IPQ (Parent 
version) 
 ✓  ✓  ✓ 
 
Questionnaire 
evaluating the CF-
BMQ-Specific 
✓  ✓  ✓  
 
 Sociodemographic 
questionnaire 
 ✓  ✓  ✓ 
 
Follow-up  I-Nebuliser data        ✓ 
Health questionnaire       ✓ 
Note: The BMQ-Specifics and CF-BMQ-Specifics are identical in item contents, with only 
the item subject changing depending on the medication category of interest. The symbol ‘✓✓’ 
denotes that this questionnaire was completed twice, once for each nebulised medication category. 
 
Data analysis 
All data analysis was completed using IBM Statistical Package for the Social Sciences (SPSS, 
version 26, 2018) with statistical significance set at p<0.05 throughout. 
Before data analysis was completed, data was verified and cleaned, allowing identification of 
outliers, missing values and other irregularities. These items, and the subsequent actions taken, are 
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discussed in the appropriate sections. Although prior to inferential statistics all variables were 
assessed for parametric test assumptions, including normality and homogeneity, it was recognised that 
the very limited sample sizes reduced the validity of these tests. Therefore, the decision was made to 
be conservative and use non-parametric statistics in inferential analysis. 
Descriptive statistics were used to summarise the samples’ demographic and clinical 
characteristics, belief subscale scores and adherence behaviour. Categorical data was expressed as 
frequencies and percentages, while most non-categorical data was represented by means and standard 
deviations. It was reasoned that on balance the mean and standard deviation would offer the fairest 
representation of the data, since unlike the median and interquartile range they consider all the 
collected data, and were computable for all the groups, unlike the interquartile range which could not 
be calculated for the smallest group. In addition, the internal reliability of the BMQ-S and CF-BMQ-S 
necessity and concern subscales were examined using Cronbach alpha. This was not examined for the 
B-IPQ, since this measure only has one question for each illness representation. However, due to the 
limited sample conclusions from this analysis were limited, this will be discussed further in the 
relevant section. 
Inferential statistics used included correlational analysis and tests of difference. The former 
was used to identify significant relationships between continuous and/or ordinal variables and was 
completed through Spearman’s rank correlation (ρ). Correlation coefficients between 0-0.39 were 
interpreted as weak, those of 0.4-0.69 moderate, and those above 0.7 strong, in accordance with 
general opinion (e.g. Mukaka, 2012). Tests of difference were used to examine whether belief 
subscales and adherence scores significantly differed between categorical variables and were 
completed through Mann-Whitney U tests. Several of these tests were however, not computed due to 
the limited sample and this is highlighted in the relevant sections. Similarly, although multiple 
comparisons were completed in this study, no adjustments were made for mass significance, since this 
study was examined as a pilot. 
Finally, the planned multiple linear regression analysis to examine whether subscales from the 
medication questionnaires could predict adherence behaviour was not completed, since the study’s 
sample size was much smaller than expected, which would have led to inadequate power, increasing 
the chance of type-II error.  
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Chapter 6: Study Two Results 
Overview 
This results section will firstly describe this sample’s demographic and clinical characteristics 
before considering patients’ adherence behaviour to nebulised medications overall, by medication 
category, and by demographic and clinical characteristics. Following this, the medication beliefs of 
adolescent patients and their parents will be presented by questionnaire version (i.e. original or 
modified) and nebulised medication category (i.e. antibiotics or mucolytics). The bivariate 
relationships between belief subscales will then be assessed, followed by their relationship to 
objectively recorded medication adherence. Finally, patients’ and parents’ illness perceptions will be 
reported, and their relationship to adherence behaviour. 
 
Descriptive statistics 
Sample characteristics  
Between June 2019 and November 2019, 27 patients (Leeds = 14, Sheffield = 8, Liverpool = 
5) and 25 of their parents were approached regarding the study across the three sites. Fewer parents 
than patients were approached, as two older adolescent patients attended their clinics alone. In total, 
16 patients (Leeds = 7, Sheffield = 6, Liverpool = 3), and 14 parents (Leeds = 5, Sheffield = 6, 
Liverpool = 3) agreed to participate, equating to an average response rate of 58%. Reasons provided 
by patient-and-parent pairs for not wishing to take part included not being interested in research and 
not having the time. 
Unfortunately, data for four of the patient-and-parent pairs who started the study is not 
included in this analysis. For three of these pairs, a significant delay in data collection occurred, as 
they either did not attend follow-up clinic appointment(s) or attended but forgot to bring I-nebuliser 
device, preventing their adherence data from being downloaded. Due to the timescale of this project, 
it was not possible to delay data acquisition further. In addition, one patient’s I-nebuliser device 
malfunctioned in the data collection period, making their adherence data irretrievable. The 
demographic and clinical characteristics of participants is summarised in Table 14 below.  
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Table 14: Demographic and clinical characteristics of each patient and their parent. 
No Patient       Parent   
 Gender Age FEV1% Inpatient 
stays in the 
last year 
 
Pseudomonas 
growths in the 
last year 
Abscess 
growths in the 
last year 
I-nebuliser 
medication 
prescription 
Gender Age Relationship 
1 Female 13y 0m 67 0 1 0 DNase, Promixin Female 44 Mother 
2 Male 12y 2m 100 0 0 0 DNase Female 47 Mother 
3 Female 16y 8m 95 0 2 0 DNase, Promixin Female 40 Mother 
4 Female 16y 1m 57 2 0 0 DNase    
5 Female 14y 11m 96 1 0 0 DNase Male 46 Father 
6 Male 12y 8m 74 1 0 0 DNase Female 52 Mother 
7 Female 12y 2m 56 5 13 0 DNase, Promixin, 
Hypertonic Saline 
Female 30 Mother 
8 Female 16y 0m 62 5 0 12 DNase    
9 Female 13y 8m 77 2 0 0 DNase, Promixin, 
Hypertonic Saline 
Female 43 Mother 
10 Male 14y 2m 76 0 0 0 DNase Male 45 Father 
11 Female 13y 7m 113 4 0 0 DNase Female 32 Mother 
12 Female 15y 0m 71 4 0 0 DNase Female 48 Mother 
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Table 14 shows that most patients (75%, n=9) and parents (80%, n=8) who participated in the 
study were female, that the average age of patients was 14.17 years (S.D 1.56), and parents 42.7 years 
(S.D. 6.94). Patients’ mean FEV1% was 78.7%, although large variability was found between 
participants (SD=18.31%). These FEV1% ratings were equally divided between normal lung function 
(n=4; >90%), and mild (n=4; 70-89%) and moderate lung disease (n=4; 40-69%). Most patients (n=8; 
66%) had at least one inpatient stay over the previous year. Of these patients, half (n=4) had two or 
fewer inpatient stays, while the other half (n=4) had four to five inpatient stays. Most of the patients in 
this sample did not acquire a pseudomonas aeruginosa infection (75%, n=9) or grow abscesses within 
the last year (91.6%, n=11), although large variability existed between patients. While two of the three 
patients who did develop a pseudomonas aeruginosa infection did so on two occasions or fewer, the 
third developed this infection 13 times. Similarly, the one individual who developed abscesses within 
the last year developed them 12 times. Since only one individual experienced abscess growths within 
this sample, this clinical characteristic was not examined further. 
In total, across all 12 patients 18 medication prescriptions were delivered through I-nebuliser 
devices, consisting of 12 prescriptions of DNase, 4 of Promixin, and 2 of Hypertonic Saline. Most 
patients were prescribed DNase alone (66%; n=8), with the remaining patients taking either DNase 
and Promixin (16.6%; n=2) or DNase, Promixin and Hypertonic Saline (16.6%; n=2). Patients 
prescribed DNase alone were required to use their I-nebuliser once a day; those also taking Promixin 
were required to use it three times, and those who also took Hypertonic Saline, four times. 
 
Adherence data characteristics 
It is important to note that while 18 medications were delivered through the I-nebuliser 
devices, adherence data was only calculated for 17 of these, since one patient’s hypertonic saline was 
prescribed on an as-required rather than regular basis, preventing calculation of an overall adherence 
percentage. The mean number of days over which the I-nebuliser adherence data was collected was 
53.41 (7.63 weeks), although large variability occurred between individuals (S.D. 23.57, range 11 – 
88 days). Further inspection revealed that the mean length of time between the baseline and follow-up 
appointment was much lower at the Sheffield site (29 days), than at the Liverpool (56 days) or Leeds 
(69 days) sites. Importantly, the timespan over which adherence data was collected was similar 
between the medication categories; it was only slightly lower and more variable for mucolytics (M = 
52.54, SD = 24.79, range 11-88) than antibiotics (M = 56.25, SD = 22.17, range 25-73).  
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Adherence to nebulised medication in adolescent patients with CF 
Overall adherence 
 The overall mean adherence percentage for both categories of nebulised medications across 
patients was 69.55% (median 77.09), although large variability was found between patients (S.D. 
28.75, range 2.13-100). Figure 4 highlights this variability by displaying each patient’s adherence 
percentage to their nebulised medication(s).  
 
Figure 4: Patient adherence percentage to their nebulised medications. 
Figure 4 shows that while 50% (n=6) of adolescent patients adhered at least 80% of the time 
to their I-nebulised medication prescriptions, 42% (n=5) adhered to them less than 60% of the time. 
Of particular note within this low adherence group is Participant 8, who adhered just 2.13% of the 
time. Although this value was not considered an outlier statistically, it varies greatly from the mean, 
and from the next-lowest adherence value of 42.86%.  
 
Adherence by medication type 
Average adherence percentages were also calculated separately by antibiotic (n=4) and 
mucolytic (n=13) medication categories. Findings showed that, on average, patients were more 
adherent to mucolytic (mean 71.05, median 81.01) than antibiotic medications (mean 66.26, median 
65.55), but that adherence was more variable for mucolytic (S.D. 30.11, range 2.13 – 100), than for 
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antibiotic medications (S.D. 20.71, range 46.43 – 87.5). This difference was not however, found to be 
significant (U=21, p=.57).  
Examination of the distribution of adherence behaviour between the medication categories 
showed a similar level of high adherence for both, with 53% of nebulised mucolytic medication 
prescriptions and 50% of antibiotic prescriptions adhered to at least 80% of the time by patients. 
However, a higher rate of low adherence was found for antibiotic than mucolytic medications; 50% of 
antibiotic prescriptions were adhered to less than 60% of the time, compared to 31% of mucolytic 
medication prescriptions. 
 
Adherence by sociodemographic and clinical characteristics  
Differences in adherence behaviour by patients’ demographic and clinical characteristics can 
be seen in Table 15 below. 
Table 15: Examining differences in nebulised medication adherence by patients’ demographic and 
clinical characteristics. 
Patient demographic and 
clinical factors 
 Adherence 
Mean and SD 
p 
Gender Male (n=3) 
Female (n=9) 
 
92.40 (5.50) 
61.94 (29.46) 
 
.079 
Age <170 months (n=6) 85.43 (16.74) .041 
 >170 months (n=6) 
 
53.68 (30.55)  
FEV1% <75% (n=6) 57.15 (35.10) .150 
 >75% (n=6) 81.97 (14.74)  
    
Inpatient stays  Yes (n=8) 
No (n=4) 
63.14 (32.34) 
82.40 (16.14) 
.308 
    
Pseudomonas growths Yes (n=5) 79.00 (22.44) .465 
No (n=7) 62.81 (32.44)  
Two-tailed significance test using Mann Whitney U. 
Table 15 shows that although adherence to nebulised medications was higher for males 
(92.40) than for females (61.94), this difference only approached significance (U = 4, p = .079). A 
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significant difference was, however, found for age; patients aged under 170 months had significantly 
higher and less variable adherence (85.43, 16.74) than those aged over 170 months (53.68, 30.55) (U 
= 5, p < 0.05). For FEV1% ratings adherence behaviour was found to be lower (57.15 vs. 81.97) and 
more variable (35.10 vs. 14.74) for those with low (<75%) rather than high ratings (>75%), though 
this difference was not found to be significant. Finally, patients who had an inpatient stay within the 
last year had lower (63.14 vs. 82.40) and much more variable (32.34 vs. 16.14) adherence behaviour 
than individuals who had not had a hospital stay, and those who had experienced a pseudomonas 
growth in the last year had higher adherence rates than those who had not (79.00 vs. 62.81). These 
differences, too, were not found to be significant. 
The relations between patients’ age, FEV1% ratings, and adherence behaviour were also 
examined. A moderately strong negative relationship was found between patient age and adherence 
(rs(12) = -.616, p = .032) and a moderately strong positive relation between patients’ FEV1% ratings 
and adherence (rs(12) = .636 , p = .026), both of which were significant. A moderate negative 
relationship was found between inpatient stays and adherence (rs(12) = -.502, p = .096) and a weak 
positive relationship between pseudomonas growths and adherence (rs(12) = .223, p = .486), neither 
of which were significant. 
 
The Belief about Medicines questionnaires 
Necessity and concern beliefs for both categories of nebulised medications were elicited 
separately, using both the original BMQ-Specific and the CF-BMQ-Specific. Importantly, the CF-
BMQ-S concern subscale had 7 items, causing the summed score to range from 7 to 35, while the 
necessity subscale for the CF-BMQ-S, and the necessity and concern subscales for the BMQ-S, all 
have 5 items, so range between 5 and 25. To allow comparisons between these measures in analysis 
and calculation of necessity-concern differentials, these summed scores were computed to means, by 
dividing each subscale by the number of items in that scale. This provided a range of 1 to 5 for the 
necessity and concern scales, and between -4 and +4 for the necessity-concern differential. When the 
BMQ-S was developed, the elicited necessity and concern belief scores were categorised into high- or 
low-strength categories to allow description, through the use of a midpoint (Horne, et al. 1999). The 
midpoint for this study was placed at 3, similarly to Horne et al., (2004) when they used this same 
scale. It is also important to note that the final item within the CF-BMQ-S necessity subscales ‘I only 
need to take my nebulised medications when I am unwell’ was reverse scored, as the nature of this 
item means that increased disagreement, rather than agreement, relates to adherence. Finally, although 
all 12 patients and 10 parents completed these questionnaires, one patient only completed one side of 
each, so the decision was made to remove their data from the analysis. No other missing data occurred 
in these questionnaires. 
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Examining reliability of the measures 
In order to assess the internal reliability of the original and adapted measures, Cronbach alpha 
was calculated for necessity and concern belief subscales across all versions of the medication belief 
questionnaires. These calculations are presented in Table 16. 
Table 16: Cronbach alpha values for each subscale in each version of the medication belief 
questionnaires. 
  Patient 
Antibiotic 
(N=3) 
 
Mucolytic 
(N=11) 
Parent 
Antibiotic 
(N=4) 
 
Mucolytic 
(N=10) 
Measure 
 
Original BMQ-S 
 
 
Necessity 
(5 items) 
 
 
0.84 
 
 
 
0.39 
 
 
-0.40 
 
 
0.87 
 Concerns 
(5 items) 
-5.30 
 
0.77 0.73 0.37 
CF-BMQ-S Necessity 
(5 items) 
0.73 0.74 0.73 0.91 
 Concerns 
(7 items) 
-2.50 0.69 -1.42 0.61 
 
Debate exists within the literature regarding the alpha value needed to ensure the internal 
consistency of a measure, although accepted thresholds often range between 0.70 and 0.95 (e.g. Bland 
& Altman, 1997; Devellis, 2003; Polit & Beck, 2004). In this study, only half (8/16) of the subscales, 
across the original and revised BMQ-Specifics for patients and parents, exceeded this minimum value 
of 0.70. Also, half (4/8) of these values on the antibiotic questionnaire versions were found to be 
negative. Further data inspection showed that removal of just one item in 5/8 of these subthreshold 
subscales would have allowed the threshold to be met for all but the Parent BMQ-S mucolytic 
concern subscale, and both Patient and Parent CF-BMQ-S antibiotic concerns subscales. Low values 
generally suggest that multidimensionality is present within a subscale, with negative values also 
suggesting inverse relations. However, the low sample sizes, particularly for the antibiotic versions, 
may have underpinned these findings. Although the literature is not consistent on the sample size 
required to ensure the reliability of Cronbach alpha (e.g. Yurdugul, 2008; Samuels, 2015; Bonnett & 
Wright, 2015; Conroy, 2016) there is some consensus that reliability analysis should not be completed 
for samples of less than 30 (e.g. Yurdugul, 2008; Conroy, 2016). In view of this, this study’s sample 
sizes are inadequate to reliably examine the internal consistency of the subscales. Therefore, great 
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caution was applied in considering these internal reliability findings, and the decision was made to 
retain all items and to complete further analysis on an exploratory basis. 
 
Examination of medication beliefs  
 Descriptive statistics for the necessity and concern subscales for the BMQ-Specific and CF-
BMQ-Specific are presented in Table 17 by medication category (i.e. antibiotic or mucolytic) and 
respondent (patient or parent). 
Table 17: Descriptive statistics for the necessity and concern subscales for the BMQ-Specific and CF-
BMQ-Specific. 
  Mean and Std. Deviation  
  Patient  Parent  
Measure Antibiotics 
(N=3) 
Mucolytics 
(N=11) 
Antibiotics 
(N=4) 
Mucolytics 
(N=10) 
BMQ-S  Necessity 
 
3.73 (1.10) 3.62 (0.49) 
 
4.55 (0.25) 
 
3.80 (0.69) 
 
 Concerns 
 
1.93 (0.23) 
 
2.00 (0.66) 
 
2.65 (0.75) 
 
2.04 (0.55) 
 
CF-
BMQ-S 
Necessity 
 
4.27(0.64) 4.54 (0.48) 
 
4.65 (0.30) 
 
4.34 (0.63) 
 
 Concerns 
 
2.19 (0.22) 
 
2.00 (0.60) 
 
2.75 (0.47) 
 
2.34 (0.61) 
 
 
Table 17 shows that mean necessity beliefs were high across all versions of the BMQ-S and 
CF-BMQ-S. Indeed, all exceeded a mean value of 3, and several exceeded a value of 4. Interestingly, 
mean necessity beliefs for the CF-BMQ-S measures exceeded 4 across medications and respondents, 
while for the BMQ-S measures, only the parent antibiotic version exceeded this value. Examination of 
these differences in mean necessity scores between the original and adapted measures showed that 
mean mucolytic necessity belief scores for patients (U = 14.5, p < .001) and parents (U = 22.5, p <. 
05)  were significantly higher on the CF-BMQ-S than the BMQ-S, but that those for antibiotic beliefs 
were not.  
Concern belief mean scores were much lower than necessity belief scores across all versions 
of the questionnaires, all falling at or below a mean value of 2.75. All mean concern scores were 
higher for the CF-BMQ-S than BMQ-S, apart from the patient-mucolytic-concern ratings, which were 
105 
 
the same across both. None of these increases in mean concern scores from the BMQ-S to the 
equivalent CF-BMQ-S were, however, found to be significant. 
Differences in mean belief scores will now be considered between medication categories and 
respondents for each measure separately. On the BMQ-S, patient necessity and concern beliefs’ mean 
ratings were found to be very similar for antibiotic and mucolytic medications. Antibiotic medications 
gained a slightly higher necessity score (3.73 vs. 3.62), and slightly lower concern score (1.93 vs. 
2.00). However, it is interesting to note that antibiotic necessity ratings were twice as variable as those 
for mucolytics. For parents, antibiotic necessity (4.55 vs. 3.80) and concern (2.65 vs. 2.04) mean 
belief scores were much higher than for mucolytic medications. This difference was found to be 
significant for necessity beliefs (U = 4, p <. 05) but not for concerns. Finally, although parents’ 
mucolytic mean necessity and concern scores were similar to those of their children (3.80 vs. 3.62, 
2.04 vs. 2.00), parents’ antibiotic mean necessity and concern ratings were much higher than their 
children’s (4.55 vs. 3.73, 2.65 vs 1.93). These differences in mean belief scores between patients and 
parents for antibiotic medications were non-significant for necessity and concern beliefs.  
On the CF-BMQ-S, patients’ necessity beliefs were lower for antibiotics than mucolytic 
medications (4.27 vs. 4.54), and concern beliefs higher for antibiotics than mucolytics (2.19 vs. 2.00). 
Neither of these differences were found to be significant.  Parents’ mean necessity and concern scores 
were found to be lower for mucolytics (4.34 vs. 2.34) than for antibiotics (4.65 vs. 2.75), but again 
neither of these differences were significant. Parents’ belief ratings were found to differ from their 
children’s for both mucolytics and antibiotics. For antibiotic medications, parents’ necessity and 
concern mean scores were higher than those of their children (4.65 vs. 4.27, 2.75 vs. 2.19), while for 
mucolytic medications, parents’ necessity scores were lower than their children’s (4.34 vs. 4.54), and 
their concern beliefs higher (2.34 vs. 2.00). All of these differences in mean belief ratings between 
patients and parents were found to be non-significant; though the increase in mean antibiotic concerns 
score in parents from patients was found to approach significance (U = 1, p = .067).  
 
Examining correlations between the original and adapted BMQ-S measures 
Correlations were computed between necessity and concern subscale scores in the original 
and adapted BMQ-S measures, in order to assess whether equivalent belief subscales scores in the 
measures positively related. They were also computed between patient and parent necessity and 
concern scores, in order to examine whether patients’ beliefs related to those of their parents in the 
equivalent measure. These correlations are first presented for antibiotics and then for mucolytics. 
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Table 18: Correlations between the subscales of the BMQ-Specific and CF-BMQ-Specific across respondents for Antibiotic medications. 
Measure 
 
  BMQ- 
Antibiotic 
   CF-BMQ 
Antibiotic 
   
   Patient  Parent  Patient  Parent  
   Necessity  Concerns Necessity Concerns Necessity Concerns Necessity Concerns 
BMQ- 
Antibiotic 
Patient Necessity 
 
1 .000 
.500 
.866 
.167 
-.500 
.333 
1.0* 
.01 
-.500 
.333 
.866 
.167 
-.500 
.333 
  Concerns 
 
 
 1 .500 
.333 
.866 
.167 
.000 
.500 
.886 
.167 
.500 
.333 
.866 
.167 
 Parent Necessity 
 
 
  1 .316 
.342 
.866 
.167 
.000 
.500 
.000 
.500 
-.500 
.250 
  Concerns 
 
   1 -.500 
.333 
1.0* 
.01 
.775 
.113 
632 
.184 
 
CF-BMQ  
Antibiotic 
Patient Necessity 
 
    1 -.500 
.333 
-.866 
.167 
-.500 
.333 
  Concerns 
 
 
     1 .866 
.167 
1.0* 
.01 
 Parent Necessity 
 
      1 .544 
.228 
 
 
 Concerns        1 
Note: * = p ≤ 0.01          
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Table 18 shows that patients’ necessity and concern belief subscale scores in the BMQ-S 
positively related to the equivalent subscales in the CF-BMQ-S for antibiotic medications. However, 
for parents, only concern beliefs positively related across the measures, with necessity beliefs showing 
no correlation. All these positive correlations were at least moderate in strength, with the relation 
between patient antibiotic necessity beliefs between the original and revised measure, showing a 
significant and perfect correlation (rs(3) = 1, p < 0.05).  
Relations between patient and parent necessity and concern subscale scores in both the BMQ-
S and CF-BMQ-S can also be viewed in Table 18. For the BMQ-S these findings showed that 
relations between patient and parent necessity and concern beliefs were positive and strong. While for 
the CF-BMQ-S, although a significant and perfect correlation was found between patients’ and 
parents’ concern beliefs (rs(3) = 1, p < 0.01), the relation between patients’ and parents’ necessity 
beliefs was strongly negatively correlated. 
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Table 19: Correlations between the subscales of the BMQ-Specific and CF-BMQ-Specific across respondents for Mucolytic medications. 
Measure 
 
  BMQ- 
Mucolytic 
   CF-BMQ 
Mucolytic 
   
   Patient  Parent  Patient  Parent  
   Necessity  Concerns Necessity Concerns Necessity Concerns Necessity Concerns 
 
BMQ- 
Mucolytic 
Patient Necessity 
 
1 -.213 
.264 
.326 
.196 
-0.82 
.417 
.428 
.095 
-.72 
.417 
.670* 
.024 
.231 
.275 
  Concerns 
 
 
 1 .505 
.083 
.233 
.273 
-.452 
.081 
.860* 
.000 
.376 
.160 
.103 
.396 
 Parent Necessity 
 
 
  1 -.252 
.241 
.057 
.442 
.588* 
.048 
.511 
.065 
-.300 
.200 
  Concerns 
 
   1 -.571 
.054 
.389 
.150 
-.494 
.073 
.663* 
.018 
 
CF-BMQ  
Mucolytic 
Patient Necessity 
 
    1 -.379 
.125 
.331 
.192 
.017 
.483 
  Concerns 
 
 
     1 .165 
.336 
.392 
.149 
 Parent Necessity 
 
      1 .165 
.336 
  Concerns 
 
       1 
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Table 19 shows that patient necessity and concern belief subscale scores in the BMQ-S 
positively related to the equivalent subscales in the CF-BMQ-S for mucolytic medications. Both of 
these relations were of a moderate strength, with the relation between patient mucolytic necessity 
beliefs between the original and adapted measures reaching significance (rs(11) = .860, p < 0.05). 
Similarly, for parents, both necessity and concern beliefs positively correlated across the measures, 
and both were of a moderate strength, with the relation between necessity beliefs between the 
measures approaching significance (rs(9) =.511, p = 0.65), and that for concerns reaching significance 
(rs(9) = .663,  p < 0.05). 
 Relations between patient and parent necessity and concern subscale scores in both the 
BMQ-Specific and CF-BMQ-Specific can also be viewed in Table 19. Findings showed that, although 
the relations between patients’ and parents’ necessity and concern subscale belief scores were positive 
in both the BMQ-S and CF-BMQ-S, they were all weak in strength and none were significant.  
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Beliefs about medicines and their relationship to medication adherence 
Table 20 shows that although all the correlations between beliefs and adherence behaviour 
were non-significant, the strength of these relations differed between medication categories, 
respondents, and belief measures, with the strongest relations occurring within antibiotic medications. 
These relationships will now be considered in detail. First, the relationships between patient mucolytic 
beliefs, as measured by the BMQ-S and CF-BMQ-S, and adherence behaviour will be examined and 
compared with those found for antibiotic medications. These same relations will then be examined 
and compared for parents, before they are considered between respondents. 
Table 20: Examining correlations between necessity and concern belief subscales, including 
the differential, as examined by the BMQ-Specific and CF-BMQ-Specific, to adherence behaviour for 
antibiotic and mucolytic medications. 
   Respondent  
Measure Medication 
Category 
Belief type Patient Parent 
   rs p rs p 
BMQ-S Mucolytic Necessity -.253 .226 .409 .120 
  Concern .279 .203 .135 .355 
  Differential -.220 .258 .231 .260 
       
 Antibiotic Necessity -.500 .333 -.316 .342 
  Concern -.866 .167 -.400 .300 
  Differential .500 .333 .200 .400 
       
CF-BMQ-S Mucolytic Necessity -.373 .129 .118 .372 
  Concern .191 .287 -.043 .453 
  Differential -.456 .080 .103 .388 
       
 Antibiotic Necessity -.500 .333 .258 .371 
  Concern -.500 .333 -.316 .342 
  Differential .500 .333 .800 .100 
Significance testing was one tailed. 
Patient mucolytic necessity beliefs and the necessity-concerns differential were found to 
negatively correlate with adherence to mucolytic medications, while concern beliefs were found to 
positively correlate with adherence. This same pattern occurred in both the BMQ-S and CF-BMQ-S. 
These relations were all weak in the BMQ-S, while in the CF-BMQ-S, the necessity-concerns 
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differential was found to moderately relate to adherence behaviour, with the latter approaching 
significance (rs(11) = -.456,  p = 0.80). 
For antibiotics, patients’ necessity and concern beliefs were both found to negatively relate to 
adherence behaviour, while the differential was found to positively relate with adherence. This same 
pattern was found in the BMQ-S and CF-BMQ-S, with all relations occurring at a moderate level, 
apart from the correlation between antibiotic concern beliefs in the BMQ-S which was strong. 
For parents, different patterns were found between mucolytic beliefs assessed by the BMQ-S 
and CF-BMQ-S, and adherence behaviour. For the BMQ-S, parents’ necessity and concern beliefs, 
and the necessity-concern differential, were all found to positively relate to their child’s adherence 
behaviour. Although these relations were weak, apart from that between necessity beliefs and 
adherence, which was moderate. The CF-BMQ-S, like the BMQ-S, found positive relations between 
necessity beliefs and the differential, but these relations were weaker. However, unlike for the BMQ-
S, the CF-BMQ-S concern scale negatively related to adherence. The patterns and strength of these 
relations in both measures did not closely resemble those of their children for either questionnaire. 
Most notably, for the BMQ-S, while patients’ necessity beliefs and the necessity-concerns differential 
negatively correlated with adherence, those of parents positively correlated (e.g. -.253 and -220 vs. 
.409 and .231), with the same pattern found for the CF-BMQ-S (e.g. -.373 and -456 vs .118 and .103). 
Also, for the CF-BMQ-S, while patients’ mucolytic concerns were found to positively relate to 
adherence, those of parents were found to negatively relate, although both relations were very weak. 
Again, for parents, different patterns were found between antibiotic beliefs and adherence 
behaviour between the BMQ-S and CF-BMQ-S. Necessity and concern beliefs as measured by the 
BMQ-S were found to negatively relate to adherence, with this relationship reaching a moderate 
strength for concerns, while the differential had a weak but positive relationship to adherence. For the 
CF-BMQ-S, although concerns also showed a moderate (albeit slightly weaker) relation to adherence, 
necessity beliefs showed a weak positive, rather than moderate negative relationship, and the 
differential showed a much stronger relationship (.200 vs .800). The relational pattern between beliefs 
and adherence behaviour for the BMQ-S matched those shown by their children for the equivalent 
measure, although the relations were all weaker than for the parent measure. For the CF-BMQ-S, the 
pattern and strength of relations differed. Most notably, necessity beliefs were negatively related to 
adherence for children but positively related for parents (-.500 vs. .258), and while the relationship 
between concerns and adherence was weaker for parents than for their children (-.500 vs. -.316), the 
relationship between the differential was stronger for parents than for their children (.800 vs .500). 
 To further examine the relations between medication beliefs and adherence behaviour the data 
will now be presented in Tables 21 (for nebulised antibiotics) and Table 22 (for nebulised mucolytics) 
and inspected on an individual level. 
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 Table 21: Individual adherence and belief subscale scores for antibiotic medications, for both patients and parents, in the BMQ-Specific and CF-BMQ-
Specific. 
No. Antibiotics 
adherence % 
Patient belief score for antibiotics Parent belief score for antibiotics 
  BMQ 
Necessity 
BMQ 
Concern 
BMQ 
Differential 
CF-BMQ 
Necessity 
CF-
BMQ 
Concern 
CF-BMQ 
Differential 
BMQ 
Necessity 
BMQ 
Concern 
BMQ 
Differential 
CF-BMQ 
Necessity 
CF-
BMQ 
Concern 
CF-BMQ 
Differential 
1 87.50 3.00 1.80 1.20 3.80 2.14 1.66 4.20 2.40 1.80 4.80 2.71 2.09 
2              
3 80.41       4.80 2.80 2.00 4.80 2.43 2.37 
4              
5              
6              
7 50.70 5.00 1.80 3.20 5.00 2.00 3.00 4.60 1.80 2.80 4.20 2.43 1.77 
8              
9 46.43 3.20 2.20 1.00 4.00 2.43 1.57 4.60 3.60 1.00 4.80 3.43 1.37 
10              
11              
12              
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 Table 21 shows that all adolescent patients’ and parents’ mean necessity scores fell at or 
above the midpoint value of 3 across the original and revised measures, showing that all participants 
held strong beliefs about the necessity of their nebulised antibiotic medications. For concerns, all 
patients’ mean scores, and all but one of parents’ mean scores, fell below midpoint, in both the 
original and revised questionnaires, indicating that all patients and nearly all parents held weak 
concerns about adverse effects from these medications. All differential subscale scores were positive, 
which shows that, for both patients and parents, beliefs in the necessity of their nebulised antibiotic 
medications outweighed their concerns in both the BMQ-S and CF-BMQ-S. 
 Regarding individual belief scores and adherence rates for nebulised antibiotics, scores for 
patients 7 and 9 are particularly notable. Patient 7, despite reporting the highest possible level of 
necessity beliefs and low concern beliefs, and their parent showing a similar belief pattern, adhered to 
nebulised antibiotics just 50.07% of the time. Patient 9 and their parent reported the highest concern 
scores in both measures and had the lowest adherence rate of 46.43%.  
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 Table 22: Individual adherence and subscale scores for mucolytic medications, for both patients and parents, in the BMQ-Specific and CF-BMQ-Specific. 
No. Mucolytic(s) 
adherence % 
Patient belief score for mucolytics Parent belief score for mucolytics 
  BMQ 
Necessity 
BMQ 
Concern 
BMQ 
Differential 
CF-BMQ 
Necessity 
CF-
BMQ 
Concern 
CF-BMQ 
Differential 
BMQ 
Necessity 
BMQ 
Concern 
BMQ 
Differential 
CF-BMQ 
Necessity 
CF-
BMQ 
Concern 
CF-BMQ 
Differential 
1 96.43 
 
2.60 2.40 .20 3.60 2.00 1.60 4.00 2.20 1.80 4.00 2.00 2.00 
2 92.13 
 
4.00 1.60 2.40 5.00 1.43 3.57 4.00 1.20 2.80 5.00 1.14 3.86 
3 36.49 
 
      3.80 1.80 2.00 4.60 2.14 2.46 
4 50.62 
 
4.00 1.00 3.00 4.80 1.00 3.80       
5 81.01 
 
3.40 1.20 2.20 5.00 1.43 3.57 3.60 1.60 2.00 4.00 2.29 1.71 
6 98.04 
 
3.80 2.00 1.80 3.80 2.43 1.37 4.00 2.00 2.00 4.60 2.14 2.46 
7 63.89 
 
4.20 2.00 2.20 4.60 1.86 2.74 3.80 2.20 1.60 5.00 2.71 2.29 
8 2.13 
 
3.80 3.20 .60 4.60 2.86 1.74       
9 96.15 
 
3.60 2.80 .80 4.80 2.71 2.09 5.00 1.60 3.40 5.00 2.29 2.71 
10 87.04 
 
4.00 1.80 2.20 4.60 2.57 2.03 4.00 3.20 .80 4.00 3.43 .57 
11 100 
 
3.40 2.40 1.00 4.00 2.14 1.86 3.60 2.40 1.20 4.20 3.00 1.20 
12 42.86 3.00 1.60 1.40 4.20 1.57 2.63 2.20 2.20 .00 3.00 2.29 .71 
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 Table 22 shows that, on the BMQ-S, nearly all of patients’ (91%) and parents’ (90%) 
mean necessity scores fell at or above the mid-point value of 3, while for the CF-BMQ-S, all patients 
mean scores fell at or above this midpoint for both patients and parents. For concerns, all but one 
patient (92%) and one parent (90%) held mean belief scores which fell below the midpoint in the 
BMQ-S, while on the CF-BMQ-S all fell below midpoint for patients, and two (20%) above midpoint 
for parents. Together, these findings suggest that almost all patients and parents held strong beliefs 
regarding the necessity of nebulised mucolytic medications, and weak beliefs regarding adverse 
effects from these medications. All differential scores were positive across the measures and 
respondents, apart from one parent score, which was neutral on the BMQ-S. This shows that all 
patients’ and nearly all parents’ beliefs in the necessity of nebulised mucolytic medications 
outweighed their concerns, across the original and revised measures.  
 Regarding individual belief scores and adherence rates for nebulised mucolytics, those for 
patient 8 are of most interest. Patient 8 reported the highest concern subscale scores in both measures 
and had the lowest adherence rate of just 2.17%. 
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Illness perceptions 
Descriptive statistics for patient and parent illness perceptions and statistical testing of the 
difference in belief strength between them, are shown in Table 23.  
Table 23: Descriptive statistics for the B-IPQ subscales for patient and parent. 
 Mean and Std. Dev Difference 
Illness perceptions 
 
Patient 
(N=11) 
 
Parent 
(N=10) 
 
p 
Consequences 5.55 (2.16) 
 
6.10 (3.35) .500 
Timeline 9.18 (1.66) 
 
10.0 (0) .083 
Personal control 6.73 (1.85) 
 
5.50 (2.37) .128 
Treatment control 8.27 (2.41) 
 
9.30 (0.82) .597 
Identity 4.45 (1.64) 
 
5.80 (2.15) .154 
Illness concern 5.36 (1.63) 
 
8.50 (2.42) .005* 
Coherence 7.73 (1.60) 
 
8.30 (1.89) .367 
Emotional representation 4.55 (3.73) 
 
6.40 (2.91) .189 
 Significance testing was two tailed. 
Overall, Table 23 shows that all illness perceptions across respondents were either moderately 
(i.e. >3) or strongly held (i.e. >7), and that all mean illness perception scores were higher for parents 
than patients, except for personal control, which was higher for patients. Patients’ strongly held illness 
perceptions were timeline, treatment control and coherence. This suggests that the majority of 
adolescent patients percieved their CF to be chronic, their treatments to be efficacious, and reported 
understanding their illness well. It is interesting, however, to note that larger variability was present in 
the mean scores for treatment control and emotional representation.  Parents’ strongly held illness 
perceptions also consisted of timeline, treatment control and coherence, but with the addition of 
illness concern.  Interestingly, for parents, no variability occurred within timeline, and very little 
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within treatment control; while within consequences and emotional representations the largest 
variability was noted. 
The largest mean subscale differences between childrens’ and parents’ illness perceptions 
were for illness concern, emotional representation, personal control and illness identity. Parents 
therefore reported higher levels of concern about the illness, increased heights of emotional distress, a 
lower sense of perceieved personal control and a higher experience of symptoms, than did their 
children. Although all subscale differences between patients and parents were examined statistically, 
only parents’ illness concern beliefs were found to be significantly higher (8.50 vs. 5.36) than those of 
their children (U = 15.5, p < 0.05), although the difference between timeline (10.00 vs. 9.18) also 
approached significance (U = 40, p = .083). 
 
Illness perceptions and medication adherence 
 Correlations were completed to examine whether illness representations reported by 
adolescent patients and their parents relate to adherence to nebulised mucolytic medications. These 
relations were only computed for mucolytic medications due to the extremely limited sample size for 
antibiotic medications. 
 Table 24: Correlations between patient and parent B-IPQ subscales and adherence to 
nebulised mucolytic medications. 
Illness perception 
 
Patient 
N=11 
 
Parent 
N = 10 
 rs p rs p 
Consequences .312 .350 .116 .750 
Timeline -.202 .551 . . 
Personal control .077 .822 .414 .235 
Treatment control .077 .821 -.697* .025 
Identity -.139 .683 -.447 .196 
Illness concern -.374 .257 -.266 .457 
Coherence .065 .848 .544 .104 
Emotional representation  -.249 .461 .357 .311 
Significance testing was two-tailed. 
Table 24 shows that all relations between patients’ illness perceptions and adherence to 
nebulised mucolytic medications were weak, and none were significant. While most of these relations 
were positive, those between timeline, identity, and illness concern were found to be negative. For 
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parents, a relationship could not be examined between timeline and adherence, as all parents’ timeline 
responses were at the maximum rating for this item (i.e. all parents fully believed that their child’s CF 
would continue forever). Of the remaining 7 illness perception items, over half (4/7) were found to 
moderately, rather than weakly, related to their child’s adherence behaviour; these included personal 
control, treatment control, identity and coherence. Of these illness perceptions, identity and treatment 
control negatively related to adherence, with this latter relationship being significant (rs(10) = .697, p 
< 0.05).  This significant relationship shows that, as parents’ beliefs in the efficacy of their child’s 
treatment increases, their child’s adherence to their nebulised mucolytic medications significantly 
decreases. 
Finally, patients were asked to complete a questionnaire assessing the accessibility and 
usability of the CF-BMQ-Specific questionnaire. They were asked to rate how well they understood 
the questionnaire items, and how well they liked them on a scale of 0-10, and to report any items that 
they did not understand, or notably disliked. Overall, 12 patients completed these questionnaires. The 
mean score for understanding the items was 7.75, with some variability (SD 1.76, range 5-9). 
However, when patients provided qualitative feedback on which items they did not understand, the 
majority of comments made (5/6) were related to items in the B-IPQ or original BMQ-S, with just one 
relating to the CF-BMQ-Specific, about the accessibility of the item ‘I sometimes worry that taking 
my nebulised mucolytics now will mean that they won't work as well in future’. Feedback regarding 
how much they liked the items was high, with a mean value of 9.58, and little variability (SD 0.90, 
range 7-10); only one comment criticised an item, again from the original BMQ-S. It appears that 
adolescents were confused about which questionnaire they were being asked to complete this 
document for, or thought it would be useful to comment on all. Either way, these limited findings do 
not give a clear view on the accessibility of the CF-BMQ-S. 
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Chapter 7: Study Two Discussion 
 
Review of study two 
The primary purpose of study two was to investigate the extent to which the Necessity-
Concerns Framework can account for differences in adherence behaviour in adolescents with CF, to 
two categories of nebulised treatments. It also aimed to examine whether these relationships were best 
captured by the original BMQ-Specific or the revised CF-BMQ-Specific. Several secondary aims 
were also explored in this study. These included: i) exploration of adherence behaviour by medication 
type, demographic and health factors; ii) examination of medication beliefs between the medication 
categories and respondents; iii) assessment of illness perceptions of respondents, and their relation to 
nebulised medication adherence. However, assessment of these aims was limited by an inadequate 
sample which underpowered statistical analysis and led to the decision to examine study two as a 
pilot. 
This section will first examine adherence behaviour, before considering medication beliefs 
descriptively, and their relation to adherence behaviour in nebulised medications, after which illness 
perceptions will be examined. For each aim, a summary of the main findings will be provided, and 
they will, where possible, be considered in relation to the literature and the literature relating to the 
Necessity-Concern framework. After this, the strengths and limitations of this study will be discussed 
in detail. 
 
Adherence behaviour 
Overall nebulised medication adherence in adolescents with CF  
 In this adolescent sample, mean adherence rates for nebulised medications were relatively 
high at 69.55% and somewhat variable, between participants. This pattern, and the adherence rates 
themselves, are comparable to previous studies which have recorded adherence to nebulised 
medications through I-nebulisers in this population (McNamara et al., 2009; Ball et al., 2013). This 
supports the generalisability of this research, corroborating existing evidence that paediatric 
adherence rates are higher and less variable than those recorded for adults in nebulised treatments 
(Latchford et al., 2009; Eakin et al., 2011; Daniels et al., 2011; Quittner et al, 2014). This is important, 
as it highlights the need for research to separately examine adherence behaviour between these 
groups. Importantly, these purely objective adherence rates are, on the whole, lower than those 
reported in studies which examined adherence through subjective and/or less reliable objective 
measures (e.g. pharmacy refill data) in this treatment and patient group (e.g. Suri, et al., 2002; Modi et 
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al, 2006; Zindani et al, 2006). This study therefore also highlights the need for future research to use 
such technology to avoid the measurement error that arises from other methods. 
 
Nebulised medication adherence by medication category in adolescents with CF  
  Importantly, this study also examined adherence behaviour between nebulised medication 
categories. Adolescent patients’ adherence to mucolytics was found to be higher, although more 
variable (mean 71.05, S.D. 30.11) than their adherence to antibiotics (66.26, S.D. 20.71). Although 
this difference was not found to be significant, the antibiotic group’s small sample size, and the 
relatively large size discrepancy between the groups (N=12 vs. N=4), will have reduced the reliability 
of inferential analysis. Despite the small sample, this study’s adherence rates for antibiotics were 
found to be very similar to a previous study by McNamara et al. (2009) which also used I-nebuliser 
technology to examine adherence to nebulised antibiotics in this population, supporting the 
generalisability of these findings. These adherence rates are much higher than equivalent research in 
the adult population, where reports range from 31% to 53% (Quinn, et al, 2004; Latchford et al., 
2009), again supporting the need for research to separately examine adherence behaviour between 
these groups. Unfortunately, the adherence levels for mucolytics could not be compared to previous 
research, since studies using such electronic devices in the paediatric and adult CF populations have 
either examined adherence behaviour to nebulised antibiotics alone, or calculated adherence in a 
combined way across nebulised medication categories,  a surprising oversight. Overall, these findings 
suggest that a difference in adherence behaviour may exist between these medication categories, and 
highlight the need for further research, especially in relation to mucolytic medications. 
 
Nebulised medication adherence by demographic and health factors in adolescents with CF  
Adherence in this sample of adolescents was found to significantly reduce with increasing 
age, supporting previous studies by McNamara et al. (2006) and Zindini et al. (2006) who also 
examined this relationship for nebulised medications in this population, but opposing the findings of 
Modi et al. (2008). Interestingly, mean adherence rates were also found to be higher for males than 
female adolescents in this sample. Importantly, no previous research exists which has explored this 
relationship in relation to nebulised medications specifically, but these findings highlight the potential 
importance of exploring this further. 
Only FEV1% ratings were found to significantly relate to nebulised adherence behaviour in 
adolescents with CF in the current study, with patients with higher ratings found more likely to adhere 
than those with lower ratings. This supports previous research which has also examined this 
relationship in this population (Modi, et al., 2006). Although adherence-rate differences were also 
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found between the remaining health factors (i.e. inpatient stays, and number of pseudomonas 
growths), these inferential statistics did not reach significance. However, it is likely that the small 
sample size may have limited this analysis. Previous research did not exist to allow further 
comparison. 
 
Nebulised medication beliefs 
Medication beliefs by nebulised medication category and respondent 
 Overall, patient and parent necessity belief scores were high for nebulised antibiotic and 
mucolytic medications, while concern beliefs were low. This suggests that both patients and parents 
understood the importance of nebulised medications for maintaining health and did not hold strong 
concerns about their potential negative effects. This pattern of high necessity beliefs and low concerns 
has also been shown in previous research within this population, including within nebulised and oral 
antibiotic treatments, chest physiotherapy, and enzyme and vitamin treatments (Bucks et al., 2009; 
Goodfellow et al., 2015), and in inhaled corticosteroid treatment in asthma (Conn et al., 2007; Koster 
et al., 2015). The mean values and level of variability in patient belief scores for nebulised antibiotic 
and mucolytic medications cannot be directly compared to previous research, as none exists which has 
separately examined these medications. However, the variability scores found for nebulised 
mucolytics were generally comparable (if on the lower side) to those found in other treatments by 
Bucks et al. (2008), while those for antibiotics were more variable. Regarding the mean belief scores 
themselves, necessity scores as assessed through the BMQ-S were found to be similar to those 
previously reported in this population for chest physiotherapy, but lower than those reported for 
enzyme supplements or antibiotics. While concern beliefs were similar to those previously reported 
for enzyme supplements, but lower than those reported for chest physiotherapy and antibiotics. For 
the CF-BMQ-S all necessity scores were inflated, causing necessity beliefs to exceed any previously 
reported within CF, and concern beliefs for nebulised antibiotics to closely resemble those found for 
antibiotics. 
 Inspection of belief data on an individual level revealed that nearly all patients and parents 
held strong necessity beliefs, weak concern beliefs, and had necessity beliefs which outweighed their 
concerns, for both medications in both questionnaires. This data was not provided for the previous 
studies completed within CF, preventing comparison. However, in inhaled treatments in other chronic 
conditions within the paediatric population, greater variability in beliefs has on the whole been found. 
For instance, although Koster et al. (2015) also found a similar percentage of patients (10%) to have 
strong concern beliefs, over half  (58.1%) were found to have weak necessity beliefs for inhaled 
corticosteroids, and, in parents, Conn et al. (2008) found approximately one third to have weak 
necessity beliefs and strong concern beliefs, with: 77% of parents’ necessity scores outweighing 
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concern; 17% of parents’ concerns outweighing necessity; 6% having equal scores. This suggests that 
the range of belief scores for nebulised treatments could be lower than for relatively similar treatments 
in other chronic conditions. One potential reason for this could be the difference in healthcare input 
between these populations. CF patients regularly attend clinic reviews at their CF centres, so have 
more exposure to their clinicians and, in turn, greater opportunity to be educated about the necessity 
of their treatments, and to have any concerns listened to and responded to. However, in asthma, due to 
less frequent contact, such information about treatments from patients' healthcare staff may be less 
readily available. 
 
 Interestingly, some variety was found in belief scores in this study between medication 
categories and respondents. Parents were found to hold stronger necessity and concern beliefs for 
nebulised antibiotic than mucolytic medications, while their children’s beliefs were comparable across 
both. Parents’ necessity and concern beliefs for antibiotic medications were also much higher than 
their children’s, while their necessity and concern beliefs for mucolytics were comparable to those of 
their children. This suggests that parents perceive nebulised antibiotic and mucolytic medications 
differently in terms of their relative benefits and concerns, and hold stronger beliefs regarding 
antibiotic medications than their children do, supporting the importance of examining these beliefs 
separately between medication categories and respondents. Although such a difference in parents’ 
beliefs between mucolytics and antibiotics is not surprising, since, as previously described, they have 
different properties, it is interesting that their adolescent children do not exhibit such differences. 
Reasons for this could be that adolescents struggle to differentiate between these medications, as both 
are delivered in the same manner, that they are less educated than their parents about these 
medications, and/or less aware of cultural narratives, especially in relation to antibiotics. Such 
narratives include the concept of antibiotic resistance and adverse effects of antibiotics on our 
immune system’s ability to resist infection (Norris, Chamberlain, Dew, Gabe, Hodgetts & Madden, 
2013). Previous research within this population has identified that parents often have stronger 
medication-related beliefs than their children across medications, supporting the difference found 
between parent and child antibiotic beliefs in this study. Goodfellow et al. (2015) found that parents 
had significantly higher necessity beliefs than their adolescent children for enzyme supplements and 
vitamins, and significantly higher necessity and concern beliefs for chest physiotherapy.  
Within this study, correlations were also completed to assess the level of interdependence 
between children’s and their parent’s beliefs. Overall, these were positive for both antibiotic and 
mucolytic medications. However, although these relations were strong, and even significant, for 
antibiotic medications, the sample size is likely to have inflated these relations, and for mucolytic 
medications, they were found to be weak, which suggests that patient and parent beliefs are somewhat 
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independent. Although no previous research exists within CF which has examined medication beliefs 
for both patients and parents, previous research in asthma and preventer treatments has been 
conflicting. While Sonney et al. (2017) found treatment perceptions to be independent between 
parents and their children, Yilmaz et al. (2012) found significant correlations between parent and 
child BMQ-S necessity and concern beliefs.  
 
Relations between medication beliefs and adherence behaviour  
Patient and parent BMQ-Specific and CF-BMQ-Specific necessity and concern subscales, 
including the necessity-concerns differential, showed no significant relation to adherence behaviour 
for either nebulised mucolytics or antibiotic medications. This lies in contrast to the two previous 
studies completed in this population, which found that predictions based on the Necessity-Concerns 
Framework were significantly related to nebulised medication adherence behaviour (Bucks et al., 
2008; Maclean et al., 2015). However, the inferential statistics used in the current study need to be 
considered with great caution, as the sample sizes within this study were very small. Eleven patients 
and ten parents completed the medication belief questionnaires for mucolytic medications, and only 
three patients and four parents completed the equivalent questionnaires for antibiotic medications. 
Therefore, to understand whether the findings support the Necessity-Concerns Framework and 
previous research, the direction and strength of relations found between the subscales in the different 
questionnaire versions and adherence behaviour will be considered.  
Surprisingly, for mucolytic medications, the direction of relationships between patients’ belief 
scores and their adherence behaviour, as assessed by both the BMQ-S and CF-BMQ-S, were in direct 
opposition to what the Necessity-Concern Framework would predict. In contrast, all relationships 
between parents’ mucolytic-related beliefs and their children’s adherence behaviour were supportive 
of the model, except the correlation between concern beliefs as measured by the original BMQ-S. 
Although most of these relationships were very weak, the correlation between parents’ necessity 
beliefs and adherence behaviour, as assessed by the BMQ-S, was of a moderate strength. Overall, 
these findings suggest that the Necessity-Concerns Framework does not explain differences between 
adolescents’ adherence behaviour for mucolytic medications when their own beliefs are examined, but 
that their parents’ necessity beliefs may offer a potential means to understand this.  
For nebulised antibiotic medications, however, unlike mucolytic medications, the direction of 
relationships between patients’ concern beliefs and necessity-concern differential scores with 
adherence behaviour supported the predictions of the Necessity-Concerns Framework, in both the 
BMQ-S and CF-BMQ-S. Only the relationships between necessity beliefs and adherence did not 
support such predictions. Most of these relationships were of moderate strength, with a very strong 
relationship between concern beliefs, as assessed by the BMQ-S, and adherence. For parents, most 
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correlations between beliefs and adherence behaviour also supported the Necessity-Concern 
Framework’s predictions, with only the relationship between necessity beliefs, as assessed by the 
BMQ-S, failing to do so. However, most of these relationships were weak - only the relationship 
between concern beliefs, as assessed by the BMQ-S, was of moderate strength, and only the 
necessity-concern differential, as examined by the CF-BMQ-S, was strongly related to adherence. 
Together, these findings suggest that patients’ and parents’ concern beliefs, and the necessity-concern 
differential, offer a potential means to understand adherence behaviour for nebulised antibiotics in this 
population, supporting the potential utility of the Necessity-Concerns Framework. Findings that the 
necessity-concerns differential relates to adherence support the cost-to-benefit weighting assumption 
of the Necessity-Concerns Framework, and calls from other researchers for future studies to consider 
this (e.g. Foot et al., 2016).  
Together, these findings suggest that different aspects of the Necessity-Concerns Framework 
may mediate adherence behaviour between the two nebulised medication categories, that these 
relationships and/or their strength may change by respondent, and that the Necessity-Concerns 
Framework is potentially of stronger utility in understanding adherence to antibiotic than mucolytic 
medications. However, as before, the relationships between antibiotic medication beliefs and 
adherence behaviour need to be treated with great caution, as only three patients and four parents 
completed these questionnaires. While correlational analysis can theoretically be completed on 
samples of two and above, it is known that relationships can appear where none are present for 
samples below six (Aggarwal & Ranganathan, 2016). Therefore, it is not known whether this 
difference in strength, and indeed the relations themselves, are a true reflection or an artefact of a very 
small sample.  
 
Previous research 
It is difficult to directly compare these findings to the two previous studies completed in this 
area for nebulised medications, since they either examined antibiotics alone, or both categories in 
combination, did not consider the necessity/concerns differential, and either did not examine patients’ 
and parents’ beliefs, or collected either in isolation. Nonetheless, the next section will offer a 
comparison to this research within and outside of nebulised medications in the CF population. 
Findings from this study that patients’ necessity beliefs did not relate to their adherence to 
nebulised medications, are in opposition to those reported by Bucks et al. (2009), who found 
significant relationships between increased adolescent patient necessity beliefs and improved 
adherence behaviour to antibiotic medications. Although this difference may have arisen as Bucks et 
al. (2009) examined both orally delivered and nebulised antibiotics, and collected adherence data 
through self-report, it may equally reflect this study’s limited sample size. Findings that concern 
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beliefs were related to antibiotic adherence behaviour support those by Maclean et al. (2015), who 
found that increased concern beliefs were significantly related to lower adherence to nebulised 
medications in a paediatric population, while findings from this study which show that patients’ 
mucolytic-related concern beliefs did not relate to adherence, appear to oppose this study. However, 
Maclean et al. (2015) only examined relationships between medication beliefs and adherence to 
nebulised medications in a combined manner (i.e. antibiotic and mucolytic medications together), so it 
is unknown whether their findings applied to one medication category or both. Also, although 
Maclean et al. (2015) examined patients’ and parents’ beliefs, they combined them to create ‘family 
beliefs’, so it is not known if the relationship they found was present for patients, parents, or both, 
preventing comparison with the present study. 
This study’s findings of potential relationships between parents’ medication beliefs and their 
adolescent children’s nebulised adherence behaviour cannot be easily compared to previous studies, 
as none exist which have examined this. They will therefore be considered in relation to research 
outside of this treatment, and/or within inhaled treatments for other diseases, since arguably these 
medications most closely resemble nebulised medications in CF. The finding in this study that 
parents’ necessity beliefs may predict their child’s adherence behaviour, has previously been shown 
within the paediatric CF population, to both enzyme supplements and chest physiotherapy 
(Goodfellow et al., 2015), and to inhaled corticosteroid treatments in asthma (e.g. Klok et al., 2012). 
Similarly, this study’s findings that parents’ concern beliefs and the differential of their necessity and 
concern beliefs alone, may predict their child’s adherence behaviour, has been previously found in 
asthma preventer medication (e.g. Conn et al., 2007; Sonney et al., 2017).  
These findings have led such authors to highlight the importance of investigating parents’ 
beliefs, to understand their possible influence on their child’s adherence behaviour. This study 
therefore lends provisional support to such research, and the importance of parents’ beliefs - indeed, 
relationships between beliefs and adherence for mucolytic medications were only present for parents’ 
necessity beliefs. This finding potentially suggests that, for nebulised mucolytic medications, parents’ 
necessity beliefs may be more important in ensuring their adolescent children’s adherence behaviour 
than the child’s own medication beliefs. This is a surprising finding when one considers that 
adolescents are considered to take a stronger role than their parents in their health management at this 
age (e.g. Modi et al., 2008), and suggests a stronger influence from parents supporting their child’s 
adherence into adolescence than might be expected. However, further research is needed to 
understand whether such relations are replicable and capable of reaching significance in this 
population and treatment. As previously discussed, CF carries a burdensome treatment regime (e.g. 
Brennan et al., 2004), which parents are often involved in managing, so it is feasible that parents’ 
beliefs may have a stronger and more prolonged impact on their children’s adherence behaviour in CF 
compared to other conditions. In view of the influence of family and support systems beliefs on 
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adherence behaviour, some authors have raised the need for the self-regulation model to be placed 
more strongly within a social context, for such patient groups (Sonney et al., 2017; Kosse et al., 
2019). 
 
Inspecting belief data and its relationship to adherence on an individual level 
Due to the limited sample, and the problem of data aggregation within adherence research, the 
data was also inspected on an individual level. Interestingly this revealed that the patient who reported 
the highest concern beliefs for nebulised antibiotics, and another who reported the highest concern 
score for mucolytics were both found to have the lowest levels of adherence to these medications. 
Importantly, this suggests that concerns may relate, but only when they reach a certain strength. As 
previously discussed, concern beliefs were on average low within this study, and little variability in 
classification strength was present. Indeed, within most of the concern subscales for the medication 
belief measures, only one patient and parent held strong concern beliefs, which will have therefore 
limited the ability of this study to detect such effects. For instance, the unpublished feasibility study 
by Maclean, et al. (2015) highlighted the following trend for nebulised medications in the paediatric 
population; participants with concern scores of >3 (i.e. strong concern scores) had adherence rates of 
<70%, while adherence rates of those with concerns score of <3 (i.e. weak concern scores) were 
>80%. This comparison was not examinable in this study. 
 
Comparison of the BMQ-S and CF-BMQ-S 
Correlations between the equivalent subscales between the measures were mainly positive, 
suggesting that the measures are related. Interestingly, findings also showed that all mean necessity 
subscales scores, and most mean concern subscale scores, for both medication types, were higher in 
the CF-BMQ-S than for the BMQ-S, for both patients and parents, and significantly so for necessity 
beliefs. This suggests that the revised measures are capturing beliefs more strongly than the original 
measure, and that the revised necessity and concern items were therefore of higher relevance to 
patients and parents. However, despite this apparent increase in relevance, overall, the subscales of 
the CF-BMQ-S were found to relate less strongly to adherence behaviour in the ways expected by the 
predictions of the Necessity-Concerns Framework than those of the original BMQ-S. For instance, for 
mucolytic medications, for parents, the relations between necessity beliefs and the differential were 
stronger on the BMQ-S than CF-BMQ-S, and for antibiotics, relationships found between concern 
beliefs and adherence behaviour were stronger when assessed through the BMQ-S than the CF-BMQ-
S, for both patients and parents. The CF-BMQ-S was only superior to the BMQ-S in capturing the 
relationship between parents’ necessity and necessity-concerns differential scores and adherence 
behaviour for antibiotic medications. Unexpectedly, this suggests that the BMQ-S is more effective 
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than the adapted CF-BMQ-S in capturing necessity and concern beliefs which relate to adherence 
behaviour. Possible reasons for this will be examined in the final discussion section, alongside 
consideration of wider literature which has also sought to develop established tools into more specific 
measures. 
 
Illness perceptions 
Illness perceptions by respondent 
Overall, patients' and parents’ illness perceptions were at least moderately strong for all 
illness perceptions assessed, and showed a relatively high level of variability. Patients' most strongly-
held beliefs were for timeline, treatment control, illness coherence and personal control, suggesting 
that the majority of adolescents in this study perceived their CF to be chronic, their treatments to be 
efficacious, reported understanding their illness well, and felt that they had personal control over it. 
Parents also held strong illness perceptions for timeline, treatment control and illness coherence. 
Interestingly, parents’ illness perceptions were stronger than those of their children for all illness 
perceptions, except personal control. The difference in strength of illness concerns was significant and 
that for timeline perceptions marginal. This suggests that parents hold more concerns about their 
child’s CF than the child does, potentially since they are more aware of the trajectory of the disease 
and its potential impact on their child’s future, so they, unlike their children, all understand that this 
disease will last forever. 
These findings are similar to the only existing study to have previously assessed illness 
perceptions in adolescent patients with CF (aged 11-17 years). Bucks et al. (2009) found 
timeline perceptions to be the most strongly-held, followed by identity, treatment, and personal 
control. However, these findings differ from those found for adults in this population: Sawicki et al. 
(2011) found personal control, illness coherence and illness consequences to be most strongly held, 
followed by treatment control and illness timeline. Interestingly, this highlights how the relative 
strength of these perceptions may change between adolescents and adults with CF. Regarding parents' 
beliefs, these findings cannot be directly compared with previous research, since this is the first study 
to have examined parents' illness perceptions in CF. Previous research within other chronic conditions 
has, however, shown parents' illness perceptions to be stronger than those of their children in 
asthma (Sonney et al., 2017) and diabetes (Olsen et al., 2008; Gaston et al., 2011), supporting the 
differences found in this study. The novel evidence of differences between patients' and parents' 
illness perceptions in CF provided by this study highlights the importance of considering parents' 
beliefs about their child's illness in such populations. 
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Illness perceptions and adherence behaviour  
For patients, no illness perceptions were found to significantly relate to adherence, and all 
were weak in nature, while for parents, several illness perceptions were found to moderately relate to 
adherence, significantly so for treatment control. This suggests that the Self-Regulatory Model only 
has predictive validity for parents in this group, however, as previously discussed, the inferential 
statistics used in the current study need to be considered with great caution due to the small sample 
sizes. Also, it is known from a meta-analysis of this research area that effect sizes between illness 
perceptions and adherence are on average very weak (Brandes & Mullan, 2014), which will have 
further reduced the power of statistical testing to detect effects. Therefore, to consider these findings 
in more detail, and their similarity to previous research, the direction and strength of the most 
promising relationships will now be considered in detail. 
For patients, the strongest relationships between illness perceptions and adherence behaviour 
were found for illness consequences, illness concerns, and emotional representations, with inverse 
relations found for the latter two. These findings suggest that as adolescents perceive more 
consequences in their daily life from their CF, they are more likely to adhere. Conversely, when their 
concerns regarding their illness grow, or they experience more negative affect, they adhere less. 
Intuitively, the first finding makes sense; as individuals perceive the impact of their CF increasing on 
their daily life, this would increase adherence behaviour as a means to manage it. Similarly, increased 
concerns are likely to compound emotional wellbeing difficulties, which are considered to relate to 
more maladaptive coping mechanisms and thereby reduced adherence (Leventhal et al., 2001). 
 Interestingly, for parents, completely different perceptions related to adherence behaviour 
than in their children: treatment control, illness coherence, illness identity and personal control. The 
direction of these relations differed; treatment control and illness identity were inversely related to 
adherence, while illness coherence and personal control positively related. It makes sense that parents’ 
increased understanding of CF would support their child’s adherence, and that an increased sense of 
personal control over it for parents would likely relate to them being more in control of their child’s 
treatments, which is also likely to improve adherence. However, the inverse relations suggest, 
rather counterintuitively, that as a parents' belief in the efficacy of their child’s treatment increases, 
and they perceive their child as experiencing more symptoms of the illness, their child is less likely to 
adhere. One could speculate that parents who have stronger beliefs in the efficacy of treatments, 
and/or who notice more symptoms in their child, may engage in stronger 'controlling' behaviours to 
attempt to increase their child’s adherence, to which the child might then rebel, effectively decreasing 
their adherence. This may be why, in this study, treatment control beliefs for patients showed the 
joint-weakest relation to adherence. Such findings potentially highlight the complex interplay between 
patients' and parents' illness perceptions and their influence on coping behaviours. Interestingly, these 
relations somewhat mirror those found above for nebulised mucolytic treatment beliefs, where 
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parents’ necessity beliefs alone related moderately positively to their children’s adherence, while their 
children’s own beliefs related negatively; suggesting that a similar dynamic could offer an explanation 
for those findings. 
It is difficult to compare the provisional relations found for patients’ illness perceptions in this 
study to previous research, as, although Bucks et al. (2009) also examined illness perceptions in the 
adolescent population in relation to adherence, they only considered identity, timeline chronicity, 
treatment control, and emotional representations. Bucks et al., (2009) findings suggested that 
perceptions that CF is not amenable to treatment control, and that CF is not permanent, significantly 
related to poorer self-reported adherence to antibiotic treatments in adolescents with CF, and showed 
these effects to be moderately strong. In this study, relations between treatment control and adherence 
were very weak, and, for timeline chronicity, weak and inverse, suggesting the opposite relationship. 
In other words, in this study, adolescent patients who were more aware of the chronicity of their 
condition appeared less likely to adhere. However, Bucks et al. (2009) examined adherence behaviour 
in relation to a different treatment, and did so through self-report, which may underlie these 
differences, although equally they may be a reflection of this study’s limited sample size. The findings 
from this study are also in direct opposition to broader previous research: Brandes and Mullan's 
(2014) meta-analysis identified personal control, treatment control and coherence to be the most 
significant predictors of adherence across conditions in both adolescents and adults, and Law et al.’s 
(2014) systematic review (N=15) highlighted the importance of treatment control to self-management, 
while, in this study, treatment control, personal control and coherence showed very weak - in fact, the 
weakest - relationships to adherence. Together, these findings suggest that illness perceptions which 
are typically found to be predictive of adherence behaviour across other treatments may be of less 
relevance to adherence behaviour in nebulised mucolytic medications. However, as previously 
discussed the sample size on which these findings are based is very low, so further research is needed 
to understand whether these findings are representative or generalisable.  
As previously noted, this is the first study to have examined relationships between parents’ 
illness perceptions and their adolescent children’s adherence behaviour in CF. As such, again findings 
cannot be directly compared to previous research, but can be considered in relation to findings from 
other chronic conditions. The finding in this study that parents’ treatment control beliefs can predict 
their child’s adherence behaviour has been previously shown in other chronic conditions, including 
within inhaled corticosteroids in asthma (Klok et al., 2012; Sonney et al., 2017), insulin treatments in 
diabetes (Gaston et al., 2011; Prikken et al. 2019), and functional constipation (Koppen et al., 2018), 
although these relations were all positive in nature, unlike in this study. Regarding the relative 
strength of predictive relations for treatment control beliefs between patients and parents, similarly to 
this study, Gaston et al. (2011) also found that only parents’ illness perceptions significantly predicted 
their child’s adherence behaviour, while others have reported similar relations for both (Koppen et al., 
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2018; Prikken et al., 2019). Interestingly, Prikken et al. (2019) noted a three-way interaction between 
patients’ and parents’ beliefs and adherence behaviour. Such findings have led these authors to 
advocate the importance of investigating the influence of parents’ illness perceptions on their 
children’s adherence behaviour, even within their adolescent years.  This study therefore lends 
provisional support to such previous research and its conclusions. 
Overall, though provisional, these findings suggest that different illness perceptions relate to 
adherence behaviour for nebulised mucolytic medications between patients and parents, and that 
parents’ beliefs appear to relate to their child’s adherence more strongly than their child’s own beliefs. 
This surprisingly suggests that the Self-Regulatory Model could be of higher predictive validity for 
parents than patients in adolescent populations. However, further research is needed to determine the 
replicability and significance of such relationships. 
Finally, it is interesting to compare the predictive relationship to adherence behaviour noted 
for illness perceptions (as considered by the Self-Regulatory Model), with those found for treatment 
beliefs (as assessed by the Necessity-Concerns Framework). As previously explained, it has been 
argued that necessity and concern beliefs are superior to illness perceptions in predicting adherence 
behaviour (Horne et al., 1999). However, although the results for this study are provisional and must 
be approached with caution, they do not appear to show an advantage for such treatment beliefs over 
illness perceptions in predicting adherence behaviour to nebulised mucolytics. Indeed, no necessity or 
concern treatment beliefs, for either patients or parents, were found to significantly relate to adherence 
behaviour, while parents’ perceptions of treatment control were found to significantly relate to their 
child’s adherence behaviour for nebulised mucolytic medications. 
   
Study two strengths and limitations 
Several strengths and limitations exist in study two, which will now be discussed in detail. 
The major strengths of this piece of research lie in its originality. It is the first known study to 
examine the utility of the Necessity-Concerns Framework, including the necessity-concerns 
differential, in accounting, separately, for adherence behaviour to the two categories of nebulised 
medications in CF, rather than examining these medications in a combined fashion. This allowed 
adherence rates and beliefs to be separately examined between these medications for the first time. 
This study recognised that the Necessity-Concerns framework is likely to extend beyond the 
individual in adolescent patients, and therefore assessed both patients’ and their parents’ beliefs, 
which have not previously been separately examined and compared, in nebulised medications. While 
several studies within the adherence-related literature have adapted the original BMQ-Specific to 
more accurately examine necessity and concern beliefs for the illness and treatment of interest, it is 
believed that this is the first study to compare the validity and reliability of the refined measure to the 
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original. This is also the first known study to have examined illness perceptions from the Self-
Regulatory Framework, for both patients and parents, within this population, and to have examined 
the predictive validity of their beliefs to adherence behaviour in nebulised medications. Finally, in this 
study, adherence data was collected through a ‘gold standard’ objective measure, thereby overcoming 
the largest methodological barrier faced in adherence research and providing accurate data for this 
study. 
 The major limitation of this study is the low sample size. Within CF research, it is 
acknowledged that large participant numbers are often not feasible due to the relatively low 
prevalence of this condition, and reduced participation in studies due to the high level of burden 
individuals experience from the condition (Brennan, et al., 2004). This has led authors to report 
successful recruitment at sample sizes which would ordinarily be considered low, e.g. 38 participants 
(Bucks et al., 2008). Although, within this context, this study’s sample size is more favourable, it is 
important to acknowledge why recruitment was so poor, especially since it was completed across the 
three sites. Several unforeseen difficulties arose during data collection; most notably, at the Leeds and 
Sheffield sites, I-nebulisers were suddenly and unexpectedly decommissioned, leading to their 
reduced use during the data collection period. Other difficulties included unexpected leave of 
physiotherapists involved in data collection at two of the sites, I-nebuliser malfunction, and families 
forgetting to bring their devices to clinic on several occasions.  
 Overall, despite the small sample size and poor recruitment rates, the sample appeared 
representative. Heterogeneity was apparent in patient and parent socio-demographics, and patients’ 
health factors, and these factors were considered by the physiotherapists involved in the project to be 
representative of the target group. The only exception was gender, where females were 
overrepresented in both the patient and parent groups. The sample was recruited from three sites 
located in separate counties across England, which will have also increased the heterogeneity of the 
sample. Importantly, adherence behaviour was varied, with individuals with both low and high levels 
of adherence behaviour agreeing to participate, and the average adherence levels found in this study 
were found to be comparable to previous research in this area. However, it appears that the limited 
sample may have reduced the variability of treatment belief data available, and thereby reduced the 
ability of this study to detect effects. 
   It is important to acknowledge the significant impact that the limited sample size had on data 
analysis within this study. It both underpowered inferential statistics and prevented completion of 
several further analyses, which ultimately limited assessment of the reliability and validity of the 
original and revised medication belief questionnaires. For instance, although the internal reliability of 
each measure was computed for each subscale through Cronbach alpha, the reliability and usefulness 
of these computations were considered to be severely limited, so, despite potential problems in 
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internal consistency being revealed, no modifications were made. It also prevented assessment of 
construct validity through a confirmatory factor analysis. This analysis would be used to establish that 
items within the BMQ-S questionnaires are measuring one component i.e. necessity or concern 
beliefs. The correlational analyses between the belief questionnaire subscales and adherence 
behaviour are also questionable in their reliability, particularly for antibiotic medications, and all these 
relations were underpowered for statistical testing. The low sample size also prevented the use of 
regression statistics. This, in turn, prevented investigation of whether a regression model could be 
identified that would allow adherence behaviour to be predicted on the basis of an individuals’ 
necessity and concern beliefs about their medications. It also limited the ability to examine the 
influence of age on medication beliefs and in turn adherence behaviour. 
Although, as previously described, a key strength of this study lies in the use of I-nebuliser 
devices to collect adherence data objectively. It should also be noted that I-nebuliser recordings do not 
discriminate between different medications taken with the same device, preventing adherence 
behaviour from being objectively calculated for individual medications. To overcome this difficulty, 
where patients took more than one medication through the same I-nebuliser device, clinicians elicited 
patients’ typical patterns of use for each medication, and used these to retrospectively identify which 
activations belonged to which medication. Although used routinely in clinical practice, and 
considered by the clinicians in this project to be robust, it is nonetheless open to error. Nonetheless, 
this project raises awareness of this method for future research to consider as a means to delineate 
adherence behaviour between these medications 
Although this study was completed at two time points to allow a prospective design, and 
thereby prediction of adherence, it involved only a single assessment of patients’ and parents’ beliefs. 
Therefore, this study is not able to ascertain the direction of causality found between medication 
beliefs and adherence behaviour (i.e. if beliefs influence adherence, or vice versa) and is unable to 
examine a key time-based assumption of the Self-Regulatory Model: that coping behaviours 
(including adherence behaviour) are regularly evaluated over time following an individual’s appraisal 
of their effectiveness in managing their illness. Longitudinal research designs are needed to address 
these shortcomings. Interestingly, a longitudinal design could also allow investigation of any possible 
transfer of beliefs from parents to children, or vice versa 
 
Conclusion 
Overall, this study provides an indication of possible relationships between the Necessity-
Concerns framework and adherence behaviour in nebulised antibiotic and mucolytic medications. For 
nebulised mucolytics, parents’ necessity beliefs most strongly related to adherence behaviour, while 
for nebulised antibiotics, both patients’ and parents’ concern beliefs, and parents’ necessity-concern 
133 
 
differential scores did. This suggests that this model relates to adherence behaviour between the two 
nebulised medication categories and responders differently. Overall, these results highlight the 
importance of considering this model separately for the two categories of medication, the need to 
consider parents’ beliefs, and the potential utility of examining the weighting of beliefs through the 
necessity-concerns differential. 
 This study also provides an indication of possible relations between patients’ and parents’ 
illness perceptions and adherence to nebulised medications, which has not previously been examined. 
As with the Necessity-Concerns Framework, parents’ perceptions most strongly related to adherence 
behaviour for nebulised mucolytic medications, further highlighting the importance of considering 
parents’ beliefs. However, once again, no firm conclusions can be drawn due to the small sample 
sizes, which unfortunately underpowered statistical testing, and may have also reduced the reliability 
of the analyses themselves. Nonetheless, this research adds to the literature in several ways, and 
provides several novel concepts and directions for future research. Interestingly, it appears that the 
original BMQ-Specific may be a more effective tool than the CF-BMQ-Specific at capturing the 
necessity and concern beliefs that influence adherence behaviour in this population, despite the latter 
being specifically and systematically refined for this purpose. This will be considered further in the 
final discussion section, as will suggestions for future research and implications for clinical practice. 
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Chapter 8: Overall Discussion 
 
This final chapter will provide an overview of the main findings from the literature review, 
and the empirical results from the two studies completed in this thesis. Following this, the theoretical 
utility of the Necessity-Concerns Framework and Self-Regulatory Model for conceptualising 
adherence to nebulised treatments in adolescent patients with CF will be outlined, alongside the utility 
of adapting the BMQ-S specifically and systematically for this purpose, discussed within the wider 
literature. Novel contributions of these studies to the non-adherence literature will then be highlighted, 
and their strengths and weaknesses described. Finally, clinical implications and possible directions for 
future research to improve understanding and treatment of non-adherence will be presented. 
  
 
Review of background and aims 
This thesis assessed the ability of the Necessity-Concerns Framework to predict adherence 
behaviour to nebulised medications in adolescent patients with CF. Chapter 1 introduced the problem 
of sub-optimal adherence in CF, particularly in adolescents and within nebulised treatments. It 
explained how studies suggest that approximately 35% of such medication is not taken as directed in 
this patient group, and highlighted the potential consequences of this for individuals and society. 
These included reduced health outcomes, increased risk of morbidity and mortality, and increased use 
of health services, hospital admissions, and resource waste. 
A critical review of the factors considered to underlie poor adherence was then presented, 
highlighting how identifying these factors and developing methods to address them is currently a 
priority for adherence research and practice. It was recognised how, although practical barriers such 
as time and forgetfulness are often reported by patients to explain poor adherence, and have been 
extensively studied, psychological barriers arising from illness and medication beliefs may be stronger 
underlying factors, and, indeed, driving factors, of practical barriers. The review introduced 
psychological models of health behaviour, which explain how such beliefs may influence behaviour, 
including treatment adherence, and the subsequent research examining their utility. From this, it was 
concluded that the exploratory power of psychological models, and in particular, the Necessity-
Concerns Framework, appears to offer a promising means to understand how beliefs may influence 
adherence behaviour in chronic illnesses, in both adult and paediatric populations. 
The Necessity-Concerns Framework provides a theoretical model for describing how beliefs 
may influence adherence behaviour. It is built upon findings which show that individuals make 
implicit common-sense appraisals regarding their illnesses and treatments to help them manage their 
health. For specific prescribed medications, these appraisals have been found to fall into two main 
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categories. The first category, necessity, refers to implicit judgements about personal need for 
medication (i.e. how much one feels they need the medication to maintain/improve current and future 
health), while the second, concerns, refers to implicit beliefs held about potential adverse side-effects 
of taking the medication as prescribed. This model predicts that these beliefs influence adherence 
behaviour differently; necessity beliefs are argued to promote adherence, while concern beliefs 
hinder it. Similarly, it predicts that their relative strength influences an individual's decision to adhere 
to treatment recommendations, with stronger necessity beliefs relative to concerns 
promoting adherence, and vice versa. It is argued that, while for some patients, non-adherence will 
represent an informed choice based on these evaluations, for others, non-adherence will arise when 
necessity and concern beliefs are based on misconceptions of their illness and treatment. Such 
misconceptions are theorised to be influenced by social, cultural and healthcare-system contexts, 
and the individual's personal experiences of their illnesses and treatments. For instance, the preventive 
nature of many treatments in CF means that direct symptom relief is not experienced, leading 
individuals to logically conclude that such medication is not effective, and therefore unnecessary. If 
found to have predictive validity to adherence, this framework would offer a convenient means for 
clinicians to elicit and address key beliefs underpinning patients’ treatment decisions, in order to 
improve adherence. 
The review highlighted how, in the past two decades, over a hundred studies have examined 
the explanatory value of the Necessity-Concerns Framework in predicting adherence behaviour across 
a wide variety of chronic conditions, healthcare settings, and cultures. In the adult population, two 
meta-analyses consolidated these findings, demonstrating the utility of this framework for such 
applications. Interestingly, the most recent study explicitly demonstrated that the strength of predicted 
relations varies across conditions: for instance, necessity beliefs were found to be of greater 
importance to asthma, while concerns were more salient for cardiovascular conditions. It was then 
considered how, in the paediatric population, multiple studies have also supported the predictions of 
this model across conditions, including two published studies in CF. However, there is less overall 
research, and less research by condition, in the paediatric population than in the adult population. 
Interestingly, across these studies, the pattern and strength of relations between belief 
subscales and adherence behaviour also seem to somewhat vary between treatments, even within the 
same condition. Ultimately, it was concluded that such findings highlight the need for more research 
in the paediatric population, and the need for the Necessity Concerns Framework to be examined by 
individual illnesses and treatments, in order to understand which treatments and conditions it 
best applies to, and in turn, to allow interventions to be developed which target the specific beliefs 
that influence patients' adherence.  
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The paediatric adherence literature also highlighted how parents often have a strong role in 
managing their children's health needs within chronic conditions, making it reasonable to assume that 
their own beliefs might, in turn, influence their children’s adherence behaviour. This could occur 
through the active support they provide to their children, or through indirect transmission of beliefs, 
thereby sustaining their influence even as children may take increasing responsibility for their own 
health needs during adolescence. It was highlighted how several studies have shown that parents' 
treatment beliefs relate to their children’s adherence behaviour, in a manner supported by the 
Necessity Concerns Framework, across various conditions, which suggests that examining beliefs of 
individuals alone may be missing a key component of this model in regards to paediatric populations. 
 
This review then described how the Beliefs about Medicines Questionnaire Specific (BMQ-S) 
was developed as a means to assess the Necessity Concerns Framework. It is a generic measure which 
aims to assess necessity and concerns that are commonly shared across chronic health conditions, 
allowing it to be applied across treatments and illnesses. Due to its generic nature, the review 
highlighted how the wording and content of the questionnaire items have been modified in several 
studies to try to better capture beliefs influencing adherence behaviour to the specific condition and 
medication of interest. Within the review, it was highlighted that without such adaptation, certain 
items of the BMQ-S might be rendered irrelevant, or that beliefs relevant only to certain unusual 
characteristics of particular conditions and treatments might be missed entirely. Improved assessment 
of idiosyncratic beliefs is therefore considered to increase the psychometric properties of a measure, 
including predictive validity. In turn, this would increase the utility of this questionnaire as a 
screening measure, and provide a better picture of how to improve negative outcomes through the 
development of specific clinical interventions which account for these beliefs. For instance, CF and its 
medications have several unique characteristics, including the fact that patients can feel relatively 
healthy and asymptomatic, even when their organ functions are declining, and the fact that nebulised 
mucolytics provide no immediate symptom relief and work prophylactically. However, although the 
rationale for adapting the BMQ-S seems logical, it was recognised that the superiority of the 
questionnaire developed from such adaptations, compared to the original measure, has been assumed 
rather than assessed. This may be limiting assessment of the framework if these adapted 
questionnaires assess beliefs which are, in fact, less strongly related to adherence than those elicited in 
the original questionnaire. It was also highlighted how the process of adapting the BMQ-S to 
treatments of interest across health conditions is often not well described, or systematic, within 
existing adherence literature, with some studies seemingly relying on the research team's knowledge 
alone to complete this task, or simply describing the process of adaptation as a 'discussion'. It was 
suggested that such assumptions could present a major unexplored methodological issue in this 
research area. 
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The largest methodological barrier faced in adherence research: its commonplace reliance on 
subjective methods to record adherence behaviour, was then considered. Research has consistently 
shown that subjective report (e.g. self-report) is inaccurate, preventing robust assessment of adherence 
behaviour, and, in turn, accurate investigation of the factors that influence it, including beliefs. It was 
highlighted how nebulised treatments in CF offer a unique means to overcome this problem through 
‘gold standard’ objective recording of adherence, provided by the I-nebuliser devices used 
to deliver nebulised medications. Therefore, examining the Necessity-Concerns Framework through 
adherence data collected by I-nebulisers offers a singular opportunity to test this model with robust 
data, something not currently afforded to other chronic illnesses and treatments. Despite this, the 
review showed that research using this measurement method is extremely sparse. 
 
The surprising paucity of research considering the Necessity Concerns Framework in relation 
to nebulised medications was then highlighted, considering the unique opportunity to robustly test this 
model afforded by I-nebuliser devices, and the key role of nebulised treatments in preventing and 
treating lung infections - primary causes of morbidity and early mortality in CF. It was recognised 
that, although the two existing studies to have examined this framework within nebulised treatments 
showed promising results, only one measured adherence through an I-nebuliser device, and both used 
a refined BMQ-S which was found to have inadequate psychometric properties on the concerns scale, 
which limited analysis. It was also highlighted how one of these studies failed to apply this model 
separately to the two categories of nebulised medications, while the other did not examine both 
categories. The Necessity Concerns Framework is intended to be applied to individual treatments, not 
categories of treatment delivery - although two medications may both be delivered in a nebulised 
manner, they may share virtually no other relevant properties. The amalgamation of different 
nebulised medications together therefore represents a significant oversight when their different 
properties and purposes are considered. Taken alongside the research highlighted above, this 
suggests that the strength and manner in which this model relates to adherence is likely 
to differ between treatments. Also, the role of parents' beliefs, although previously considered in one 
of these studies, were combined with their children’s beliefs rather than examined separately. It was 
considered that further research was warranted to overcome these shortcomings in adherence 
measurement and questionnaire development, and two studies were devised to address this in this 
thesis. 
  
Study one, presented in chapter 2, aimed to develop and explicitly describe a process for 
adapting the BMQ-S to separately examine necessity and concern beliefs pertinent to nebulised 
antibiotic and mucolytic medications in CF, and to create a second version of each questionnaire for 
completion by patients’ parents. Study two, presented in chapter 5, assessed whether the beliefs 
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elicited by the original and/or adapted measure could account for differences in adherence behaviour 
within either/both category of nebulised treatments, in accordance with the predictions of the 
Necessity-Concerns Framework, and assessed whether one was superior to the other. It also 
considered whether patients’ or parents’ beliefs captured these relations differently. Further, 
secondary aims included: i) exploration of adherence behaviour by medication type, 
sociodemographic and health factors; ii) examination of medication-related beliefs between the 
medication categories and respondents; iii) assessment of illness-related beliefs between respondents, 
and their relation to nebulised medication adherence. 
 
 
Summary of findings 
Study one: Developing the CF-BMQ-S 
Study one used a modified two-round Delphi survey to systematically gain feedback from a 
panel of experts (individuals with clinical expertise in supporting adherence to nebulised medications 
in CF) on the content of items within two BMQ-S questionnaires that the research team had already 
partially adapted from the original. These questionnaires aimed to capture necessity and concern 
beliefs relevant to nebulised antibiotic and mucolytic medications that may influence adherence 
behaviour in adolescent CF patients. The first round aimed to assess consensus from the 
panel regarding the items’ usefulness and clarity, while the second round aimed to increase 
this consensus with final revisions, driven by the first round's feedback. In each round, participants 
rated the usefulness and clarity of each item in both questionnaires, and were asked to comment on 
their ratings and/or provide suggestions for new items. 
 
In round one, initial consensus was positive regarding the value of items in both 
questionnaires, but findings regarding clarity were more variable. Of the 21 items rated, just 4 items 
failed to achieve statistical consensus for value, while 10 failed to attain consensus for clarity, and 
seven suggestions were provided for new items. As a result, for the second round, three concern items 
(two from the CF-BMQ-A and one from the CF-BMQ-M) were removed, eight items (four necessity 
and four concern) were identically revised in each questionnaire, and one new necessity and two new 
concern items were created. In round two, only two items failed to reach statistical consensus for 
value (one on each questionnaire, including a newly-added concern item), all items attained consensus 
for clarity, and just one suggestion was made for a new item. As a result of this high level of 
consensus, no further alterations were made. It was considered by the supervisory team that any 
further alterations were equally likely to reduce consensus as improve it, and that there would be no 
further means to assess this, as the final round was already concluded. Importantly, the decision was 
also made by the supervisory team to make both questionnaires the same in content (differing only in 
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their reference to 'mucolytics' or 'antibiotics'), even though some items were considered of potentially 
less relevance to either medication treatment category, in order to support direct comparison between 
these questionnaires and their relation to adherence behaviour, in study two. The parent and patient 
versions of both questionnaires only differed in reference to 'my' or 'my child's' medication, for the 
same reason. 
 
Study two: Evaluating the CF-BMQ-S  
Study two explored the relationship between necessity and concern beliefs about medicines, 
as measured through the original BMQ-S and the adapted CF-BMQ-S, and adherence behaviour. 
Overall, findings showed no significant relationships between patients’ or parents’ necessity or 
concern beliefs, and adherence behaviour to either medication category, using either the BMQ-S or 
CF-BMQ-S. However, these correlational analyses were underpowered due to an inadequate sample 
size, leading the direction and strength of these relationships to be considered as an indicator of 
possible relations. For nebulised mucolytic medications, findings suggested that adolescents’ own 
beliefs do not explain their adherence behaviour in accordance with the predictions of the Necessity-
Concerns Framework, but that their parents’ necessity beliefs may offer a potential means to 
understand this. For nebulised antibiotics, findings suggest that patients’ and parents’ concern beliefs, 
and the necessity-concern differential, offer a potential means to understand adherence behaviour 
in this population. These findings support the potential utility of the Necessity-Concerns 
Framework and highlight how this model may relate to adherence differently between medication 
categories and responders.  
 
Findings also unexpectedly showed that these correlations between necessity and 
concern subscales and adherence behaviour were generally weaker for the CF-BMQ-S than for 
the unmodified BMQ-S, suggesting that the original measure is superior in assessing beliefs which 
relate to adherence behaviour in this population. Interestingly, this occurred despite mean necessity 
and concern belief scores being higher in the CF-BMQ-S than the BMQ-S across medication types 
and respondents, which suggested that these adapted items were indeed of increased relevance to 
patients and parents. These relations between treatment beliefs and adherence behaviour were also 
inspected on an individual level. Interestingly, this revealed that the patients who gained the highest 
concern scores for each medication type also had the lowest adherence rates to each. This potentially 
suggests that concern beliefs may only impact adherence once they achieve a certain strength - this 
will be considered further in the future research section. 
 
 Finally, relations between illness perceptions and adherence behaviour were considered. 
Overall, although this study’s findings showed no significant relationships between patients’ illness 
140 
 
representations and adherence behaviour, they did reveal a significant relation between parents’ 
treatment control perceptions and their child’s adherence behaviour to nebulised mucolytic 
medications. This finding counterintuitively suggests that, as parents’ beliefs in the efficacy of the 
child’s treatment increases, their child’s adherence behaviour decreases. It was reasoned that this may 
occur as parents who strongly hold such beliefs may be more likely to engage in behaviours which 
they believe will support their child to adhere, but which inadvertently cause their child to ‘rebel’ and 
adhere less. Such findings further highlight the potential importance of parents’ beliefs on adherence 
in this population. Perhaps most importantly, these findings suggest that treatment beliefs do not 
appear to be superior to illness perceptions in predicting adherence behaviour to nebulised 
medications. However, as discussed throughout, the provisional nature of these results prevents firm 
conclusions. The implications of these findings will not be discussed further here, as examining these 
relations was a secondary aim of this study. Reasons why the adapted measure could seemingly have 
more relevance, but more poorly relate to, the outcome of adherence, will be considered next and 
discussed within a wider empirical literature, where other studies have also adapted generic 
questionnaires in order to increase their clinical utility. 
 
Adapting questionnaires measures within the context of psychological research 
A convention exists within psychological research which assumes that measures become 
more meaningful as they are adapted to the specific topic of interest. As such, the BMQ-Specific has 
been adapted for certain conditions, in the belief that this will allow beliefs idiosyncratic to a 
particular illness and treatment to be measured more accurately, thereby increasing the psychometric 
properties of this measure. Several such adaptations of the BMQ-S have sought to improve the 
predictive validity of this measure for adherence. Across chronic conditions, such modifications 
have involved minor revisions to existing items, removals, and illness/treatment-specific 
additions targeting beliefs considered likely to influence adherence behaviour. Although the validity 
and reliability of these adapted measures has been examined, albeit to different levels, and has usually 
been found to be acceptable, no study was found during the review which compared the predictive 
validity of the original BMQ-S to an adapted version. Therefore, this is the first known study 
to directly compare the predictive validity of the original BMQ-S in adherence behaviour with that 
of an adapted measure. 
 
Therefore, in order to support discussion of such findings, wider literature which has adapted 
the Illness Perception Questionnaire-Revised (IPQ-R; Moss-Morris et al., 2002) was considered, in 
order to examine if such comparisons have been made for this measure. The IPQ-R is the most highly 
researched illness perception measure. It was developed and structurally validated as a generic 
measure to provide quantitative assessment of illness perceptions across patient groups, as 
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conceptualised through the Self-Regulatory Model of adherence behaviour. Relationships have been 
shown, as predicted, between illness perceptions and a range of outcomes, including adherence, 
coping strategies and quality of life (e.g. Kosse et al., 2019; Knowles, Apputhrai; O’Brien, Ski, 
Thompson & Castle, 2020). As with the BMQ-S, researchers are encouraged to modify items in order 
to suit particular illnesses, cultural settings or populations (Moss-Morris et al., 2002). Modifications to 
increase specificity can range from the simple act of substituting the term ‘illness’ with the name of 
the specific condition being investigated, to removing, adding, or re-wording items, especially in the 
'causes' and 'illness identity' subscales. These larger modifications are considered to allow in-depth 
insight into idiosyncratic beliefs held by specific patient groups, and thereby to improve the 
psychometric properties of the revised measure (French & Weinman, 2008). 
 
Several studies have completed such modifications and validated them, for illnesses including 
fibromyalgia (van Wilgen, van Ittersum, Kaptein & van Wijhe, 2009), cancer (Moon, Moss-Morris, 
Hunter & Hughes, 2017), memory difficulties (Hurt, Brown & Barrowclough, 2010) and atrial 
fibrillation (Taylor, O’Neill, Hughes & Moss-Morris, 2018). Such validation has included assessment 
of test-retest reliability, internal consistency and construct validity. Again, the process of completing 
these modifications varies in its robustness; while some studies have relied on the clinical experience 
of the authors alone (e.g. van Wilgen et al., 2009), others have reported a clearer and more systematic 
process, including the use of qualitative interviews and think-aloud techniques (Moon, et al., 2017; 
Taylor et al., 2018). Indeed, within this research area, a mixed-method approach is advocated when 
modifying and validating the questionnaire (French & Weinman, 2008). Although, as described, these 
measures have been found to have adequate psychometric properties, no comparisons appear to have 
been made against the original measure within this validation process, or in subsequent studies. 
  
The question of why the refined CF-BMQ-S may have related less strongly to adherence 
behaviour than the original questionnaire, despite it appearing of greater relevance to patients, will 
now be considered. One factor could be that the refinements made weakened the strength of item 
statements, causing the variability of participant 'agree/disagree' responses to decrease. For instance, 
adaptations included changes which employed more moderate language: ‘Without 
my nebulised medication I would be very ill’ became ‘Without my nebulised medications, my health 
would be much worse’. However, average variability scores in the necessity and concern subscales 
were largely comparable between the original and refined BMQ-S, across medication types and 
responders. The only exceptions were in the patient necessity subscale for antibiotics, and in the 
parent concerns subscale for antibiotics, where average variability was higher in the BMQ-S than in 
the CF-BMQ-S. Therefore, although reduced variability in some of the overall CF-BMQ-S subscales 
may account for some of the weakened relations between these measures and outcome, it does not 
offer a full explanation. 
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Another reason could be that some items were made more specific in the refined measure. 
During refinement of the BMQ-S, it was recognised that certain items were vague and general in their 
wording, particularly in the concerns scale. It was considered that this could lead to individuals having 
difficulty in interpreting the items, and/or cause participants to interpret them in different ways. For 
instance, in the original item “I sometimes worry about becoming too dependent on my medications”, 
the word 'dependent' could be interpreted in terms of addiction, interference on daily life, or 
diminishing medication effects. This item was replaced with the most plausible interpretation of a 
dependence concern for this client group “I sometimes worry that taking my nebulised medications 
now will mean that they won't work as well in future”. Although this refinement sought to increase the 
item's clarity, it may have inadvertently reduced the ability of participants to interpret the question 
more broadly, and thereby reduced the ability of the measure to capture wider concerns that influence 
their adherence behaviour. 
 
A further reason could simply be that the new items in the CF-BMQ-S genuinely related less 
strongly to adherence behaviour than the original items. In the development of the CF-BMQ-S, two 
fundamentally new items were added, extending the nature of 'necessity' and 'concern' within this 
questionnaire. These items were “I only need to take my nebulised medications regularly if I feel 
unwell” and “Taking my nebulised medications is embarrassing”. The first was considered to broaden 
the definition of necessity, by considering not only if a medication is needed to maintain or improve 
current health, but also when, or how frequently, it needs to be taken. Although an interesting item, as 
it illustrates how symptom perceptions influence patients’ perception of medication necessity, in 
retrospect it may be more of a surface belief; one could know logically that they need to take 
medication regardless of their current health, but could still believe that it does not work for them. The 
second refinement is considered to extend the definition of concern, by moving from concerns 
regarding health and the medication itself, to the medication delivery system, and related social 
aspects. Although it is interesting to consider the I-nebuliser as a delivery device alongside beliefs 
concerning the medications themselves, it is not known if such beliefs influence adherence. 
 
Overall strengths and limitations 
The individual strengths and limitations of both studies that comprise this thesis have been 
considered in their respective discussion sections, so this section will present them in an aggregate 
manner. Ultimately, the strengths of this project are its areas of originality, and how it was 
implemented through a two-part process, which uniquely allowed the CF-BMQ-S to be both 
developed and then evaluated for its utility. This is the first known study to have adapted the BMQ-S 
to nebulised medication categories in CF. It is also the only known study to have examined the 
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predictive validity of the Necessity-Concerns Framework to adherence behaviour separately for the 
two medication categories in nebulised treatment, and to have compared these relations between the 
original and revised measures, and between patients’ and parents’ beliefs. The findings which arose 
from these novel elements have extended the existing body of research and raised several clinical and 
research implications for current practice, which will be discussed in the following section. 
The overall weakness shared by both studies within this thesis was their limited sample sizes, 
which, importantly, limited the psychometric assessment of the original and revised medication belief 
questionnaires in both studies. In study one, only clinicians evaluated the questionnaire items, and 
only the minimal number required took part. This small sample, alongside the homogeneity of 
respondents, is very likely to have reduced the variability of group judgements, and thereby the face 
validity and generalisability of the developed CF-BMQ-S.  Research recommends that a heterogenous 
panel of experts by both profession and experience is needed to support the face validity of a measure 
(e.g. Hardy et al., 2004). Therefore, due to poor recruitment, the face validity of this measure was 
only partly ascertained; future input by patients and parents with lived experiences of these 
medications would be needed to fully assess the face validity of the CF-BMQ-S. 
 
In study two, the sample size was so limited that the reliability of the analyses themselves 
were rendered unclear, the statistical tests that were completed were underpowered, and several 
analyses could not be undertaken at all. Most importantly, this limited the assessment of the predictive 
validity of the original and revised BMQ-S questionnaires, since the reliability and statistical 
significance of the correlations were unclear, particularly for antibiotic medications. Regression 
analysis could also not be computed, so this study was unable to examine how much of the variance 
within nebulised adherence behaviour could be accounted for by medication beliefs, nor determine the 
utility of a predictive model to allow adherence behaviour to be predicted on the basis of an 
individuals’ necessity and concern beliefs about their medications. Ultimately, the assessment of 
predictive validity in this study was limited to providing an indication of potential relations between 
the belief subscales and adherence behaviour. The small sample also prevented assessment of the 
construct validity of the CF-BMQ-S through confirmatory factor analysis. As previously discussed, 
several revisions were made to items from the original BMQ-S when developing the revised 
questionnaires, and it is subsequently unknown whether these revised items would fit within the 
original two-factor structure of this questionnaire and model, and how strong the item loadings would 
be. Also, although the internal reliability of each measure was computed for each subscale through 
Cronbach alpha, the reliability and usefulness of these computations was highly questionable, so, 
despite potential problems in internal consistency being revealed, no actions could be taken. More 
broadly, this study was also unable to examine how certain variables, such as age, may have mediated 
relations between beliefs and adherence behaviour, or allow examination of data by belief strength; 
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for instance, adherence behaviour between respondents with strong and weak beliefs could not be 
compared, or separately related. 
 
Clinical implications and future research 
This study has several implications for clinical practice and future adherence research. In 
relation to adherence rates, the findings show that poorer adherence to nebulised medications is more 
likely in older adolescents, and suggest that adherence may be poorer for nebulised antibiotics than 
nebulised mucolytics. However, further research is needed with a larger sample to generalise this. 
Nonetheless, the finding that adherence rates may differ between these medication types highlights 
the need for future research to consider separate medications separately in order to properly 
understand adherence to them. More broadly, such insights raise the likelihood that different factors 
affect adherence to different medications, even within the same patient and treatment category. 
Importantly, this is the only study to have produced objective adherence data for mucolytic 
medications in this population, despite mucolytics’ daily consumption by most CF patients, which 
strongly highlights the need for future research to focus on this treatment. For clinical practice, such 
findings suggest that health professionals may need to take a more active role in monitoring adherence 
for older than younger adolescents, and for nebulised antibiotics than nebulised mucolytics. Finally, 
the finding that reported adherence rates in this study were comparable to previous research using I-
nebuliser devices, but lower than those generated from subjective and/or less reliable objective 
measures, further reinforces the need for future research to use such objective adherence measurement 
to avoid measurement error from subjective methods, as advocated by previous authors. 
Regarding medication beliefs, findings suggested that parents hold weaker beliefs, both 
necessity and concerns, for nebulised mucolytics than nebulised antibiotics, and that both such beliefs 
about antibiotics were stronger than those of their children. This shows that nebulised medication 
beliefs may differ by respondent and medication category. Again, while the ability of this study to 
assess the significance of these differences was limited, such findings nonetheless highlight the need 
for future research to examine treatment beliefs separately by nebulised medication category and 
respondent, rather than aggregating this data, in order to understand the beliefs that different 
individuals hold towards these treatments, and how they relate to different outcomes. This research 
was unable to examine differences in medication-related beliefs between younger and older 
adolescents, due to the limited sample size. It would be interesting for future research to assess 
whether beliefs of older adolescents differ from those of younger adolescents for nebulised 
medications, and how both compare to those of their parents. 
 
As previously discussed, this study is unable to provide firm conclusions on the ability of the 
Necessity-Concerns Framework to account for differences in adherence behaviour to nebulised 
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medications. Nonetheless, the results suggest that the belief subscales, including the necessity-
concerns differential, may mediate adherence behaviour in separate ways for both medication 
categories. These findings highlight the need for future research to assess the replicability of these 
findings. As discussed in the introduction, if adherence to these medications can be accounted for by 
this framework, it would offer clinicians a means to quickly identify those at risk of non-adherence 
through the BMQ-S, or an adaptation of it, and subsequently apply a targeted intervention to modify 
unhelpful beliefs, thereby increasing adherence. Inspection of the individual data also suggested that 
concern beliefs may only affect adherence once they reach a certain strength. The limited sample, 
alongside the almost exclusively weak level of concern beliefs across this sample, prevented further 
analysis. To examine this question, future research could divide participants into two groups, in order 
to relate ‘low’ concerns and ‘high’ concerns to adherence. Such examination of attitudinal groups is 
common practice in several other studies in adult and paediatric populations (e.g. Clatworthy et al., 
2009; Koster, et al., 2012; Goodfellow et al., 2015), since it is considered that beliefs may only relate 
to adherence when they are of a certain strength, or display a certain pattern. 
 
Findings that parents’ beliefs alone related to adherence for nebulised mucolytics, and that 
parents’ beliefs related to adherence behaviour for nebulised antibiotic medications, raises the 
potential importance of considering parents’ beliefs within this framework. If such findings can be 
replicated, they would highlight the potential need for the Self-Regulation Model to be placed more 
strongly within a social context, and for subsequent research to examine both patients' and 
parents' beliefs, and their separate and combined influence on adherence behaviour. These ideas 
support those of Sonney et al. (2017), who reformulated this model to create the Common Sense 
Model of Parent–Child Shared Regulation, which considers parent and child illness representations as 
separate constructs, but also places parent and child illness representations together to form a shared 
overall illness representation which reflects shared illness management. In practice, replications of 
such findings would suggest that clinicians should consider family beliefs, rather than patient beliefs 
alone, in order to identify individuals at higher risk of low adherence. It would also suggest that 
interventions could be more effective if targeted at a family rather than individual level, and that 
future research should in turn seek to examine the efficacy of individual vs. family-based 
interventions. It would also be interesting for future research to more closely examine these relations; 
for instance, whether the relative importance of patients' or parents'/family beliefs change as 
adolescents age - perhaps until a specific age - due to parents being less actively involved in their 
children's treatments as they get older. Such findings may show that aggregating data from older and 
younger adolescents, as in much previous research (e.g. Bucks et al., 2009; Goodfellow et al., 2015; 
Koster et al., 2015), and indeed this study itself, might be a methodological flaw. 
 
146 
 
Overall, study two requires replication with a larger sample, and, ideally, a longitudinal 
design. A larger sample would allow assessment of whether these findings can be replicated, and 
therefore, are generalisable. It would allow several further analyses to be completed, including 
regression analysis, and further assessment of the validity and reliability of both the adapted and 
original BMQ-S measures. The former analysis would reveal whether predictive models can be 
identified for these treatments, allowing adherence behaviour to be predicted based on treatment-
related beliefs. The latter would allow assessment of the psychometric properties of the original 
BMQ-S and CF-BMQ-S as applied to this population and treatment, potentially leading to further 
refinement of the questionnaire content. A longitudinal design would help to clarify the direction of 
the relationship between medication beliefs and adherence behaviour, which would, in turn, help to 
determine causality. It would also allow assessment of the stability of such beliefs over time, 
and of adherence behaviour itself, in this group. This would then allow assessment of the time-based 
assumption of the Self-Regulatory Model, within which the Necessity-Concerns Framework sits, i.e. 
that adherence decisions are regularly reviewed over time, following an individual’s appraisal of the 
effectiveness of their current behaviours in managing their illness. Such longitudinal studies have 
been completed in other medical conditions, including HIV, depression, Rheumatoid arthritis and 
diabetes (e.g., Aikens et al., 2005; Horne et al. 2007; de Thurah et al. 2010; Aikens & Klinkman, 
2012), but not within CF.  
 
The findings in this study highlighted how the targeted and systematically-adapted CF-BMQ-
S appeared, surprisingly, inferior to the original BMQ-S in assessing how necessity and concern 
beliefs influence adherence to nebulised medications. This result has potentially important 
implications for research within this field, including questioning whether adaptation of the original 
BMQ-S is needed at all, and, if so, how best to undertake such a process. As previously discussed, 
current research within this field simply assumes that adapting the BMQ-S will increase its validity - 
however, the findings of this study highlight that this may be based on a false premise. This, in turn, 
highlights the need for future research to compare the psychometric properties of the original and 
adapted measures, in order to ensure that the utility of the Necessity-Concerns Framework is not 
being compromised by inadequate and/or inappropriate adaptations. The importance of future 
research having more systematic and explicit processes for such adaptation is also likely to be 
significant. This study presents the Delphi survey to support this process, however, other methods 
such as a think-aloud qualitative methodology could also be used to complement this approach, as has 
been used in adaptation of the IPQ-R (Moon et al., 2017; Taylor et al., 2018). This would allow 
additional understanding of how questionnaire items are interpreted, and how the questionnaires are 
completed by patients and parents. However, more broadly, further qualitative research is needed to 
explicitly explore necessity and concern beliefs for nebulised medications for adolescents and their 
parents. Although, as discussed in the introduction, some such research exists which has examined 
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this, these studies either considered several medications which limited detailed exploration (George et 
al., 2010), or were only conducted with adults (Hogan et al. 2015; Hoo et al. 2017). 
 
This thesis also raised the subject of the medication delivery device, and its potential impact 
on beliefs regarding the medications, and thereby, adherence to them. Indeed, it is likely that many of 
individuals' beliefs about their medications will include the means by which they are taken; for 
instance, concerns regarding swallowing might affect appraisals of oral antibiotics, or the time burden 
of cleaning a nebuliser might affect appraisals of nebulised antibiotics, but neither represents 
a necessity or concern belief about the antibiotics themselves. It would therefore be interesting for 
future research to further consider the delivery mechanisms of treatments, and potentially complete a 
qualitative study with patients about this. In the first instance, such research could aim to identify 
whether medication-related beliefs do differ when the same medication is administered in different 
ways. It is likely that for devices such as a nebuliser, such beliefs may generalise across conditions 
such as asthma and COPD, which also use inhaler delivery devices. 
 It is important to recognise that the Necessity-Concerns Framework is just one means of 
examining the potential impact of beliefs on adherence behaviour, and that the application of one 
model alone, even to assess only beliefs as a factor, is very likely to be an over-simplification. 
Adherence behaviour is a complex and multifaceted subject which is likely to be impacted by a range 
of practical and psychological factors, differentially for each individual treatment, in each 
individual. As such, recent research in this field is increasingly examining how several models, 
applied together, may improve our understanding of the role of health beliefs in medication-taking 
behaviour, and how multivariate analysis is needed to detect such effects. For instance, Foot et al. 
(2019) examined interactions between the BMQ-S, B-IPQ (Brief Illness Perception Questionnaire), 
MHLCS (Multidimensional Health Locus of Control Scale; Wallston, Stein & Smith, 1994), and self-
reported adherence to inhaled corticosteroids in adult asthma patients, and found interactions between 
these measures, suggesting that the manner in which beliefs relate to adherence behaviour changes 
depending on other beliefs individuals hold. Overall, they argue that failure to recognise these 
interactions risks diluting or obscuring the relations between beliefs and adherence behaviour, and 
thereby potential effect sizes. This could be a fruitful next step for future research, once the usefulness 
of the Necessity-Concerns Framework on adherence behaviour to nebulised medications has been 
adequately determined, and the BMQ-S itself appropriately adapted, if necessary. 
 
Conclusion 
This thesis, completed through two studies, describes the systematic adaptation and 
application of the BMQ-Specific questionnaire, to assess the extent to which the Necessity-Concerns 
Framework can explain objectively-validated adherence behaviour to nebulised antibiotic and 
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mucolytic medications in adolescents with CF. It represents the first known study to have explicitly 
and systematically adapted the BMQ-S to nebulised medications in CF, to have examined and 
compared the predictive validity of the Necessity-Concerns Framework through both an original and 
adapted measure, and to have assessed these relations separately for the two medication categories of 
nebulised treatment, and for both patients’ and parents’ beliefs. However, such examination by either 
the revised or the original BMQ-S, was limited due to inadequate sample size, which underpowered 
statistical testing, and may have also reduced the reliability of the analyses themselves, leading this 
study to be examined as a pilot.  
Nonetheless, findings provided an indication of possible relationships between the Necessity-
Concerns Framework and adherence behaviour to nebulised CF medications in adolescents. The 
results suggest that the model relates to adherence behaviour between the two nebulised medication 
categories and responders differently, and, crucially, that the original BMQ-Specific might be a more 
effective tool than the adapted measure in capturing the necessity and concern beliefs that influence 
adherence behaviour in this population. Importantly, the novelty of this study's design, even with only 
provisional results, provides several recommendations and directions for future research. These 
include: the importance of considering this model separately for multiple categories of medication, of 
considering the influence of parents’ medication beliefs on their child’s adherence behaviour, and, 
perhaps most crucially, the importance of critically comparing the adapted and original BMQ-S 
questionnaires, rather than simply assuming that refined or adapted versions will necessarily display 
increased psychometric properties. 
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Appendices 
 
Appendix A: study one invitation email to clinicians 
 
 
Dear Clinician,  
 
 You are being invited to take part in an online survey which seeks to gain your views on two 
questionnaires that we have adapted from an existing measure called the Beliefs about Medicines 
Questionnaire-Specific. Our revised questionnaires aim to examine beliefs that adolescents with cystic 
fibrosis and their parents may hold towards nebulised mucolytic and antibiotic medications. 
 
This survey will be completed in two rounds. In the first round, you will be asked to give your 
opinion on how valuable and clear you think the items are in the two questionnaires, and in the second 
round, you will be asked to reconsider your rating after also viewing the ratings and comments of 
other reviewers. On average, the first-round survey should take 15 minutes to complete, and the 
second, 20 minutes. Your responses will be anonymised and analysed as part of a Leeds Doctorate of 
Clinical Psychology thesis project, and are likely to be presented and published in a journal. 
 
We are using this survey to gain feedback from patients, parents and professionals. We hope 
that this survey will allow us to develop a valid and reliable tool to examine beliefs in this population 
and therapy. 
 
Please read the attached participant information sheet for more information and details 
regarding the study.  
 
If you decide that you would like to take part, please complete the participant eligibility form 
and email this to Bronwyn Stirzaker at umbms@leeds.ac.uk. Your eligibility form will then be 
assessed, if it meets our criteria and recruitment is ongoing you will be emailed a link to our online 
survey.  
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Appendix B: study one information sheet for clinicians  
 
 
 
INFORMATION SHEET FOR CLINICIANS 
(Version 2: 24/11/18, IRAS: 249889)  
 
Project title: Refining the Beliefs about Medicines Questionnaire-Specific to nebulised medication 
categories in Cystic Fibrosis 
 
 
Introduction  
You are being invited to take part in a two-part online Delphi survey which aims to gain 
feedback on two questionnaires that we have revised from an established measure. These 
questionnaires aim to examine specific treatment beliefs that adolescents (aged 12-17) with cystic 
fibrosis and their parents hold towards nebulised mucolytic and antibiotic medications. 
 
These questionnaires have been developed from the Beliefs about Medicines Questionnaire-
Specific (BMQ-Specific), a measure developed to access treatment beliefs across chronic conditions 
(Horne, Weinman & Hankins, 1999). This measure is commonly adapted to the condition and 
medication of interest (commonly asthma, diabetes) through the rewording, removal, and, where 
relevant, addition of items. However, it has rarely been examined with respect to cystic fibrosis and 
has never been specifically adapted to nebulised medications. 
 
This questionnaire is based on the Necessity-Concerns Framework (Horne & Weinman, 
1999), which suggests that primary common-sense evaluations that people make about treatment fall 
into two categories. The first category, necessity, refers to implicit judgements about personal need 
for medication (e.g. how much one feels they need this treatment to maintain and/or improve current 
and future health). The second, concerns, refers to implicit beliefs individuals hold about potential 
adverse reactions and consequences from using their prescribed medication. We have revised the 
questionnaire to incorporate necessity and concern beliefs that we feel are pertinent for nebulised 
mucolytic and antibiotic medications in this client group. 
 
We hope to use this survey to gain feedback from patients, parents and professionals alike, on 
the value and acceptability of our adapted questionnaires. We hope to use these revised questionnaires 
to help us improve support for patients in completing their nebulised treatments.  
 
What is a Delphi survey? 
A Delphi survey is used to ask experts about a topic through a series of questionnaires with 
the aim of combining opinions and achieving agreement. The responses from each round of 
questionnaires are fed back to the experts through an updated questionnaire.  
 
Who is organising the research? 
This study is being completed by Bronwyn Stirzaker (Psychologist in Clinical Training) as 
part of her degree at the University of Leeds, alongside Dr. Gary Latchford and Dr. Alistair Duff, who 
are Clinical Psychologists in the Leeds CF unit. It is important that you read the information below 
before making your decision about whether you want to take part.  
 
Why have we been invited to take part? 
 You have been chosen to take part because you are a healthcare professional who has worked 
within CF for at least a year, and as you have experience of discussing nebulised medications with 
your patients. 
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What will I need to do? 
We will ask you to complete a series of two online surveys. In the first round you will be 
asked to read our two questionnaires (one for mucolytics and one for antibiotics) and to rate the value 
and clarity of each questionnaire item. A text box will also be made available so that you can write 
any comments that you may have. At the end of the survey, a text box will also be available to enable 
you to suggest new items. Within 14-30 days, the second-round survey will be sent. You will be 
asked to rate the same questionnaires, but this time, you will also see your answers from the first 
survey, the average score from all participants for each item, and some of their comments. This means 
that other participants may see your comments, but they will be anonymous. You will be asked to re-
evaluate your ratings after considering the views of others. On average, it is expected that it will take 
you approximately 15 minutes to evaluate our questionnaires the first time, and 20 minutes the second 
time. 
 
We will require you to complete the questionnaires within 14 days of receiving the links, 
though we would prefer for you to complete them as soon as you are able to, since we are only able to 
create and email out the second-round surveys once all the responses from the first round have been 
received. If you haven’t completed it within 7 days, we will send you a reminder by email. 
 
If you wish to take part, please complete the eligibility criteria document and email this to 
Bronwyn Stirzaker at umbms@leeds.ac.uk. Your eligibility form will then be assessed if we are still 
recruiting. We plan to recruit the first few clinicians who reply and who are eligible for the study. We 
will send an email to you to let you know whether you have or have not been selected. If you have 
been selected, we will email you with a link to access the first round of the online survey. 
  
 
What are the possible advantages or disadvantages of taking part?   
If you take part, we cannot promise that this study will have any direct benefit for your 
patients / practice, but it might help other CF centres or future treatment. We are looking at this to 
help CF centres understand the beliefs that young people and their parents hold towards their 
nebulised medication, so that they can improve the support they offer to help young people to take 
these medications.  
 
Do I have to take part? 
No, it is up to you whether you wish to take part and you may discontinue at any time. If you 
choose not to take part or discontinue, this will have no consequence and you will not be expected to 
give a reason. If you begin a survey but wish to withdraw before completing it, you can do so by 
exiting from the questionnaire screen. In this instance, your data will not have been stored, as you will 
have exited the survey prematurely. If you complete a survey but later wish to withdraw your data, 
you can do so up to 7 days after completing the survey by emailing the researcher: Bronwyn Stirzaker 
(umbms@leeds.ac.uk). After this time data analysis will have started, so you will be unable to 
withdraw your data. 
What happens to the information and who will see it? 
Your data will initially be stored on the secure Online Survey database. It will later be 
downloaded to a secure drive at the University of Leeds to allow data analysis to be completed. Your 
questionnaire responses will be stored under a participant number, will be kept in a password-
protected file on a password-protected computer, and will only be accessible to members of the 
research team. Your identifiable information (i.e. your name and email address) will be stored and 
accessed in the same way but will be kept in a separate electronic file. Your survey responses will be 
deleted in 3 years’ time, and your personal details will be deleted after the second survey has been 
completed, or when no further correspondence is required between yourself and the researcher. 
This study will be written into a thesis document which will be made available online. We 
also hope to publish this study in online academic journals and to present the results to other 
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professionals; this will include your ratings and may include your comments, but you will not be 
identifiable. If you would like to receive a summary of the findings, please email Bronwyn Stirzaker 
on umbms@leeds.ac.uk. 
 
Contacts for further information 
If you could like any further information or would like to make a complaint, please contact: 
Researcher: Bronwyn Stirzaker, Psychologist in Clinical Training,  or the Project supervisors: Dr 
Gary Latchford, Joint Programme Director, Clinical Psychology Training Programme, Leeds Institute 
of Health Sciences, g.latchford@leeds.ac.uk and Dr Alistair Duff, Clinical Psychologist, The Leeds 
Regional Cystic Fibrosis Centre, A.J.Duff@leeds.ac.uk. You can also contact Dr Alistair Duff or Dr 
Gary Latchford, through telephone through contacting the Leeds CF centre on 0113 3927125. You 
will be asked to leave a name and a contact number so that they can return your call.  
 
Who has reviewed the study? 
This study was given ethical approval by the Research Ethics Committee (ref: 18/YH/0496). 
  
Thank you for reading, please do email to ask any questions that you may have. 
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Appendix C: study one clinician eligibility form 
 
 
  
 
ELIGIBILITY FORM FOR CLINICIANS 
(Version 2: 24/11/18, IRAS: 249889)  
 
Title: Refining the Beliefs about Medicines Questionnaire-Specific to nebulised medication 
categories in Cystic Fibrosis 
 
Lead researcher: Bronwyn Stirzaker 
Supervisors: Dr Gary Latchford and Dr Alistair Duff 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please read the following and confirm if the following statements are true by checking the box. 
 
1. I have worked in CF services for at least one year as a clinician ☐ 
 
2. I am a qualified Physiotherapist ☐ 
 
3. I have experience of discussing nebulised medications with patients ☐ 
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Appendix D: study one patient and parent information sheets 
Appendix D.1: study one patient information sheet 
 
 
 
 
INFORMATION SHEET 
(Version 2: 24/11/18, IRAS: 249889)  
 
Project title: Refining the Beliefs about Medicines Questionnaire-Specific to nebulised medication 
categories in Cystic Fibrosis 
 
 
What is the study about?   
You and your parent are being invited to take part in a in a two-part online Delphi survey, 
which aims to provide us with feedback on two questionnaires that we have developed. We want to 
use these questionnaires to measure thoughts that young people (aged 12-17) and their parents have, 
about nebulised mucolytic and antibiotic medications.  
 
More specifically, we want to use these questionnaires to measure how necessary people 
think these nebulised medications are to control their/their child’s symptoms and to keep them 
healthy, both now and in the future. We also want to know what they think the consequences of 
taking nebulised medications are, and how concerned they are about these. We hope to gain the 
opinions of patients, parents and professionals on our questionnaires, so that we can make sure that 
we are asking useful questions which are easy to understand. 
 
What is a Delphi survey? 
A Delphi survey is used to ask experts about a topic through a series of questionnaires with 
the aim of combining opinions and achieving agreement. The responses from each round of 
questionnaires are fed back to the experts through an updated questionnaire.  
 
Who has made the study? 
This study is being run by Bronwyn Stirzaker (Psychologist in Clinical Training) as part of 
her doctorate degree at the University of Leeds, alongside Dr. Gary Latchford and Dr. Alistair Duff, 
who are Clinical Psychologists in the Leeds CF unit. It is important that you read the information 
below before making your decision about whether you want to take part. You can talk to other people 
(e.g. friends, family, medical professionals) about it if you like. 
 
Why have we been invited to take part? 
 You have been chosen to take part because you have CF, you have used nebulised antibiotics 
and mucolytics within the last 12 months for at least 2 months, and you are aged between 16 and 17 
years. 
 
What will I need to do?   
We will ask you to complete a series of two online surveys. In the first round you will be 
asked to read our two questionnaires and let us know how useful and clearly-worded you think each 
question is. You will also be able to write comments about each question, and, at the end, you will 
also be able to suggest ideas that you may have for additional questions. When you complete the 
survey the second time, you will be able to see your answers from the first time, as well as the 
average score other people gave the questions, and some of their comments. This means that other 
participants may see your comments, but they will be anonymous. You will be asked to make your 
ratings again after looking at what other people thought. 
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 It should take around 15 minutes for you to complete the questions the first time, and 20 
minutes the second time. You would need to complete these this survey yourself without asking your 
parent for answers, but they can help you to understand other things if you are unsure. We will need 
you to complete the questionnaires within 14 days of receiving the links, and ideally as soon as you 
are able. We are unable to make and email out the second-round survey until everyone has completed 
the first round.  If you haven’t completed the first survey within 7 days, we will send you a reminder 
by email to help you remember.  
 
If you, your parent or both of you decide that you would like to take part, then you will need 
to email the researcher (Bronwyn Stirzaker) directly on umbms@leeds.ac.uk.  We will select the first 
patient and the first parent who email us to take part in the project. We will send an email to you 
know whether you have or have not been selected. If you have been selected, we will send an email to 
you with a link to our survey. You will be asked to complete our survey twice, approximately 14 to 
30 days apart.  
 
 
Do I have to take part?  
No, it is up to you whether you wish to take part and you can take this information sheet 
away to think about it. If you choose not to take part, or leave the study early, this will not have any 
consequence or effect on your treatment. You do not need to give a reason if you do not want to 
complete the study or if you decide to leave the study early. If you begin a survey but wish to 
withdraw before completing it, you can do so by exiting from the questionnaire screen. In this 
instance, your data will not have been stored, as you will have exited the survey prematurely. If you 
complete a survey but later wish to withdraw your data, you can do so up to 7 days after completing 
the survey by emailing the researcher: Bronwyn Stirzaker (umbms@leeds.ac.uk). After this time data 
analysis will have started, so you will be unable to withdraw your data.  
 
What are the possible advantages or disadvantages of taking part?   
If you take part, we cannot promise that this study will have any direct benefit for you, but it 
might help your CF centre. We are looking at this to help CF centres understand the beliefs that 
young people and their parents hold about their nebulised medication, so that they can improve the 
support they offer to help young people to take these medications.  
 
What happens to the information and who will see it? 
Your data will initially be stored on the secure Online Survey database. It will later be 
downloaded to a secure drive at the University of Leeds to allow data analysis to be completed. Your 
questionnaire responses will be stored under a participant number, will be kept in a password-
protected file on a password-protected computer, and will only be accessible to members of the 
research team. Your identifiable information (i.e. your name and email address) will be stored and 
accessed in the same way but will be kept in a separate electronic file. Your survey responses will be 
deleted in 3 years’ time, and your personal details will be deleted after the second survey has been 
completed, or when no further correspondence is required between yourself and the researcher. 
 
We hope to write about what we find, put these findings on research related 
websites and present them to other professionals. This may include your ratings and 
comments, but these will be presented anonymously. If you would like to receive a 
summary of the findings, please email Bronwyn Stirzaker on umbms@leeds.ac.uk. 
  
Can I get further information?  
If you would like any more information about the study before you and your parent make 
your decision, or would like to make a complaint please contact Bronwyn Stirzaker at 
umbms@leeds.ac.uk, or the projects supervisor’s Dr Alistair Duff or Dr Gary Latchford who are 
based at the Leeds CF centre, and can be contacted on 0113 3927125. You will be asked to leave a 
name and a contact number so that they can return your call. 
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Who has reviewed the study? 
Before any research goes ahead, it must be checked by an independent group of people called 
the Research Ethics Committee (REC).  They make sure the research is fair. They approved this study 
(ref: 18/YH/0496). 
 
Thank you for reading this information! Please ask any questions that you have.  
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Appendix D.2: study one parent information sheet 
 
 
 
 
INFORMATION SHEET 
(Version 2: 24/11/18, IRAS: 249889)  
 
Project title: Refining the Beliefs about Medicines Questionnaire-Specific to nebulised medication 
categories in Cystic Fibrosis 
 
 
Introduction  
You and your child are being invited to take part in a two-part online Delphi survey, which 
aims to provide us with feedback on two questionnaires that we have developed. We want to use these 
questionnaires to measure beliefs that young people (aged 12-17) and their parents have about 
nebulised mucolytic and antibiotic medications.  
 
More specifically, we want to use these questionnaires to measure how necessary people 
think these nebulised medications are to control their/their child’s symptoms and to keep them 
healthy, both now and in the future. We also want to know what they think the consequences of 
taking nebulised medications are, and how concerned they are about these. We hope to gain the 
opinions of patients, parents and other professionals on our questionnaires, to ensure that we are 
asking useful and relevant questions, which are clear to understand. 
 
What is a Delphi survey? 
A Delphi survey is used to ask experts about a topic through a series of questionnaires with 
the aim of combining opinions and achieving agreement. The responses from each round of 
questionnaires are fed back to the experts through an updated questionnaire.  
 
Who is organising the research? 
This study is being run by Bronwyn Stirzaker (Psychologist in Clinical Training) as part of 
her doctorate degree at the University of Leeds, alongside Dr. Gary Latchford and Dr. Alistair Duff, 
who are Clinical Psychologists in the Leeds CF unit. It is important that you read the information 
below before making your decision about whether you want to take part. You can talk to other people 
(e.g. friends, family, medical professionals) about it if you like. 
 
Why have we been invited to take part? 
 You have been chosen to take part because your child is aged 16-17, has CF, and has within 
the last year used nebulised antibiotics and mucolytics for at least 2 months. 
 
What will I need to do? 
We will ask you to complete a series of two online surveys. In the first round you will be 
asked to read our two questionnaires. We will ask you how useful and clearly-worded you think each 
question is. You will also be able to write comments about this and will have the opportunity to 
suggest ideas you may have for additional questions at the end. When you complete the survey the 
second time, you will be able to see your answers from first time, the average score other people gave 
the questions, and some of their comments. This means that other participants may see your 
comments, but they will be anonymous. You will be asked to make your ratings again after 
considering the opinions of others alongside your own. 
 
It should take you approximately 15 minutes to evaluate our questionnaires the first time, and 
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20 minutes the second time. We will need you to complete the questionnaires within 14 days of 
receiving the links, and ideally as soon as you are able. We are unable to make and email out the 
second-round survey until everyone has completed the first round. If you haven’t completed the first 
survey within 7 days, we will send you a reminder by email to help you remember. 
 
Should your child also be selected to participate, we asked that you evaluate our 
questionnaires individually and do not help each other choose answers, as we are interested in your 
and your child’s separate opinions. You could, however, help your child to understand what they are 
doing if they are unsure. 
 
If you, your child or both of you decide that you would like to take part, then you will need to 
email the researcher (Bronwyn Stirzaker) directly on umbms@leeds.ac.uk. We will select the first 
patient and parent who email us to take part in the project. We will send an email to let you know 
whether you have or have not been selected. If you have been selected, we will send an email to you 
with a link to our survey. You will be asked to complete our survey twice, approximately 14 to 30 
days apart.  
 
 
Do I have to take part? 
No, it is up to you whether you wish to take part and you can take this information sheet 
away to think about it. If you choose not to take part, or leave the study early, this will not have any 
consequence or effect on your child’s treatment. You do not need to give a reason if you do not want 
to complete the study or if you decide to leave the study early. If you begin a survey but wish to 
withdraw before completing it, you can do so by exiting from the questionnaire screen. In this 
instance, your data will not have been stored, as you will have exited the survey prematurely. If you 
complete a survey but later wish to withdraw your data, you can do so up to 7 days after completing 
the survey by emailing the researcher: Bronwyn Stirzaker (umbms@leeds.ac.uk). After this time data 
analysis will have started, so you will be unable to withdraw your data.  
 
 
What are the possible advantages or disadvantages of taking part?   
If you take part, we cannot promise that this study will have any direct benefit for you or 
your child, but it might help your CF centre. We are looking at this to help CF centres understand the 
beliefs that young people and their parents hold towards their nebulised medications, so that they can 
improve the support they offer to help young people to take these medications.  
 
 
What happens to the information and who will see it? 
Your data will initially be stored on the secure Online Survey database. It will later be 
downloaded to a secure drive at the University of Leeds to allow data analysis to be completed. Your 
questionnaire responses will be stored under a participant number, will be kept in a password-
protected file on a password-protected computer, and will only be accessible to members of the 
research team. Your identifiable information (i.e. your name and email address) will be stored and 
accessed in the same way but will be kept in a separate electronic file. Your survey responses will be 
deleted in 3 years’ time, and your personal details will be deleted after the second survey has been 
completed, or when no further correspondence is required between yourself and the researcher. 
This study will be written into a thesis document which will be made available online. We 
also hope to publish this study in online academic journals and to present the results to other 
professionals; this will include your ratings and may include your comments, but you will not be 
identifiable. If you would like to receive a summary of the findings, please email Bronwyn Stirzaker 
on umbms@leeds.ac.uk. 
 
Can I get further information? 
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If you would like any more information about the study or would like to make a complaint, 
please contact Bronwyn Stirzaker at umbms@leeds.ac.uk, or the projects supervisor’s Dr Alistair 
Duff or Dr Gary Latchford, who are based at the Leeds CF centre, and can be contacted on 0113 
3927125. You will be asked to leave a name and a contact number so that they can return your call. 
 
Who has reviewed the study? 
Before any research goes ahead, it must be checked by an independent group of people called 
the Research Ethics Committee (REC) to ensure the research complies with the relevant ethical 
standards. They approved this study (ref: 18/YH/0496). 
 
  
Thank you for taking the time to read this information. Please ask any questions that you may 
have. 
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Appendix E: study one ethics approval 
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Appendix F: study one draft CF-BMQ-A and CF-BMQ-M 
Appendix F.1: study one initial draft CF-BMQ-A 
 
 
 
 
 
 
 
  
sn1 
My health at present depends on me taking my nebulised antibiotics 
 
sc1 
Having to take nebulised antibiotics worries me 
 
sc2 
I sometimes worry about long-term effects of taking my nebulised antibiotics 
 
Sn2 
Without my nebulised antibiotics I would be very ill 
 
sc3 
I don’t understand why I need to take my nebulised antibiotics 
 
Sn3 
My health in the future will depend on my nebulised antibiotics  
 
sc4 
Taking my nebulised antibiotics disrupts my life  
 
sc5 
I sometimes worry about becoming too dependent on my nebulised antibiotics 
 
Sn4 
My nebulised antibiotics stop me from becoming worse 
Sc6 
Taking my nebulised antibiotics is unpleasant 
Sc7 
My nebulised antibiotics cause unpleasant short-term side-effects 
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Appendix F.2: study one initial draft CF-BMQ-M 
 
 
 
 
 
 
 
 
 
 
 
  
sn1 
My health at present depends on me taking my nebulised mucolytics 
 
sc1 
Having to take nebulised mucolytics worries me 
 
sc2 
I sometimes worry about long-term effects of taking my nebulised mucolytics 
 
Sn2 
Without my nebulised mucolytics I would be very ill 
 
sc3 
I don’t understand why I need to take my nebulised mucolytics  
Sn3 
My health in the future will depend on my nebulised mucolytics 
 
sc4 
Taking my nebulised mucolytics disrupts my life  
 
sc5 
I sometimes worry about becoming too dependent on my nebulised mucolytics 
 
Sn4 
My nebulised mucolytics stop me from becoming worse 
Sc6 
My nebulised mucolytics cause unpleasant short-term side-effects 
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Appendix G: study one CF-BMA-A and CF-BMQ-M following Delphi survey round one 
Appendix G.1: study one CF-BMQ-A following Delphi survey round one 
 
 
 
 
 
  
sn1 
To be healthy now, I need to take my nebulised antibiotics 
 
sc1 
Having to take my nebulised antibiotics worries me 
sc2 
I sometimes worry about the long-term effects of taking my nebulised antibiotics 
Sn2 
Without my nebulised antibiotics my health would be much worse 
sc3 
I don’t understand why I need to take my nebulised antibiotics 
Sn3 
To be healthy in the future, I need to take my nebulised antibiotics now 
sc4 
Taking my nebulised antibiotics gets in the way of my life 
sc5 
I sometimes worry that taking my nebulised antibiotics now will mean that they won't work 
as well in future 
Sn4 
My nebulised antibiotics stop my health from becoming worse 
Sc6 
My nebulised antibiotics can cause unpleasant side-effects (e.g. bad taste, coughing, feeling 
sick) 
Sc7 
Taking my nebulised antibiotics is embarrassing 
Sc8 
I only need to take my nebulised antibiotics when I feel unwell 
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Appendix G.2: study one CF-BMQ-M following Delphi survey round one 
 
 
 
 
 
 
 
 
 
  
sn1 
To be healthy now, I need to take my nebulised mucolytics 
sc1 
Having to take my nebulised mucolytics worries me 
sc2 
I sometimes worry about the long-term effects of taking my nebulised mucolytic 
Sn2 
Without my nebulised mucolytics my health would be much worse 
sc3 
I don’t understand why I need to take my nebulised mucolytics 
Sn3 
To be healthy in future, I need to take my nebulised mucolytics now 
sc4 
Taking my nebulised mucolytics gets in the way of my life 
Sn4 
My nebulised mucolytics stop my health from becoming worse 
Sc6 
My nebulised mucolytics can cause unpleasant side-effects (e.g. bad taste, coughing, 
feeling sick) 
Sc7 
Taking my nebulised mucolytics is embarrassing 
Sc8 
I only need to take my nebulised mucolytics when I feel unwell 
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Appendix H: study one CF-BMA-A and CF-BMQ-M following Delphi survey round one 
Appendix H.1: study one final CF-BMQ-A following Delphi survey round two 
 
The CF Beliefs about Medicines Questionnaire Specific  
ADOLESCENT ANTIBIOTICS 
(Version 1: 14/04/19, IRAS: 249889) 
 
 
Patient Identification Number:  
 
   
YOUR VIEWS ON THE NEBULISED MEDICATION PRESRIBED FOR YOUR CYSTIC 
FIBROSIS 
 
 
We would like to ask you what you think about the nebulised medication prescribed for your CF. 
 
These are statements that other people have made about their medications. Please show how much 
you agree or disagree with them by ticking the appropriate box. 
 
There are no right or wrong answers. We are just interested in what you think. Please complete this 
without asking your parent/guardian for the answers. Please only tick one box per question. 
 
 
Please only consider …………………. (nebulised Antibiotic) when you answer. 
 
 
 
 
Strongly 
agree 
Agree Uncertain Disagree 
Strongly 
disagree  
  
1. 
 
To be healthy now, I need to take 
my nebulised Antibiotics 
 
     
 
2.  
Having to take my nebulised 
Antibiotics worries me 
 
     
 
3.  
I sometimes worry about the long-
term effects of my nebulised 
Antibiotics 
 
     
4.  
Without my nebulised Antibiotics 
my health would be much worse 
 
     
5.  
I don’t understand why I need to 
take my nebulised Antibiotics 
 
     
 Strongly 
agree 
Agree Uncertain Disagree 
Strongly 
disagree 
184 
 
6.  
To be healthy in future, I need to 
take my nebulised Antibiotics now 
 
     
7.  
Taking my nebulised Antibiotics 
gets in the way of my life 
 
     
8.  
I sometimes worry that taking my 
nebulised Antibiotics now will 
mean that they won’t work as well 
in future 
 
     
9.  
My nebulised Antibiotics stop my 
health from becoming worse 
 
     
10.  
My nebulised Antibiotics can 
cause unpleasant side-effects (e.g. 
bad taste, coughing, feeling sick) 
 
     
11.  
Taking my nebulised Antibiotics 
is embarrassing 
 
     
12.  
I only need to take my nebulised 
Antibiotics when I feel unwell 
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Appendix H.2: study one final CF-BMQ-M following Delphi survey round two 
The CF Beliefs about Medicines Questionnaire Specific  
ADOLESCENT MUCOLYTICS 
(Version 1: 14/04/19, IRAS: 249889) 
 
 
Patient Identification Number:  
 
   
YOUR VIEWS ON THE NEBULISED MEDICATION PRESRIBED FOR YOUR CYSTIC 
FIBROSIS 
 
 
We would like to ask you what you think about the nebulised medication prescribed for your CF. 
 
These are statements that other people have made about their medications. Please show how much 
you agree or disagree with them by ticking the appropriate box. 
 
There are no right or wrong answers. We are just interested in what you think. Please complete this 
without asking your parent/guardian for the answers. Please only tick one box per question. 
 
 
Please only consider …………………. (nebulised Mucolytic) when you answer. 
 
 
 
 
Strongly 
agree 
Agree Uncertain Disagree 
Strongly 
disagree  
  
1. 
 
To be healthy now, I need to take 
my nebulised Mucolytics 
 
     
 
2.  
Having to take my nebulised 
Mucolytics worries me 
 
     
 
3.  
I sometimes worry about the long-
term effects of my nebulised 
Mucolytics 
 
     
4.  
Without my nebulised Mucolytics 
my health would be much worse 
 
     
5.  
I don’t understand why I need to 
take my nebulised Mucolytics 
 
     
 Strongly 
agree 
Agree Uncertain Disagree 
Strongly 
disagree 
6.  
To be healthy in future, I need to 
take my nebulised Mucolytics now 
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7.  
Taking my nebulised Mucolytics 
gets in the way of my life 
 
     
8.  
I sometimes worry that taking my 
nebulised Mucolytics now will 
mean that they won’t work as well 
in future 
 
     
9.  
My nebulised Mucolytics stop my 
health from becoming worse 
 
     
10.  
My nebulised Mucolytics can 
cause unpleasant side-effects (e.g. 
bad taste, coughing, feeling sick) 
 
     
11.  
Taking my nebulised Mucolytics 
is embarrassing 
 
     
12.  
I only need to take my nebulised 
Mucolytics when I feel unwell 
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Appendix I: study two information sheets for patients and parents 
Appendix I.1: study two patient information sheet 
 
Phase 2 Information sheet for adolescents 
 
 
 
INFORMATION SHEET 
(Version 3: 26/04/19, IRAS: 249889)  
 
Project title: The role of beliefs in predicting adherence to nebulised therapy in adolescents with 
Cystic Fibrosis 
 
What is the study about?  
You are being invited to take part in a study. The study is looking at how often young people 
take their nebulised CF medications, and whether this is affected by what they and/or their 
parents/guardian think about inhaled medication. The study is taking place at three 
CF centres in England: at Leeds, Liverpool and Sheffield. 
 
Who has made the study? 
This study is being run by Bronwyn Stirzaker (Psychologist in Clinical 
Training) as part of her degree at the University of Leeds, with Dr. Gary Latchford 
and Dr. Alistair Duff, who work in the Leeds CF centre as Clinical Psychologists. 
It is important that you read the information below before making your decision about whether you 
want to take part. Please also talk to other people (e.g. friends, family, medical professionals) about it 
if you like. 
 
Why have I been asked to take part? 
 You have been chosen to take part as you are aged between 12-17 years, have CF, and use 
nebulised medications. 
 
What will happen if I do the study?   
If you agree to take part, we will ask you and your parent/guardian to complete some short 
questionnaires. If you take nebulised mucolytics only, we will ask you to complete 3 questionnaires 
(which should take about 15 minutes). If you take both nebulised mucolytic and antibiotic 
medications, we will ask you to complete 5 questionnaires (this takes about 25 minutes). All but one 
of the questionnaires will list a set of beliefs a person might have about taking their nebulised CF 
medication, and it will ask you to say how much you agree with them. These questionnaires will often 
ask the same or very similar questions, but it is important that you complete them as carefully as you 
can. One other questionnaire will list beliefs a person might have about CF, and will, again, ask you 
how much you agree with them.  
 
It is important that you fill out the answers to your questionnaires yourself without asking 
your parent/guardian for their opinions, as we are interested in what you think. However, your parents 
and/or medical professionals can help you if you don’t understand something. 
 
We will also ask to have access to the information stored on your nebuliser that is routinely 
collected on your clinic visits. This will tell us how often you’re taking your medication. We also 
want to gain some information about you and your family e.g. who lives at your home and where you 
live, we will ask your parent for this. We will also ask you if your clinician can give us some 
information from your medical file, as we want to know what medications you take and how healthy 
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you are.  
 
What are the possible advantages or disadvantages of taking part?   
If you take part, we can’t promise that this study will have any direct benefit for you, but it 
might help your CF centre and future patients like you. We are doing this study to help CF centres 
understand how they can improve the support offered to help young people to take their medication.  
 
Do I have to do it?  
No. You choose. You can take this information sheet away and think about it, and you can 
ask other people (e.g. friends and family) what they think. If you decide to take part, you will be 
asked to sign an assent form (if you are less than 16 years old), or a consent form (if you are 16 years 
old or above), on your next visit. If you choose not to take part, this will not affect your treatment. 
You can also change your mind about doing the study at any time and you don’t need to give a 
reason. If you take part, but later do not wish for us to use your data, you can 
contact us and let us know up to two weeks after completing the study. 
 
What happens to the information and who will see it? 
We will photocopy your consent/assent form and your parents’, so that we have 
three copies. The first will go in your medical file, so anyone who sees this will 
know that you and your parent have agreed to take part in this study. The second is for you to keep, 
and the third will be put in a research file at your CF centre before being moved to the University of 
Leeds. It will be stored safely in a locked cabinet and only the research team will look at them. The 
questionnaires that you, your parent and Physiotherapist complete will be stored in the same way. 
Your individual questionnaire answers will not be shown to, or discussed with, any member of staff 
in your care. Your iNebuliser data will be stored on a secure network drive at your CF centre before 
being moved to a secure drive at the Leeds CF centre (if this is not your centre) and at the University 
of Leeds 
Your and your parents’ research data will be pseudo-anonymised. This means that none of 
your questionnaires or your I-nebuliser data will have your name on, instead it will have a research 
number. We will have a separate document that matches this number with your name. Again, this 
will be stored securely and will be password-protected. Your data will be moved to the University of 
Leeds by the researcher once you have finished the study. At this time your paper-based 
questionnaire answers and details will be transferred to a secure computer database to allow the 
researcher to analyse it. All of the data collected in the study will be deleted in 3 years’ time. 
 
What will you do with what you find? 
We hope to write about what we find, put these findings on relevant research websites and 
present them to other professionals. If you would like to receive a summary of the findings, please let 
your physiotherapist know. They will be able to give you this in a future 
appointment once the study has been completed.  
 
Can I get further information?  
If you would like any more information about the study before making 
your decision or would like to make a complaint, please email Bronwyn Stirzaker on 
umbms@leeds.ac.uk. Or contact Dr Alistair Duff or Dr Gary Latchford, they work at the Leeds CF 
centre, and you or your parents can call them on 0113 3927125. You will be asked to leave a name 
and a contact number so that they can return your call. 
 
Who has reviewed the study? 
Before any research goes ahead, it must be checked by an independent group of people called 
a Research Ethics Committee (REC).  They make sure the research is fair. They approved this study 
(ref: 18/YH/0496). 
 
Thank you for reading! Please ask any questions you have. 
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Appendix I.2: study two parent information sheet 
 
 
 
INFORMATION SHEET 
(Version 3: 26/04/19, IRAS: 249889)  
 
Project title: The role of beliefs in predicting adherence to nebulised therapy in adolescents with 
Cystic Fibrosis 
 
Introduction 
You and your child are being invited to take part in a study which looks at how often young 
people take their nebulised CF medications, and whether this is affected by what they and their 
parents/guardians think about such medication. The study is taking place at three CF centres in 
England: at Leeds, Liverpool and Sheffield.  
 
Who is organising the research?  
This study is being run by Bronwyn Stirzaker (Psychologist in Clinical Training) as part of 
her research degree at the university of Leeds, alongside Dr. Gary Latchford and Dr. Alistair Duff, 
who are Clinical Psychologists in the Leeds CF unit. It is important that you read the following 
information before making your decision. Please also discuss this with other individuals (e.g. friends, 
family, medical professionals) if you like. 
 
Why have I been asked to take part? 
 You have been chosen to take part as your child is aged between 12-17 years, has CF, and 
uses nebulised medication. 
 
What will happen if I decide to take part? 
If you and your child decide to take part, we will ask you both to complete some short 
questionnaires. If your child takes nebulised mucolytics only, we will ask you to complete 3 
questionnaires (which should take about 15 minutes), and if your child takes nebulised mucolytic and 
antibiotic medications we will ask you to complete 5 (about 25 minutes). All but one of your child’s 
questionnaires contain a set of beliefs a person with CF might have about taking their medication. 
Your questionnaires are similar, listing the same beliefs but from a parent’s perspective. The 
questionnaires you will be asked to complete will often ask the same or very similar questions, so it is 
important that you read them carefully. The other questionnaire will list a set of beliefs that a person, 
and their parent/guardian, may hold about their CF in general, and you are again asked to consider 
this from a parent’s perspective. 
 
 You will need to fill out your questionnaire independently of your child, as we are interested 
in each of your and their views separately. For this reason, we ask that you avoid helping them to 
choose answers, but you can of course help them if they don’t understand something. Please ask a 
member of staff if anything is unclear. 
 
We will also ask to have access to the information that is stored on your child’s nebuliser 
which is routinely collected on your outpatient visits to the clinic. This will tell us how often your 
child is taking their medication. Lastly, we will ask you to provide some social and demographic 
information, and we will ask to have access to information from your child’s medical file i.e. their 
medication prescriptions and current health status. This will be given to us by a member of their 
clinical care team, we will not directly look at your child’s records. 
 
What are the possible advantages or disadvantages of taking part?   
If you take part, we cannot promise that this study will have any direct benefit for you or your 
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child, but it might help the CF centre that your child attends. We are undertaking this study to help CF 
centres understand how they can improve the support offered to help young people to take their 
nebulised medication.  
 
Do I have to take part?  
No. It is your and your child’s decision whether you take part in this study. You can both 
take your information sheets away and take time to think. If you do decide to take part, you will be 
asked to sign a consent form, and your child will be asked to sign an assent or consent form 
depending on their age. If your child is aged under 16 years, you will also be asked to sign a consent 
form to indicate their agreement. 
 
 If you choose not to take part, this will not have any effect on your child’s future treatment 
at the Centre. You can change your mind about participating at any time, without needing to give a 
reason for wanting to leave the study, and this will not impact your child’s treatment. If you take 
part, but later do not wish for us to use your data, you can contact us and let us know up to two 
weeks after completing the study. 
 
Who will know about my taking part and what happens to the information?  
Three copies of your and your child’s consent forms will be made. The first, the original, will 
be kept in your child’s medical file. This means that any professionals who usually have access to 
your child’s medical file will know that you and your child have agreed to participate in this study. 
The second copy you will be able to take away for your reference. The third will be placed in a 
research file in the CF centre before being moved to the University of Leeds. It will be stored in 
locked cabinets in access-controlled rooms at both sides, to ensure the data remains secure and 
confidential. Your and your child’s questionnaire responses, and other paper-based details (i.e. socio-
demographic, prescription and health information) will be stored in the same manner, but in a 
separate cabinet to support anonymity. Your individual questionnaire responses will not be shown to, 
or discussed with, any member of staff involved in your child’s care. Initially your child’s iNebuliser 
information will be stored on a secure network drive at your CF centre, before being moved to a 
secure drive at the Leeds CF centre (if this is not your centre) and at the University of Leeds. 
 
Your and your child’s research data will be pseudo-anonymised. This means that none of 
your questionnaires or your I-nebuliser data will have your name on, instead it will have a research 
number. We will have a separate document that matches this number with your name. Again, this 
will be stored securely and will be password-protected. The research data will be moved to the 
University of Leeds by the researcher once you have finished the study. At this time your paper-
based questionnaire responses and details will also be transferred to a secure computer database to 
allow data analysis. All of the data collected in the study will be deleted in 3 years’ time. 
 
What will happen to the results of the study? 
We hope to publish this study in an academic journal which is made available on relevant 
research websites. We also hope to present the results to other professionals. If you would like to 
receive a summary of the findings please let the physiotherapist know. They will be able to give you 
this in a future appointment once the study has been completed. 
 
Can I get further information? 
If you would like more information about the study before making your decision or would 
like to make a complaint, please email Bronwyn Stirzaker on umbms@leeds.ac.uk. Or speak to Dr 
Alistair Duff or Dr Gary Latchford, they are based at the Leeds CF centre and can be contacted on 
0113 3927125. You will be asked to leave a name and a contact number so that they can return your 
call. 
 
Who has reviewed the study? 
Before any research goes ahead it must be checked by an independent group of individuals on 
a Research Ethics Committee (REC). They approved this study (ref: 18/YH/0496). 
191 
 
 
Thank you for taking the time to read this information. Please ask any questions you have 
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Appendix J: study two ethics approval 
 
Amendment Categorisation and Implementation Information   
  
Dear Miss Stirzaker, 
IRAS Project ID: 249889 
Short Study Title: 
Role of beliefs in predicting adherence to 
nebulised therapy in CF 
Date complete amendment submission received: 20th August 2019 
Amendment No./ Sponsor Ref: Non-Substantial Amendment 1 
Amendment Date: 20 August 2019 
Amendment Type: Non-substantial 
Outcome of HRA and HCRW Assessment 
This email also 
constitutes HRA and HCRW Approval 
for the amendment, and you should not 
expect anything further. 
Implementation date in NHS organisations in 
England and Wales 
35 days from date amendment 
information  together with this email, is 
supplied to participating 
organisations (providing conditions are 
met) 
For NHS/HSC R&D Office information 
Amendment Category A 
Thank you for submitting an amendment to your project. We have now categorised your 
amendment and please find this, as well as other relevant information, in the table above. 
What should I do next? 
Please read the information in IRAS, which provides you with information on how and when you can 
implement your amendment at NHS/HSC sites in each nation, and what actions you should take now. 
If you have participating NHS/HSC organisations in any other UK nations please note that we 
will forward the amendment submission to the relevant national coordinating function(s). 
If not already provided, please email to us any regulatory approvals (where applicable) once available. 
When can I implement this amendment? 
You may implement this amendment in line with the information in IRAS. Please note that you may 
only implement changes described in the amendment notice. 
Who should I contact if I have further questions about this amendment? 
If you have any questions about this amendment please contact the relevant national coordinating 
centre for advice: 
• England – hra.amendments@nhs.net 
• Northern Ireland – research.gateway@hscni.net  
• Scotland – nhsg.NRSPCC@nhs.net  
• Wales – HCRW.amendments@wales.nhs.uk 
Additional information on the management of amendments can be found in the IRAS guidance.   
User Feedback 
The Health Research Authority is continually striving to provide a high quality service to all 
applicants and sponsors. You are invited to give your view of the service you have received and the 
application procedure. If you wish to make your views known please use the feedback form available 
on the HRA website: http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/. 
Please do not hesitate to contact me if you require further information. 
Kind regards 
Miss Jane Harker 
Approvals Administrator 
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Health Research Authority 
Ground Floor | Skipton House | 80 London Road | London | SE1 6LH 
E.hra.amendments@nhs.net 
W. www.hra.nhs.uk 
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Appendix K: study two parent demographic form 
 
 
 
 
Parent Identification Number:  
 
  
 
DEMOGRAPHICS FORM FOR PARENT TO COMPLETE 
(Version 3: 14/04/19, IRAS: 249889)  
 
Title: The role of beliefs in predicting adherence to nebulised therapy in adolescents with Cystic 
Fibrosis 
 
Lead researcher: Bronwyn Stirzaker 
Supervisors: Dr Gary Latchford and Dr Alistair Duff  
 
Please complete the following in relation to yourself, NOT your child. 
 
Your gender: 
 
 
Your age: 
 
Your ethnicity: 
 
 
Your religion: 
Your job: 
 
 
Your education level: (e.g. high school, 
college, university) 
 
 
Your postcode: 
 
 
 
 
1. What is your relationship to the patient?  ……………………………  
2. Are you currently married?  …………………………… 
3. How many adults live in your home?  …………………………… 
4. How many children live in your home?  …………………………… 
 
Please complete the following in relation to your child: 
 
Religion: 
 
 
Ethnicity: 
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Appendix L: study two patient demographic and health status form 
 
 
 
 
 
Patient Identification Number:  
 
 
DEMOGRAPHICS AND HEALTH STATUS FORM FOR CLINICIAN TO COMPLETE 
(Version 1: 17/08/18, IRAS: 249889)  
 
Title: role of beliefs in predicting adherence to nebulised therapy in adolescents with Cystic Fibrosis 
 
Lead researcher: Bronwyn Stirzaker 
Supervisors: Dr Gary Latchford and Dr Alistair Duff  
 
Patients age: 
 
Gender: 
 
Current FEV rating: 
 
 
Inpatient stays in last year: 
Current prescribed nebulised medications, including dose (please list). Please indicate 
which are currently taken through an I-neb devise. 
 
1. 
 
2. 
 
3. 
 
4. 
Changes to prescribed nebulised medications within the data collection period? (includes 
types and dose). Please provide details and dates: 
 
1. 
 
 
 
2. 
 
 
 
 
3. 
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Appendix M: study two patient BMQ-A and BMQ-M 
Appendix M.1: study two patient BMQ-A 
The Beliefs about Medicines Questionnaire Specific  
ADOLESCENT ANTIBIOTICS 
(Version 2: 14/04/19, IRAS: 249889) 
 
 
Patient Identification Number:  
 
   
YOUR VIEWS ON THE NEBULISED MEDICATION PRESRIBED FOR YOUR CYSTIC 
FIBROSIS 
 
 
We would like to ask you what you think about the nebulised medication prescribed for your CF. 
 
These are statements that other people have made about their medications. Please show how much 
you agree or disagree with them by ticking the appropriate box. 
 
There are no right or wrong answers. We are just interested in what you think. Please complete this 
without asking your parent/guardian for the answers. Please only tick one box per question. 
 
 
Please only consider …………………. (nebulised Antibiotic) when you answer. 
 
 
 
 
Strongly 
agree 
Agree Uncertain Disagree 
Strongly 
disagree  
1.  
My health, at present, depends on 
my nebulised Antibiotics 
 
     
 
2.  
Having to take nebulised 
Antibiotics worries me 
 
     
 
3.  
My life would be impossible 
without my nebulised Antibiotics 
 
     
4.  
I sometimes worry about the long-
term effects of my nebulised 
Antibiotics 
 
     
5.  
Without my nebulised Antibiotics 
I would be very ill 
 
     
 Strongly 
agree 
Agree Uncertain Disagree 
Strongly 
disagree 
6.  
My nebulised Antibiotics are a 
mystery to me 
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7.  
My health in the future will 
depend on my nebulised 
Antibiotics 
 
     
8.  
My nebulised Antibiotics disrupt 
my life 
 
     
9.  
I sometimes worry about 
becoming too dependent on my 
nebulised Antibiotics 
 
     
10.  
My nebulised Antibiotics protect 
me from becoming worse 
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Appendix M.2: study two patient BMQ-M 
The Beliefs about Medicines Questionnaire Specific  
ADOLESCENT MUCOLYTICS 
(Version 2: 14/04/19, IRAS: 249889) 
 
 
Patient Identification Number:  
 
   
YOUR VIEWS ON YOUR PRESRIBED NEBULISED MEDICATION FOR YOUR CYSTIC 
FIBROSIS 
 
 
We would like to ask you what you think about the nebulised medication prescribed for your CF. 
 
These are statements that other people have made about their medications. Please show how much 
you agree or disagree with them by ticking the appropriate box. 
 
There are no right or wrong answers. We are just interested in what you think. Please complete this 
without asking your parent/guardian for the answers. Please only tick one box per question. 
 
 
Please only consider …………………. (nebulised Mucolytic) when you answer. 
 
 
 
 
 
Strongly 
agree 
Agree Uncertain Disagree 
Strongly 
disagree  
  
1. 
 
My health, at present, depends on 
my nebulised Mucolytics 
 
     
 
2.  
Having to take nebulised 
Mucolytics worries me 
 
     
 
3.  
My life would be impossible 
without my nebulised Mucolytics 
 
     
4.  
I sometimes worry about the long-
term effects of my nebulised 
Mucolytics 
 
     
5.  
Without my nebulised Mucolytics 
I would be very ill 
 
     
 
 
Strongly 
agree 
Agree Uncertain Disagree 
Strongly 
disagree 
6.  
My nebulised Mucolytics are a 
mystery to me 
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7.  
My health in the future will 
depend on my nebulised 
Mucolytics 
 
     
8.  
My nebulised Mucolytics disrupt 
my life 
 
     
9.  
I sometimes worry about 
becoming too dependent on my 
nebulised Mucolytics 
 
     
10.  
My nebulised Mucolytics protect 
me from becoming worse 
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Appendix N: study two parent BMQ-A and BMQ-M 
Appendix N.1: study two parent BMQ-A 
             
The Beliefs about Medicines Questionnaire Specific 
PARENT/GUARDIAN ANTIBIOTICS 
 (Version 2: 14/04/19, IRAS: 249889) 
 
 
Parent Identification Number:  
 
  
  
 
YOUR VIEWS ON THE NEBULISED MEDICATION PRESRIBED FOR YOUR CHILD’S CYSTIC 
FIBROSIS 
 
 
We would like to ask you about your personal views of the nebulised medication prescribed for your child’s 
CF.  
 
These are statements that other people have made about their medications. Please show how much you 
agree or disagree with them by ticking the appropriate box. 
 
There are no right or wrong answers. We are just interested in what your personal views are. Please 
complete this without speaking to your child about your answers. Please only tick one box per question. 
 
 
Please only consider …………………. (nebulised Antibiotic) when you answer. 
 
 
 
 
Strongly 
agree 
Agree Uncertain Disagree 
Strongly 
disagree  
  
1. 
 
My child’s health, at present, 
depends on their nebulised 
Antibiotics 
 
     
 
2.  
My child having to take nebulised 
Antibiotics worries me 
 
     
 
3.  
My child’s life would be 
impossible without their nebulised 
Antibiotics 
 
     
4.  
I sometimes worry about the long-
term effects of my child’s 
nebulised Antibiotics 
 
     
 Strongly 
agree 
Agree Uncertain Disagree 
Strongly 
disagree 
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5.  
Without their nebulised 
Antibiotics my child would be 
very ill 
 
     
6.  
My child’s nebulised Antibiotics 
are a mystery to me 
 
     
7.  
My child’s health in the future 
will depend on their nebulised 
Antibiotics 
 
     
8.  
My child’s nebulised Antibiotics 
disrupt their life 
 
     
9.  
I sometimes worry about my child 
becoming too dependent on their 
nebulised Antibiotics 
 
     
10.  
 Nebulised Antibiotics protect my 
child from becoming worse 
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Appendix N.2: study two parent BMQ-M 
 
The Beliefs about Medicines Questionnaire Specific 
PARENT/GUARDIAN MUCOLYTICS 
 (Version 2: 14/04/19, IRAS: 249889) 
 
 
Parent Identification Number:  
 
  
 
YOUR VIEWS ON THE NEBULISED MEDICATION PRESRIBED FOR YOUR CHILD’S CYSTIC 
FIBROSIS 
 
 
We would like to ask you about your personal views of the nebulised medication prescribed for your child’s 
CF. 
 
These are statements that other people have made about their medications. Please show how much you 
agree or disagree with them by ticking the appropriate box. 
 
There are no right or wrong answers. We are just interested in what your personal views are. Please 
complete this without speaking to your child about your answers. Please only tick one box per question. 
 
 
Please only consider …………………. (nebulised Mucolytic) when you answer. 
 
 
 
 
 
Strongly 
agree 
Agree Uncertain Disagree 
Strongly 
disagree  
1.  
My child’s health, at present, 
depends on their nebulised 
Mucolytics 
 
     
 
2.  
My child having to take nebulised 
Mucolytics worries me 
 
     
 
3.  
My child’s life would be 
impossible without their nebulised 
Mucolytics 
 
     
4.  
I sometimes worry about the long-
term effects of my child’s 
nebulised Mucolytics 
 
     
 
Strongly 
agree 
Agree Uncertain Disagree 
Strongly 
disagree 
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5.  
Without their nebulised 
Mucolytics my child would be 
very ill 
 
     
6.  
My child’s nebulised Mucolytics 
are a mystery to me 
 
     
7.  
My child’s health in the future 
will depend on their nebulised 
Mucolytics 
 
     
8.  
My child’s nebulised Mucolytics 
disrupt their life 
 
     
9.  
I sometimes worry about my child 
becoming too dependent on their 
nebulised Mucolytics 
 
     
10.  
 Nebulised Mucolytics protect my 
child from becoming worse 
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Appendix O: study two patient and parent B-IPQ 
Appendix O.1: study two patient B-IPQ 
 
 
Patient Identification Number:  
 
 
Please read the following statements and circle the number that best fits your views. 
 
There are no right or wrong answers. I am just interested in what you think. Please complete this 
without asking your parent what they think. 
 
1 
 
How much does your CF affect your life? 
 
 0 1 2 3 4 5 6 7 8 9 10 
 no effect          severely 
 at all          affects my life 
            
 
2 
 
How long do you think your CF will continue? 
 
 0 1 2 3 4 5 6 7 8 9 10 
 a very          forever 
 short time           
     
 
3 
 
How much control do you feel you have over your CF? 
 
 0 1 2 3 4 5 6 7 8 9 10 
 absolutely 
no control 
         extreme amount 
           of control 
 
            
4 How much do you think your treatment can help your CF? 
 
 0 1 2 3 4 5 6 7 8 9 10 
 not at all          extremely 
  
 
         helpful 
 
    
5 How much do you experience symptoms from your CF? 
 
 0 1 2 3 4 5 6 7 8 9 10 
 no symptoms 
at all 
        many severe 
symptoms 
The Brief Illness Perception Questionnaire  
ADOLESCENT  
(Version 2: 14/04/19, IRAS: 249889) 
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6 
 
 
How concerned are you about your CF? 
 
 0 1 2 3 4 5 6 7 8 9 10 
 not at all          extremely 
 concerned   
 
       concerned 
      
7 How well do you feel you understand your CF? 
 
 0 1 2 3 4 5 6 7 8 9 10 
 don't  
understand 
at all 
        understand 
very clearly 
 
            
 
8 
 
How much does your CF affect you emotionally? (e.g. does it make you angry, scared, upset 
or depressed? 
 
 
              0 1 2 3 4 5 6 7 8 
9
               10 
      not at all             extremely 
      affected             affected 
      emotionally             emotionally 
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Appendix O.2: study two parent B-IPQ 
 
 
Parent Identification Number:  
 
             
 
Please read the following statements and circle the number that best fits your views. 
 
There are no right or wrong answers. I am just interested in what you think. Please complete this 
without asking your child what they think. 
 
 
1 
 
How much does your child’s CF affect their life? 
 
 0 1 2 3 4 5 6 7 8 9 10 
 no effect          severely 
 at all          affects their life 
            
 
2 
 
How long do you think your child’s CF will continue? 
 
 0 1 2 3 4 5 6 7 8 9 10 
 a very          
short time 
         forever 
            
 
3 
 
How much control do you feel your child has over their CF? 
 
 0 1 2 3 4 5 6 7 8 9 10 
 absolutely 
no control 
         extreme amount 
           of control 
 
            
4 How much do you think your child’s treatment can help their CF? 
 
 0 1 2 3 4 5 6 7 8 9 10 
 not at all          extremely 
           helpful 
 
    
5 How much does your child experience symptoms from their CF? 
 
 0 1 2 3 4 5 6 7 8 9 10 
 no symptoms at 
all 
        many severe 
symptoms 
            
The Brief Illness Perception Questionnaire  
PARENT  
(Version 2: 14/04/19, IRAS: 249889) 
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6 
 
How concerned are you about your child’s CF? 
 
      0 1 2 3 4 5 6 7 8 9 10 
 not at all          extremely 
 concerned   
 
       concerned 
      
7 How well do you feel you understand your child’s CF? 
 
       0 1 2 3 4 5 6 7 8 9 10 
 don't understand         understand 
very clearly 
 at all 
 
          
 
8 
 
How much does your child’s CF affect you emotionally? (e.g. does it make you angry, 
scared, upset or depressed? 
 
                   0 1 2 3 4 5 6 7 8 9               10 
     not at all          extremely 
     affected          affected 
     emotionally          emotionally 
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Appendix P: study two patient and parent consent forms 
Appendix P.1: study two patient consent form 
 
 
 
 
Patient Identification Number:  
 
 
CONSENT FORM FOR PATIENTS AGED 16 YEARS OR ABOVE 
(Version 2: 14/04/19, IRAS: 249889)  
 
Title of Project: The role of beliefs in predicting adherence to nebulised therapy in adolescents with 
Cystic Fibrosis 
 
Lead researcher: Bronwyn Stirzaker 
Supervisors: Dr Gary Latchford and Dr Alistair Duff  
 
Please initial all boxes if you wish to take part in the study 
 
1. I confirm that I have read and understood the participant information sheet (Version 
1 dated 17/08/18) for the above study, and that I have received enough information 
to know what the project will entail. 
 
2. I confirm that I have had the opportunity to consider the information, ask questions, 
and that I have had these answered satisfactorily. 
 
3. I understand that my participation is voluntary and that I am free to withdraw from 
this study at any time without giving a reason, and without my medical care being 
affected. I understand that I can withdraw my data up to the point of analysis, which is 
two weeks after I complete the study. 
 
4. I understand that my medical notes and data collected during the study may be 
looked at by individuals at my CF centre, regulatory authorities, the sponsor or the 
NHS Trust, where this is relevant to my participation in the research. I give 
permission for these individuals to have access to my records.  
 
5. I agree that readings taken from my iNebuliser from the past 2 months and for the 
next 2 months can be collected for use in this study.  
 
6. I understand that all my data from the questionnaires and my I-nebuliser will be 
pseudo-anonymised, and I agree for my responses, to be used in: reports, 
presentations, web pages and potential publications.  
 
7. I understand that my data will be kept confidential and stored securely.  
 
8. I agree to take part in the above study.  
 
 
 
209 
 
Name of patient Date Signature 
 
 
 
Name of researcher Date Signature 
 
 
 
Thank you very much 
 
When completed: 1 for participant, 1 for researchers file, 1 (original) to be kept in medical notes
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Appendix P.2: study two patient assent form 
 
 
 
 
Patient Identification Number:  
 
  
 
ASSENT FORM (for patients less than 16 years old) 
(Version 3: 14/04/19/, IRAS: 249889)  
 
Title: The role of beliefs in predicting adherence to nebulised therapy in adolescents with Cystic 
Fibrosis 
Lead researcher: Bronwyn Stirzaker 
Supervisors: Dr Gary Latchford and Dr Alistair Duff  
 
 
Please circle your answers to the following questions: 
 
Has somebody else explained this study to you? Yes/No  
 
Do you understand what this study is about? Yes/No  
 
Have you asked all the questions you want to? Yes/No  
 
Are you happy to take part? Yes/No  
 
You and the person who explained this study to you need to fill in your name, today’s date and sign 
below: 
Your name: Today’s date: Your signature: 
 
 
 
Name of person                  Date:                                  Signature: 
taking assent:         
 
 
 
 
 
Thank you very much for your help! 
When completed: 1 for participant, 1 for researchers file, 1 (original) to be kept in medical 
notes. 
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Appendix P.3: study two parent consent form 
 
 
 
       
 
Parent Identification Number:  
 
 
PARENTAL CONSENT FORM 
(Version 1: 14/04/19, IRAS: 249889)  
 
Title of Project: The role of beliefs in predicting adherence to nebulised therapy in adolescents with 
Cystic Fibrosis 
 
Lead researcher: Bronwyn Stirzaker 
Supervisors: Dr Gary Latchford and Dr Alistair Duff 
  
 
Please mark all boxes if you wish to take part in the study 
 
1. I confirm that I have read and understood the participant information sheet 
(Version 1 dated 17/08/18) for the above study, and that I have received enough 
information to know what the project will entail. 
 
2. I confirm that I have had the opportunity to consider the information, ask 
questions, and that I have had these answered satisfactorily.  
 
3. I understand that our participation is voluntary and that I am free to withdraw 
myself and my child from this study at any time without giving a reason, and 
without my child’s medical care being affected. I understand that our data can 
be withdrawn up to the point of analysis. 
 
4. I understand that sections of my child’s medical notes and data collected during 
the study may be looked at by individuals at our CF centre, the sponsor, 
regulatory authorities or the NHS Trust, where this is relevant to my child’s 
participation in the research. I give permission for these individuals to have 
access to my child’s records.  
 
5. I agree that readings taken from my child’s iNebuliser from the past 2 months 
and for the next 2 months can be collected for use in this study.  
 
6. I understand that all my and my child’s data from the questionnaires and my 
child’s I-nebuliser will be pseudo-anonymised, and I agree for our responses, to 
be used in: reports, presentations, web pages and potential publications.  
 
7. I understand that our data will be kept confidential and stored securely. 
 
8. I agree for myself and my child to take part in the above study.   
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Name of parent/guardian Date Signature 
 
 
 
Name of consent taker Date Signature 
 
 
 
 
Thank you very much 
 
 
When completed: 1 for participant, 1 for researchers file, 1 (original) to be kept in medical 
notes. 
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Appendix Q: study two accessibility and usability of questionnaires form 
 
 
 
 
Patient Identification Number:  
 
 
 
EVALUATING THE CF-BMQ SPECIFIC 
 
(Version 3: 14/04/19, IRAS: 249889)  
 
Title: The role of beliefs in predicting adherence to nebulised therapy in adolescents with Cystic 
Fibrosis 
Lead researcher: Bronwyn Stirzaker 
Supervisors: Dr Gary Latchford and Dr Alistair Duff  
 
 
We want to know what you thought of our CF-BMQ Specific questionnaire(s). Please read the 
following questions and circle the number that best fits your views. 
 
 
 
1. Did you understand the questions in our questionnaire(s)? 
 
 0 1 2 3 4 5 6 7 8 9 10  
I did not  
understand any 
         I understood 
all of them 
 
2. Please write any questions that you did not understand in this box. 
 
 
 
 
 
 
 
 
3. Were there any questions that you didn’t like in our questionnaire(s)? 
 
 0 1 2 3 4 5 6 7 8 9 10  
I did not like any 
of the questions 
         I liked all the 
questions 
 
4. Please write the questions that you did not like in this box. 
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Appendix R: study two health and demographics form 
 
 
 
 
Parent Identification Number:  
 
  
 
DEMOGRAPHICS FORM FOR PARENT TO COMPLETE 
(Version 3: 14/04/19, IRAS: 249889)  
 
Title: The role of beliefs in predicting adherence to nebulised therapy in adolescents with Cystic 
Fibrosis 
 
Lead researcher: Bronwyn Stirzaker 
Supervisors: Dr Gary Latchford and Dr Alistair Duff  
 
Please complete the following in relation to yourself, NOT your child. 
 
Your gender: 
 
 
Your age: 
 
Your ethnicity: 
 
 
Your religion: 
Your job: 
 
 
Your education level: (e.g. high school, 
college, university) 
 
 
Your postcode: 
 
 
 
 
1. What is your relationship to the patient?  ……………………………  
2. Are you currently married?  …………………………… 
3. How many adults live in your home?  …………………………… 
4. How many children live in your home?  …………………………… 
 
Please complete the following in relation to your child: 
 
Religion: 
 
 
Ethnicity: 
 
 
 
 
